Back grey_arrow_rt.gif
 
Latest articles about Hepatitis C.
 
null.gif
 
 
  1. Achillion Announces Nomination of ACH-2684 as Lead Clinical Candidate in Resistance-Focused HCV Program - (02/04/10)
     
  2. Conatus Pharmaceuticals Initiates Phase II Clinical Trial of CTS-1027 in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV) - (02/04/10)
     
  3. A glimpse of future hepatitis C virus treatment paradigms - telaprevir - (01/29/10)
     
  4. We Can Cure HCV - (01/28/10)
     
  5. Dynavax Reports Positive Phase 1b Data for SD-101 in Chronic Hepatitis C Infection - (01/27/10)
     
  6. HCV & HBV Medicaid/Medicare Training by NYS DOH - (01/26/10)
     
  7. HCV Drug Update for Vertex, Roche, Idenix - (01/26/10)
     
  8. Lessons From HIV Therapy Applied to Viral Hepatitis Therapy: Summary of a Workshop - (01/26/10)
     
  9. Liver cancer: From molecular pathogenesis to new therapies: Summary of the EASL single topic conference - (01/21/10)
     
  10. Pharmasset Initiates Phase 2a Trial with PSI-7977, a Chirally Pure Isomer of PSI-7851 - (01/21/10)
     
  11. Limit of Fibroscan - (01/20/10)
     
  12. New HCV Drug IDX184 - New Data; Idenix Pharmaceuticals Highlights Progress in Three HCV Programs - (01/12/10)
     
  13. Achillion Announces Additional Positive Phase 1b Data With ACH-1625 to Treat Hepatitis C, 5-day monotherapy - (01/12/10)
     
  14. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C - Report from the Institute of Medicine (IOM) pdf of full report attached - (01/12/10)
     
  15. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety - (01/06/10)
     
  16. What is Liver Cancer? - (12/02/09)
     
  17. What Is Cirrhosis? What Causes Cirrhosis? - (12/02/09)
     
  18. Therapeutic Silencing of MicroRNA-122 by SPC3649 in Primates with Chronic Hepatitis C Virus Infection - (01/10/10)
     
  19. Effects of Coffee Consumption on Fasting Blood Glucose and Insulin Concentrations Randomized controlled trials in healthy volunteers - (01/07/10)
     
  20. Caffeine Increases Ambulatory Glucose and Postprandial Responses in Coffee Drinkers With Type 2 Diabetes - (01/07/10)
     
  21. Coffee, Caffeine, and Risk of Type 2 Diabetes A prospective cohort study in younger and middle-aged U.S. women - (01/07/10)
     
  22. Does Coffee Consumption Reduce the Risk of Type 2 Diabetes in Individuals With Impaired Glucose? - (01/07/10)
     
  23. Decaffeinated coffee and glucose metabolism in young men. pdf attached - (01/07/10)
     
  24. Does Coffee Consumption Reduce the Risk of Type 2 Diabetes in Individuals With Impaired Glucose? - (01/07/10)
     
  25. Caffeine May Affect Blood Glucose Levels - (01/07/10)
     
  26. Glucose Abnormalities in Patients with Hepatitis C Virus Infection Epidemiology and pathogenesis - (01/07/10)
     
  27. Peginterferon Alfa-2a Plus Ribavirin Is More Effective Than Peginterferon Alfa-2b Plus Ribavirin for Treating Chronic Hepatitis C Virus Infection - pdf publication attached - (01/06/10)
     
  28. Liver Stiffness Measurements & Fibrosis Detection After Liver Transplant - full text of publication follows below - (01/06/10)
     
  29. HCV & HBV National Strategy Report from the Institute of Medicine - Monday Jan 11 Release & Conference Call - (01/06/10)
     
  30. London's teenage 'It Girl' - (12/28/09)
     
  31. Factors Associated with HCV Transmission from Male to Female with No IDU History in WIHS - (12/23/09)
     
  32. AASLD: Combination of IDX184, a Nucleotide Prodrug Polymerase Inhibitor, with Other Classes of HCV Inhibitors is Additive to Synergistic in the HCV Replicon in vitro - (12/21/09)
     
  33. Scripps Research Scientists Identify Novel Hepatitis C Inhibitors: four small-molecule inhibitors of dimerization of the viral core protein - (12/17/09)
     
  34. hepDART: The Business of HCV Antiviral Agents: 2010 and Beyond (12/17/09)
     
  35. hepDART: Longitudinal clonal resistance analysis of treatment-naïve patients with chronic Hepatitis C (CHC) genotype 1 infection treated with MK-7009, a Novel NS3/4a Protease Inhibitor, in combination with Pegylated Interferon Alfa-2a and Ribavirin for 28 day (12/17/09)
     
  36. Achillion Announces Positive Preliminary Phase 1b Proof of Concept Data With ACH-1625 to Treat Hepatitis C - Achieves 3.94 log10 Reduction in HCV RNA With Continued Safety and Tolerability - (12/16/09)
     
  37. Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial -- full text pdf of published study attached - (12/14/09)
     
  38. hepDART: Safety and Tolerability of Filibuvir, a Non nucleoside Inhibitor of HCV Polymerase (12/10/09)
     
  39. 4th Intl Wrkshp HCV Resistance & New Compounds Analysis of antiviral resistance to MK-7009 in protocol 004, a phase 1b monotherapy study - (12/09/09)
     
  40. hepDART: Pharmacokinetics of a Polymerase Inhibitor, ABT-333, in Treatment-naïve HCV Genotype 1-Infected Subjects Following Treatment with 2 days of ABT-333 Followed by 26 Days of ABT-333 Plus Pegylated Interferon and Ribavirin (12/08/09)
     
  41. hepDART: Pharmacokinetics and Tolerability of the HCV Protease Inhibitor ABT-450 Following Single Ascending Doses in Healthy Adult Volunteers with and Without Ritonavir (12/08/09)
     
  42. hepDART: Pharmacokinetics, Safety and Tolerability of the HCV Protease Inhibitor ABT-450 with Ritonavir Following Multiple Ascending Doses in Healthy Adult Volunteers (12/08/09)
     
  43. hepDART: Safety, Tolerability, Pharmacokinetics and Antiviral Activity of the HCV Polymerase Inhibitor ABT-072 Following Single and Multiple Dosing in Healthy Adult Volunteers and Two Days of Dosing in Treatment-Naïve HCV Genotype 1-Infected Subjects (12/08/09)
     
  44. AASLD: Asian and White Patients With Chronic Hepatitis C (CHC) Achieve Similar Response Rates With Peginterferon (PEG-IFN) Alfa-2b Plus Ribavirin (RBV) in Genotypes (G) 2 and 3: Subanalysis of the REDD 2/3 Study - (12/07/09)
     
  45. AASLD: Identifying HCV genotype 2/3 patients who could receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin - (12/07/09)
     
  46. AASLD: Ribavirin priming enhances efficacy of chronic hepatitis C re-treatment in patients who had not responded to previous combination therapy - (12/07/09)
     
  47. AASLD: PREDICT Study Final Results: Efficacy and Safety of 24-Wk Regimen of Peginterferon alfa-2b Plus Weight-based Ribavirin in Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 (G1) With Low Viral Load Who Achieve Rapid Viral Response - (12/07/09)
     
  48. Santaris Study Shows HCV Drug Inhibits miRNA Target in Chimps - (12/03/09)
     
  49. New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C - (12/03/09)
     
  50. Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection -Science Magazine article today - full text pdf attached - (12/03/09)
     
  51. Vitamin D Boosts Treatment of Chronic Hepatitis C - (12/02/09)
     
  52. HUMAN GENOME SCIENCES SUBMITS BIOLOGICS LICENSE APPLICATION TO FDA FOR ZALBIN™ (albuferon)s - (12/02/09)
     
  53. Pharmasset HCV Drug Pipeline - (12/02/09)
     
  54. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients -- attached is the full-text pdf - (12/02/09)
     
  55. AASLD: Standard versus higher induction doses of peginterferon alfa-2a (40KD) and/or higher ribavirin (RBV) in HCV G1 patients with high viral load and body weight ≥85 kg: Final results of the PROGRESS study - (12/02/09)
     
  56. AASLD: SVR Results of Weight-based Taribavirin Versus Weight-based Ribavirin, Both with Peginterferon alfa-2b, in Naïve Chronic Hepatitis C, Genotype 1 Patients - (11/30/09)
     
  57. NS2 Protease - Multitasking may be Achilles heel for hepatitis C - (11/25/09)
     
  58. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C - (11/23/09)
     
  59. FDA Perspectives on Clinical Trial Design for New HCV Products, Early Access, presented by Kim Struble at EATG meeting Nov 21 2009, Brussels - (11/20/09)
     
  60. ITMN-191 HCV Protease Study High Dose Modified Side Effect Reported - (11/20/09)
     
  61. AASLD: Efficacy and safety of albinterferon alfa-2b in combination with ribavirin in treatment-naïve patients with chronic hepatitis C genotype 1 - (11/10/09)
     
  62. EACS: Fatty Liver in HIV & HCV - (11/17/09)
     
  63. EACS: Rough Group Sex--Not Just Anal Sex--May Explain HCV Epidemic in HIV+ Gays - (11/13/09)
     
  64. AASLD: New Drug Boceprevir Boosts HCV Clearance for Nonresponders - (11/11/09)
     
  65. AASLD: Once-Daily HCV Protease Inhibitors Show Early Promise - (11/11/09)
     
  66. DISCOVERY OF POTENT, BIOAVAILABLE HCV NS3/4A PROTEASE INHIBITORS THAT DISPLAY UNIMPAIRED ACTIVITY AGAINST AN NS3 SEQUENCE VARIANT ASSOCIATED WITH RESISTANCE TO LINEAR TETRAPEPTIDES AND MACROCYCLIC INHIBITORS - (11/11/09)
     
  67. AASLD: Phase 2 Study of Telaprevir Administered q8h or q12h with Peginterferon Alfa-2a or Alfa-2b and Ribavirin in Treatment-Naïve Patients with Genotype 1 Hepatitis C: Final Results - (11/10/09)
     
  68. AASLD: Telaprevir Vertex hep C protease inhibitor drug works well in twice daily dosing - (11/10/09)
     
  69. AASLD: More than 80% of Hepatitis C Patients Treated in Study C208 Achieved an SVR with Telaprevir-Based Regimens - press release from Vertex - (11/10/09)
     
  70. AASLD: 2 Oral HCV Drug Combination R7227+R7128 Without Interferon/ribavirin in INFORM Study - (11/09/09)
     
  71. AASLD: SVR Improves Survival, Risk for Liver Cancer, Decompensated Liver Disease and Liver Transplant/Death - Also, Transient Viral Suppression (breakthroughs/relapsers) Improves Clinical Outcomes Too - (11/09/09)
     
  72. AASLD: KINETIC ANALYSIS OF VIRAL REBOUND AND DRUG-RESISTANT VIRAL VARIANT DYNAMICS IN PATIENTS TREATED WITH ITMN-191 (RG7227) MONOTHERAPY SUGGESTS A HIGH BARRIER TO VIRAL ESCAPE - (11/09/09)
     
  73. AASLD: INCIDENCE OF VIROLOGIC ESCAPE OBSERVED DURING ITMN-191 (R7227) MONOTHERAPY IS GENOTYPE DEPENDENT, ASSOCIATED WITH A SPECIFIC NS3 SUBSTITUTION, AND SUPPRESSED UPON COMBINATION WITH PEGINTERFERON ALFA-2a/RIBAVIRIN - (11/09/09)
     
  74. AASLD: Telaprevir, Peginterferon Alfa-2a and Ribavirin Improved Rates of Sustained Virologic Response (SVR) in "Difficult-to-Cure" Patients With Chronic Hepatitis C (CHC): a Pooled Analysis From the PROVE1 and PROVE2 Trials - (11/09/09)
     
  75. AASLD: Telaprevir PROVE3 Final Results: treatment-experienced patients - (11/06/09)
     
  76. AASLD: HCV Response Linked Strongly to Gene Variant IL28B - (11/06/09)
     
  77. AASLD: HCV antibody seroconversion in a U.S. HIV-infected male clinical trials population - (11/06/09)
     
  78. AASLD: SILEN-C1: Early Antiviral Activity and Safety of BI 201335 Combined with Peginterferon alfa-2a and Ribavirin in Treatment-naïve Patients with Chronic Genotype 1 HCV infection - (11/06/09)
     
  79. AASLD: Treatment-naïve, genotype-1 HCV-infected subjects show significantly greater HCV RNA decreases when treated with 28 days of ABT-333 plus peginterferon and ribavirin compared to peginterferon and ribavirin alone - (11/06/09)
     
  80. AASLD: HCV Sex Transmission Among HIV+ MSM in NYC Study Report from Mt Sinai Researchers - (11/06/09)
     
  81. AASLD: Genotypic and Phenotypic Analysis of Samples From HCV-Infected Subjects Treated with BMS-650032 in a Single Ascending Dose Study - (11/06/09)
     
  82. AASLD: Early Viral Response Rates in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Infection Treated with MK-7009, a Novel NS3/4a Protease Inhibitor, in Combination with Pegylated Interferon Alfa-2a and Ribavirin for 28 Days - (11/05/09)
     
  83. AASLD: Safety and Antiviral Activity of NS5B Polymerase Inhibitor MK-3281in Genotype 1 and 3 HCV-Infected Patients - (11/05/09)
     
  84. AASLD: COMBINATION THERAPY WITH NUCLEOSIDE POLYMERASE (RG7128) AND PROTEASE (RG7227) INHIBITORS IN GENOTYPE 1 HCV INFECTED PATIENTS: INTERIM RESISTANCE ANALYSIS OF INFORM-1 COHORTS A-D - (11/05/09)
     
  85. AASLD: Antiviral activity and safety of TMC435 combined with pegylated interferon and ribavirin in hepatitis C patients with genotype 1 who had previous exposure to TMC435 - (11/05/09)
     
  86. AASLD: A Phase 1b Dose-Ranging Study of 4 Weeks of PEG-Interferon (IFN) Lambda (PEG-rIL-29) in Combination with Ribavirin (RBV) in Patients with Chronic Genotype 1 Hepatitis C Virus (HCV) Infection - (11/05/09)
     
  87. AASLD: Antiviral Activity, Pharmacokinetics, Safety, and Tolerability of PSI-7851, a Novel Nucleotide Polymerase Inhibitor for HCV, Following Single and 3 Day Multiple Ascending Oral Doses in Healthy Volunteers and Patients with Chronic HCV Infection - (11/05/09)
     
  88. AASLD: PHARMACOKINETICS/PHARMACODYNAMICS (PK/PD) OF COMBINATION RG7227 AND RG7128 THERAPY FROM INFORM-1 DEMONSTRATES SIMILAR EARLY HCV VIRAL DYNAMICS WHEN RG7227 IS COMBINED WITH EITHER PEG-IFN/RIBAVIRIN (SOC) OR RG7128 - (11/05/09)
     
  89. AASLD: Boceprevir in Genotype 1 Null-Responders with Peg/RBV Lead-In - (11/05/09)
     
  90. AASLD: Merck HCV Protease MK-7009 - (11/05/09)
     
  91. AASLD: HCV/MSM Sex Transmission in HIV+ in New York City - (11/05/09)
     
  92. AASLD: Combination Therapy With A Nucleoside Polymerase (RG7128) And Protease (RG7227/ITMN-191) Inhibitor In HCV: Safety, Pharmacokinetics, And Virologic Results From INFORM-1 - (11/04/09)
     
  93. AASLD: Safety, Tolerability, Pharmacokinetics and Antiviral Activity following Single- and Multiple-Dose Administration of BMS- 650032, a Novel HCV NS3 Inhibitor, in Subjects with Chronic Genotype 1 HCV Infection - (11/04/09)
     
  94. AASLD: High Sustained Virologic Response in Genotype 1 Null Responders to Peginterferon α-2b + Ribavirin When Treated with Boceprevir Combination Therapy Results From HCV Sprint-1 - (11/04/09)
     
  95. AASLD: Once Daily Narlaprevir (SCH 900518) in Combination with Peginterferon alfa-2b/ Ribavirin for Treatment-Naive Patients with Genotype-1 Chronic Hepatitis C: Interim Results from the NEXT-1 Study - (11/04/09)
     
  96. AASLD: BI 207127 is a potent HCV RNA polymerase inhibitor during 5 days monotherapy in patients with chronic hepatitis C - (11/04/09)
     
  97. AASLD: Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting - Schering Plough press release - (11/01/09)
     
  98. AASLD: Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C - (11/01/09) Schering Plough press release
     
  99. AASLD: GlobeImmune's Hepatitis C Therapeutic Vaccine Combined With Standard of Care Increases End of Treatment Response Rate by 15% - (11/01/09) press release
     
  100. AASLD: Virological response and safety of BI 201335 protease inhibitor, peginterferon alfa 2a and ribavirin treatment of HCV genotype-1patients with compensated liver cirrhosis and non-response to previous peginterferon/ribavirin - (11/01/09)
     
  101. AASLD: Schering hep C drug promising in Phase II study - (11/01/09)
     
  102. AASLD: Telaprevir PROVE3 Final Results: treatment-experienced patients - (11/01/09)
     
  103. AASLD: Boceprevir in Genotype 1 Null-Responders with Peg/RBV Lead-In - (11/01/09)
     
  104. AASLD: Merck HCV Protease MK-7009 - (11/01/09)
     
  105. HCV Drives Down Kidney Function - (11/01/09)
     
  106. Viral Hepatitis and Liver Cancer Control and Prevention Act Introduced in Congress: call your representative to express support - (11/01/09)
     
  107. Rep Honda Introduces Bi-Partisan Bill to End Hepatitis Epidemic in America - (10/29/09)
     
  108. ZymoGenetics Initiates Phase 2 Clinical Trial of PEG-Interferon lambda in Hepatitis C with Bristol-Myers Squibb - (10/27/09)
     
  109. New HCV Polymerase Drug - (10/26/09)
     
  110. Vertex New HCV Drugs/Studies Update - (10/26/09)
     
  111. Public health impact of antiviral therapy for hepatitis C in the United States - 50% Undiagnosed - (10/20/09)
     
  112. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin - (10/20/09)
     
  113. Hepatitis C drug development at a crossroads - Comments from the Editors - (10/08/09)
     
  114. Pharmasset Nominates PSI-879 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development - (10/07/09)
     
  115. Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-2125, a TLR9 Agonist, in Combination with Ribavirin for Chronic Hepatitis C Virus Infection - (10/07/09)
     
  116. New Data on Four Bristol-Myers Squibb Compounds to Be Presented at AASLD 2009: new HCV NS3 inhibitor - (10/04/09)
     
  117. Bristol-Myers Squibb and ZymoGenetics to Present Final Phase Ib Data on PEG-Interferon Lambda at AASLD 2009 - (10/04/09)
     
  118. Hepatitis C virus infection and its clearance alter circulating lipids: Implications for long-term follow-up - (10/04/09)
     
  119. Hepatitis C drug development at a crossroads - Comments from the Editors - (10/04/09)
     
  120. AASLD: Viral Responses in African Americans, Latinos, and Caucasians in the US Phase 2 Study (PROVE1) of Telaprevir with Peginterferon Alfa-2a and Ribavirin in Treatment-Naive, Genotype 1-Infected Patients with Hepatitis C - (9/29/09)
     
  121. Schering-Plough Highlights Boceprevir, Narlaprevir (SCH 900518) and PEGINTRON(R) Data at the American Association for the Study of Liver Diseases (AASLD) 2009 Annual Meeting - (10/17/09)
     
  122. Once Monthly Interferon: Alios BioPharma Issued Broad U.S. Patent for Glyco-Engineered Interferons - (10/17/09)
     
  123. Achillion Completes Phase 1a Trial of ACH-1625; Begins Dosing in Phase 1b Segment With HCV-Infected Patients - (09/29/09)
     
  124. Vertex Takeover Rumors - (09/29/09)
     
  125. New HCV Nucleotide PSI-7851 - (09/26/09)
     
  126. ICAAC: Acute HBV & HCV Infection Among MSM: CDC Data from Population-Based Surveillance, 2006-2008 - (09/25/09)
     
  127. The many faces of hepatitis C: Liver disease and type 2 diabetes - (09/17/09)
     
  128. Addiction, HCV & Prisons - (09/14/09)
     
  129. The many faces of hepatitis C: Liver disease and type 2 diabetes - (09/11/09)
     
  130. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598 - (09/11/09)
     
  131. CDC HCV Surveillance Study 2006-2007 Published - (09/11/09)
     
  132. Medtronic Initiates Phase II Hepatitis C Clinical Study ''COPE-HCV'' to Determine Tolerability and Safety of Continuous Interferon Infusion for Patients with HCV - (09/03/09)
     
  133. The model for end-stage liver disease score (MELD) is the best prognostic factor in HIV 1-infected patients with end-stage liver disease: A prospective cohort study - (09/03/09)
     
  134. Viable strategies to facilitate liver transplantation for HIV/HCV coinfection - Editorial - (09/03/09)
     
  135. Viral Hepatitis (HCV, HBV) Sign-On Letter: letter pdf attached
     
  136. HEP DART December 6 2009
     
  137. Roche, InterMune Commence Mid-Stage Trial Of Hepatitis C Protease Drug ITMN-191 and Ritonavir Boosting Study - (08/19/09)
     
  138. Anadys HCV Drug Problems: Anadys Moves Hepatitis C Drug Ahead on its Own - (08/19/09)
     
  139. Rate of Sustained Virologic Response in Relation to Baseline Hepatitis C Virus (HCV) RNA Level and Rapid Virologic Clearance in Persons with Acute HCV Infection: genotype 1 can achieve high SVR rate is treated during acute infection - (08/18/09)
     
  140. Gilead Caspase Inhibitor for Liver Disease - (08/18/09)
     
  141. Abbott HCV Protease & Polymerase Drug Development Program - (08/18/09)
     
  142. Genes Tied to Gap in Treatment of Hepatitis C: "principal reason for the disparity between the races"....."genetic test based on the finding would be of great interest to patients and physicians" - (08/17/09)
     
  143. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C - (08/17/09)
     
  144. Quality of life considerations for patients with chronic hepatitis C: "SVR improves long-term prognosis & health-related quality of life - mental health, physical & general health/virality, emotional health" - (08/17/09)
     
  145. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis - (08/17/09)
     
  146. Community-based hepatitis B screening programs in the United States in 2008: CDC recommends HBsAg testing to identify HBV-infection for foreign-born persons from areas with HBsAg prevalence 2% or greater - (08/17/09)
     
  147. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance; for African-Americans, Hispanics, East Asians - (08/15/09)
     
  148. Blueberry Chemical Blocks HCV Replication - (08/15/09)
     
  149. Telaprevir PROVE1 Study: Telaprevir with Peginterferon and Ribavirin for Chronic Genotype 1 Infection - (08/15/09)
     
  150. PROVE2: Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection (genotype 1) - (08/15/09)
     
  151. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a - (08/14/09)
     
  152. Coinfection with Hepatitis C Virus and HIV: More than Double Trouble - EDITORIAL COMMENTARY - (08/14/09)
     
  153. ANA773 HCV Toll-Receptor Reduced Viral Load, oral inducer of endogenous interferons that acts via the toll like receptor 7 (TLR7) pathway, 10-day monotherapy study - (08/14/09)
     
  154. State Health Department Launches Media Campaign To Increase Public Awareness About Hepatitis C - (08/14/09)
     
  155. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin - pdf of published study attached - (08/14/09)
     
  156. PTC THERAPEUTICS ANNOUNCES ACHIEVEMENT OF MAJOR MILESTONE IN SCHERING-PLOUGH HEPATITIS C COLLABORATION - (08/14/09)
     
  157. Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy (HCV, IVDU) - (08/12/09)
     
  158. New Expanded Access Rules to Investigational Drugs for Treatment Use and Charging for Investigational Drugs - (08/12/09)
     
  159. FDA Expands Access to Investigational Drugs - (08/12/09)
     
  160. Increased liver-related mortality to hepatitis C viremia defined on the 20th anniversary of its identification- Editorial : HCV carriers had a significantly higher rate of overall mortality - (08/05/09)
     
  161. Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study - (08/05/09)
     
  162. Effect of hepatitis C virus and its treatment on survival: HCV associated with mortality, treatment reduces risk - dah - (08/05/09)
     
  163. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus - (08/05/09)
     
  164. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients - press release - (08/01/09)
     
  165. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial -- attached is pdf and appendix with adverse events - (08/04/09)
     
  166. New HCV Nucleotide Polymerase PSI-7851 Achieves 1 log Reduction in Viral Load in 3-Day Study - (08/01/09)
     
  167. 5th IAS: HIV Regimens Lacking Nucleosides Tied to Higher SVR Rate With HCV Therapy - written by Mark Mascolini - (07/29/09)
     
  168. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) - (07/25/09)
     
  169. Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the united states population - (07/15/09)
     
  170. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam - (07/15/09)
     
  171. Vertex Pharmaceuticals Announces Intention to Sell Its Rights to European Milestone Payments for Telaprevir - (07/12/09)
     
  172. 4th Intrntnl Wrkshp Clncl Pharm HCV: Meeting Report - The 4th International Workshop on Clinical Pharmacology of Hepatitis Therapy - written by Jennifer J. Kiser, Pharm.D - (07/12/09)
     
  173. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development - (07/09/09)
     
  174. Pharmasset Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development - (07/08/09)
     
  175. ELEVATE Phase III Study- for Eltrombopag To raise platelet count - (07/07/09)
     
  176. Hepatitis C Virus Infection and the Risk of Coronary Disease - (07/03/09)
     
  177. 4th Intrntnl Wrkshp HCV Resist: New HCV Drugs, Special Population (Coinfectio) Access: 4th International Workshop on Hepatitis C, Resistance and New Compounds 25-26 June 2009, Boston, MA U - (06/30/09)
     
  178. Time-Released Interferon Locteron Study Enrollment Completed - (06/30/09)
     
  179. 4th Intrntnl Wrkshp HCV Resist: FDA Loosens Up HCV Drug Development - HCV Boston Meeting June 27, 2009 - (06/30/09)
     
  180. "Maintenance Therapy Did Not Reduce Incidence of HCC in the HALT-C Study" - (06/21/09)
     
  181. HCC Surveillance is Needed in USA - Hepatitis C and Hepatocellular Carcinoma: Grist for the Mill EDITORIAL - (06/21/09)
     
  182. Low-fat Diet Helps Genetically Predisposed Animals Avoid Liver Cancer - (06/15/09)
     
  183. Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients - (06/10/09)
     
  184. Progenics Stops PRO 206 HCV Entry Inhibitor - (06/10/09)
     
  185. CDC Updated Viral Hepatitis Surveillance - (06/05/09)
     
  186. Liver Disease 'Shrunk' By Blood-pressure Drug - (06/05/09)
     
  187. Liver Cancer Rates Triple: Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005 - (06/03/09)
     
  188. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results - (06/01/09)
     
  189. Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal - (06/01/09)
     
  190. Causes of Liver Cancer in HCV: Hepatitis C virus-induced hepatocarcinogenesis (HCC)) - (06/01/09)
     
  191. EASL: Early EPO Use Increased SVR Rates and Reduced Discontinuation Rate ! (05/29/09)
     
  192. EASL: New HCV Drug Report: "Using a new palette of treatment options to paint the portrait of cure for patients infected with hepatitis C on our clinical canvas." - written by Robert Gish MD - (05/28/09)
     
  193. Hepatitis Advocacy Update: Congressional Black Caucus Requests Federal Funding, for African-Americans The HCV Prevalence Rate is Double Compared To All Others in the USA; Congressmen Request Funding Support; Pres Obama Recognizes hepatitis with a Statement - (05/28/09)
     
  194. EASL: EXTENDED TREATMENT DURATION TO 72 Weeks IN CHRONIC HEPATITIS C GENOTYPE 1-INFECTED SLOW RESPONDERS: FINAL RESULTS OF THE SUCCESS STUDY (SUCCESS) - (05/27/09)
     
  195. EASL: BI 201335, a potent HCV NS3 protease inhibitor, in treatment-naïve and -experienced chronic HCV genotype-1 infection: genotypic and phenotypic analysis of the NS3 protease domain - (05/27/09)
     
  196. EASL: Preclinical characterization of PRO 206, an orally active HCV entry inhibitor - (05/27/09)
     
  197. Consequences of Hepatitis C Virus (HCV): Costs of a Baby Boomer Epidemic of Liver Disease MAY 2009 - (05/18/09)
     
  198. Evidence of a Large, InternationaL Network of HCV Transmission in HIV-Positive Men Who Have Sex With Men - (05/18/09)
     
  199. EASL: EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A 360 µg/WEEK IN COMBINATION WITH RIBAVIRIN IN HEPATITIS C GENOTYPE 1 PATIENTS - IMPACT Of CIRRHOSIS: ANALYSIS FROM THE CHARIOT STUDY - (05/14/09)
     
  200. EASL: EASL Analysis, New Oral HCV Drugs What's Expected - (05/14/09)
     
  201. EASL: Histologic Outcomes in Hepatitis C-Infected Patients With Breakthrough or Relapse to Interferon-Based Treatments: there was a positive correclation between viral response and improved fibrosis - (05/13/09)
     
  202. EASL: BASELINE CHARACTERISTICS AND WEEK 4 RESPONSE AMONG CHRONIC HEPATITIS C PATIENTS INFECTED WITH HCV GENOTYPE 1, 2, 3 OR 4: INTERIM RESULTS OF THE PROPHESYS TRIAL - (05/13/09)
     
  203. EASL: Identifying Patients Infected With HCV Genotype 1 Who May Benefit From Extended Peginterferon Alfa-2a/Ribavirin Therapy Beyond 48 Weeks - (05/13/09)
     
  204. EASL: IDENTIFYING PATIENTS WITH A HIGH LIKELIHOOD OF ACHIEVING AN SVR FOLLOWING RE-TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN: USE OF POSITIVE PROGNOSTIC FACTORS (PPF'S) - (05/12/09)
     
  205. EASL: Ursodeoxychic Acid Improved NASH, Not So Sure About Rosiglitazone - (05/12/09)
     
  206. EASL: Single and Multiple-Dose Assessments of the Safety and Pharmacokinetics of SCH 900518 and Its Effect on the Pharmacokinetics of Midazolam in Healthy Subjects - (05/12/09)
     
  207. EASL: Preclinical Characterization of SCH 900518,A Novel Mechanism-Based Inhibitor of HCV NS3 Protease - (05/12/09)
     
  208. EASL: Individualized treatment duration with peginterferon alfa-2b and ribavirin for 24, 30 or 36 weeks in HCV genotype 1-infected patients with undetectable HCV-RNA early during therapy (INDIV-2 study) - (05/12/09)
     
  209. EASL: A Regional Gastrointestinal Absorption Study of the HCV NS3 Protease Inhibitor SCH 900518 in Healthy Volunteers: "remote-controlled drug delivery device that delivers any form of drug to key regions of the human gastrointestinal (GI) tract." - (05/12/09)
     
  210. EASL: Preclinical Pharmacokinetic and Safety Profile of IDX375, A Novel and Potent Non-Nucleoside HCV Polymerase Inhibitor - (05/11/09)
     
  211. EASL: Preclinical Profiles of IDX136 and IDX316, Two Novel Macrocyclic HCV Protease Inhibitors - (05/11/09)
     
  212. EASL: IDENTIFICATION AND PROFILE OF POTENT AND SELECTIVE INHIBITORS OF HCV NS5A PROTEIN - (05/11/09)
     
  213. Phase 2a Study to Evaluate the Safety and Tolerability and Anti-Viral Effect of 4 Doses of a Novel, Controlled-Release Interferon Alfa-2b (LocteronTM) Given Every 2 Weeks for 12 Weeks in Treatment-Naive Patients with Chronic Hepatitis C (Genotype 1) (AASLD 2007) - (05/08/09)
     
  214. Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection...PROVE1 in NEJM 4/2009 - (05/08/09)
     
  215. Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection....A total of 334 patients who had chronic infection with HCV genotype 1 and had not been treated previously (PROVE2) - (05/08/09)
     
  216. A Step Forward in Therapy for Hepatitis C EDITORIAL - NEJM 4/2009 - (05/08/09)
     
  217. EASL: Albuferon vs Pegasys Genotype 2/3 - (05/07/09)
     
  218. EASL: Albuferon vs Pegasys Genotype 1 - (05/07/09)
     
  219. EASL: Co Press Release: Biolex presents Locteron US Phase 2a hepatitis C data at EASL - (05/07/09)
     
  220. EASL: Identification and Characterization of VCH-222, a Novel Potent and Selective Non-Nucleoside HCV Polymerase Inhibitor - (05/07/09)
     
  221. EASL: Activity & Genotypic and Phenotypic Analysis of HCV NS5B Variants Selected from Patients Treated with VCH-916 - (05/07/09)
     
  222. EASL: Randomized Trial Comparing Systemic and Local Reactions to Controlled-release Interferon Alpha2b and Pegylated-interferon Alpha2b in Hepatitis C Patients Who Failed Prior Treatment - (05/07/09)
     
  223. EASL: Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide with Peginterferon Alfa-2a and Ribavirin in Nonresponders (NR) with Chronic HCV Genotype 1: Week 28 Interim Analysis - (05/07/09)
     
  224. EASL: Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide Plus Peginterferon and Ribavirin in HCV Genotype 1 Naïve Patients: Interim Analysis Shows Increase in EVR - (05/07/09)
     
  225. EASL: Preclinical Pharmacokinetic and ADME Characterization of VCH-222, a Novel Non-Nucleoside HCV NS5B Polymerase Inhibitor from Vertex/ViroChem - (05/07/09)
     
  226. EASL: IDX184, A Liver-Targeted Nucleotide HCV Polymerase Inhibitor: Results of a First-in-Man Safety and Pharmacokinetic Study - (05/07/09)
     
  227. EASL: Antiviral Activity of the Liver-Targeted Nucleotide HCV Polymerase Inhibitor IDX184 Correlates with Trough Serum Levels of the Nucleoside Metabolite in HCV-infected Chimpanzees - (05/07/09)
     
  228. EASL: Pharmacokinetics, Safety and Tolerability of the HCV Polymerase Inhibitor ABT-333 Following Multiple Ascending Doses and Effect of Co-Administration of Ketoconazole in Healthy Subjects - (05/05/09)
     
  229. EASL: Characterization of Resistance Mutations Selected In Vitro by Non-Nucleoside HCV Polymerase Inhibitors ABT-333 and ABT-072 - (05/05/09)
     
  230. EASL: US Hepatitis C Burden Assessment from a Transmission Model: HCV burden reduced by new HCV drugs - (05/05/09)
     
  231. EASL: Pharmacokinetics and Tolerability of the HCV Polymerase Inhibitor ABT-333 Following Single Ascending Doses in Healthy Adult Volunteers - (05/05/09)
     
  232. EASL: Safety, Tolerability and Pharmacokinetics of the HCV Polymerase Inhibitor VCH-222 Following Single Dose Administration in Healthy Volunteers and Antiviral Activity in HCV-infected Individuals - (05/05/09)
     
  233. EASL: Safety, Tolerability, and Pharmacokinetics of GS-9450 in Healthy Male and Female Volunteers - (05/05/09)
     
  234. EASL: Abbott/Enanta - Potent HCV Protease Inhibitors with the Potential for Once-daily Dosing and Broad Genotype Coverage - (05/05/09)
     
  235. EASL: Preclinical Characterization of ABT-072: A Novel Non-Nucleoside HCV Polymerase Inhibitor - (05/05/09)
     
  236. EASL: Preclinical Potency, Pharmacokinetic and ADME Characterization of ABT-333, A Novel Non-Nucleoside HCV Polymerase Inhibitor - (05/05/09)
     
  237. EASL: 2 Schering HCV Protease Inhibitors; Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients - (05/04/09)
     
  238. Recombinant (EPO) human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials - (05/04/09)
     
  239. EASL: EFFICACY AND SAFETY OF THE CYCLOPHILIN INHIBITOR DEBIO 025 IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN IN PREVIOUSLY NULL-RESPONDER GENOTYPE 1 HCV PATIENTS - (05/01/09)
     
  240. EASL: SAFETY AND ANTIVIRAL ACTIVITY OF SCH 900518 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2B TO NAIVE AND TREATMENT-EXPERIENCED HCV-1 INFECTED PATIENTS - (04/30/09)
     
  241. EASL: PegIntron Maintenance Therapy in Cirrhotic (METAVIR F4) HCV Patients Who Failed to Respond to Interferon/Ribavirin (IR) Therapy: Final Results of the EPIC3 Cirrhosis Maintenance Trial - (04/30/09)
     
  242. EASL: HCV SPRINT-1: Final Results SVR 24 NS3 Protease Inhibitor Boceprevir plus PegIFN alpha-2b/Ribavirin HCV 1 Treatment Naïve Patients - (04/30/09)
     
  243. EASL: Antiviral Activity and Safety of ITMN-191 (R7227) in Combination with Peginterferon alfa-2a and Ribavirin in Patients with Chronic Hepatitis C Virus - (04/29/09)
     
  244. EASL: Antiviral activity and safety of TMC435 combined with peginterferon a-2a and ribavirin in patients with genotype-1 hepatitis C infection who failed previous IFN-based therapy - (04/29/09)
     
  245. EASL: Antiviral Activity of Filibuvir in Combination with Pegylated Interferon Alfa-2a and Ribavirin for 28 Days in Treatment-Naive Patients Chronically Infected with HCV Genotype 1 - (04/29/09)
     
  246. EASL: Subgroup Analysis Confirms Efficacy, Safety of Sorafenib in Patients With Late-Stage Liver Cancer: Presented at EASL - (04/29/09)
     
  247. EASL: A FIRST CLINICAL TRIAL OF THERAPEUTIC VACCINATION USING NAKED DNA DELIVERED BY IN VIVO ELECTROPORATION SHOWS ANTIVIRAL EFFECTS IN PATIENTS WITH CHRONIC HEPATITIS C - (04/29/09)
     
  248. EASL: Safety, Tolerability, and Pharmacokinetics after Single and Multiple Doses of MK-3281 in Healthy Subjects - (04/28/09)
     
  249. EASL: MK-7009 Significantly Improves Rapid Viral Response (RVR) in Combination with Pegylated Interferon Alfa-2a and Ribavirinin Patients with Chronic Hepatitis C (CHC) Genotype 1 Infection - (04/28/09)
     
  250. EASL: Metabolic Syndrome Hikes Mortality in Hepatitis C - (04/28/09)
     
  251. EASL: Ground-Breaking Combination of 2 All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen (ITMN-191 protease + R7128 NRTI) - (04/28/09)
     
  252. EASL: FDA Regulations for HCV Drug Development - are they too Strict? - (04/28/09)
     
  253. EASL: Can Peginterferon and Ribavirin Be Eliminated from Therapy - (04/28/09)
     
  254. EASL: Roche and Pharmasset start phase IIb clinical trial of R7128 nucleoside polymerase inhibitor for chronic hepatitis C - (04/28/09)
     
  255. EASL: OPERA-1 trial (Study TMC435-C201): interim analysis of safety and antiviral activity of TMC435 in treatment-naïve genotype-1 HCV patients - (04/28/09)
     
  256. EASL: TELAPREVIR IN HEPATITIS C GENOTYPE-1-INFECTED PATIENTS WITH PRIOR NON-RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE TO PEGINTERFERON-ALFA-2A/B AND RIBAVIRIN THERAPY: SVR RESULTS OF THE PROVE3 STUDY - (04/28/09)
     
  257. EASL: Potent Antiviral Activity With A Nucleoside Polymerase (R7128) And Protease (R7227/ITMN-191) Inhibitor Combination in HCV Genotype 1: Initial Safety, Pharmacokinetics, And Virologic Results From INFORM-1 - (04/28/09)
     
  258. EASL: EASL Day 3 Saturday - (04/28/09)
     
  259. EASL: HCV Protease ITMN-191 + Peg/RBV for 14 Days - safety, antiviral activity - (04/28/09)
     
  260. EASL: SCH-900518 New Schering Protease Inhibitor Monotherapy & with Peg/RBV 7-14 days - (04/28/09)
     
  261. EASL: Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C - (04/28/09)
     
  262. EASL: Peg-Interferon lambda + Ribavirin 4 Weeks - (04/28/09)
     
  263. EASL: Telaprevir Effective for Genotype 2 But Not For Genotype 3 - (04/27/09)
     
  264. EASL: Maintenance Therapy: we don't know if it provides benefit - (04/27/09)
     
  265. EASL: HIV positive and HIV negative patients have similar survival rates following liver transplant - (04/27/09)
     
  266. EASL: Anadys shares plunge on hepatitis C drug ANA598 safety concerns - (04/27/09)
     
  267. EASL: Schering's protease boceprevir phase 2; Schering symposium - (04/27/09)
     
  268. EASL: Safety, pharmacokinetics and antiviral effect of BI 207127, a novel HCV RNA polymerase inhibitor, after 5 days' oral treatment in patients with chronic hepatitis C - (04/27/09)
     
  269. EASL: ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients - (04/24/09)
     
  270. EASL: Tibotec HCV Protease TMC435 I Treatment-Naives Genotype 1, Monotherapy & Combination with Peg/RBV - (04/24/09)
     
  271. EASL: New HCV Drugs II: Schering's protease boceprevir phase 2; Abbott/Enanta HCV Protease Inhibitors; Progenics PRO-206 HCV Entry Inhibitor - (04/24/09)
     
  272. EASL: Taribavirin vs Ribavirin - (04/24/09)
     
  273. EASL: New HCV Drugs Today at EASL 1st Day - (04/24/09)
     
  274. EASL: EASL New HCV Drugs - (04/23/09)
     
  275. EASL: EPIC Study Shows Maintenance Therapy Provides Benefits - (04/23/09)
     
  276. Low-Dose Naltrexone Eases Pain and Fatigue of Fibromyalgia - (04/22/09)
     
  277. Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-{alpha}2b - (04/22/09)
     
  278. New Gilead HCV Drug GS-9190 - (04/22/09)
     
  279. Celsion Receives Orphan Drug Designation for ThermoDox to Treat Primary Liver Cancer - (04/20/09)
     
  280. IDUs Risky Behavior: < 32% share syringes/63% have unprotected vaginal sex, CDC Study - (04/10/09)
     
  281. The cyclophilin inhibitor Debio 025 combined with PEG IFN2a significantly reduces viral load in treatment-naive hepatitis C patients: efficacy & safety - (04/09/09)
     
  282. AASLD Practice Guidelines: Diagnosis, management, and treatment of hepatitis C: An update, pdf attached - (04/06/09)
     
  283. HALT-C Patient Subgroups That Appear To Benefit From Maintenance Therapy - (04/06/09)
     
  284. Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses - (04/02/09)
     
  285. Treatment of HBV/HCV Coinfection: Releasing the Enemy Within - (04/02/09)
     
  286. Improved Virologic Response in Chronic Hepatitis C Genotype 4 Treated With Nitazoxanide, Peginterferon, and Ribavirin - (04/02/09)
     
  287. Nitazoxanide: Beyond Parasites Toward a Novel Agent for Hepatitis C - (04/02/09)
     
  288. EHDRW: Virologic Outcome After geno2pheno Versus Trofile: Controversy on Using Genotype to Predict Coreceptor Use Before Maraviroc - Written by Mark Mascolini (04/01/09)
     
  289. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV) - (04/01/09)
     
  290. ISHLVD: Screening for Acute Hepatitis C Virus Infection (AHCV) among At-Risk Patients in an HIV Clinic - (03/30/09)
     
  291. ISHLVD: TMC435 HCV Protease Inhibitor Safety/antiviral activity OPERA Study doses 25 & 75 mg once daily - (03/30/09)
     
  292. Racial Differences in Response to Interferon-Based Antiviral Therapy for Hepatitis C Virus Infection: A Hardwiring Issue? EDITORIAL COMMENTARY - (03/27/09)
     
  293. Early Changes in Hepatitis C Virus (HCV) Levels in Response to Peginterferon and Ribavirin Treatment in Patients with Chronic HCV Genotype 1 Infection - (03/27/09)
     
  294. Hep C in HIVers may cause rapid liver disease - (03/27/09)
     
  295. HALT-C in the final analysis: A molehill out of a mountain - does peginterferon maintenance therapy work? - (03/27/09)
     
  296. Vertex Telaprevir & VCH-222 Preentations at EASL April 2009 - (03/20/09)
     
  297. CROI: Effect of HIV Co-infection on the Outcome of Viral Cirrhosis Liver Transplant Candidates on the Waiting List at a Reference Center from 2001 to 2008 - (03/17/09)
     
  298. CROI: HCV Inflames the Brain in HIV Coinfected in Acute HCV - (03/17/09)
     
  299. CROI: 5-Year Survival of HCV/HIV-co-infected Liver Transplant Recipients in Spain: A Case/Control Study - (03/17/09)
     
  300. CROI: Interruption of ART and Changes in Hyaluronic Acid as Marker of Liver Fibrosis Progression in Strategies for Management of ART Viral Hepatitis-co-infected Participants and Matched Controls - (03/17/09)
     
  301. CROI: Hyaluronic Acid as a Prognostic Marker of Hepatic Coma and Liver-related Death in HIV/Viral Hepatitis Co-infected Patients - (03/17/09)
     
  302. FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C - (03/16/09)
     
  303. Bidding for HCV NNRTI ANA598 - (03/16/09)
     
  304. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients - "No patient had conclusive evidence of virologic relapse" - (03/11/09)
     
  305. In Pakistan 9 million with HCV, 5.6 million with HBV 9m suffering from hepatitis C in Pakistan, Senate told - (03/11/09)
     
  306. Human Genome Sciences Announces Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C - (03/11/09)
     
  307. HCV NNRTI ANA598 News Update: Anadys Keeps Surging, as Hepatitis C Drug Data Trickles In - (02/27/09)
     
  308. Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C - (02/27/09)
     
  309. ABBOTT AND ENANTA INITIATE PHASE 1 CLINICAL TRIAL ON ABT-450 HCV PROTEASE INHIBITOR - (02/27/09)
     
  310. Inhibitex Completes Phase I Clinical Trials for FV-100 and Selects Lead HCV Compounds for Advanced Preclinical Studies - (02/10/09)
     
  311. Hepatology 2009 Textbook Online by Mauss et al - (02/06/09)
     
  312. Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients - (01/28/09)
     
  313. Clinical Update - Debio 025 in Hepatitis C - Debiopharm starts phase IIb triple therapy study, a promising therapeutic avenue - (01/26/09)
     
  314. Sorafenib: A glimmer of hope for unresectable hepatocellular carcinoma? - (01/23/09)
     
  315. Complete cure of HBV-HDV co-infection after 24weeks of combination therapy with pegylated interferon and ribavirin in a patient co-infected with HBV/HCV/HDV/HIV - (01/22/09)
     
  316. AASLD: Antiviral Efficacy of the HCV RNA Polymerase Inhibitor ANA598 in the Chimpanzee Model of HCV Infection - (01/21/09)
     
  317. AASLD: Results of A Phase I Safety, Tolerability and Pharmacokinetic Study of ANA598, A Non-nucleoside NS5B Polymerase Inhibitor, in Healthy Volunteers - (01/21/09)
     
  318. AASLD: In Vitro Studies Demonstrate that Combinations of Antiviral Agents that Include HCV Polymerase Inhibitor ANA598 have the Potential to Overcome Viral Resistance - (01/20/09)
     
  319. Treatment of Fibromyalgia Syndrome With Antidepressants - (01/20/09)
     
  320. PEGASYS Proven Effective as Hepatitis C Treatment for Latino Patients - (01/15/09)
     
  321. Peginterferon Alfa-2a and Ribavirin in Latino and Non-Latino Whites with Hepatitis C: LATINO Study NEJM - (01/15/09)
     
  322. LATINO Study Comments by Jules Levin - (01/15/09)
     
  323. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans - (01/14/09)
     
  324. The Accelerating Pace of HCV Research: A Summary of the 15th International Symposium on Hepatitis C Virus and Related Viruses - (01/13/09)
     
  325. Bristol-Myers to Buy Rights to Hep C Drug Peg-Interferon lambda - (01/13/09)
     
  326. Bristol-Myers to Develop Hepatitis C Drug Peg-Interferon Lambda With ZymoGenetics - (01/13/09)
     
  327. InterMune Reports Results from Triple Combination Study of ITMN-191 - (01/13/09)
     
  328. Peg-Interferon Lambda Phase 1b in HCV+ Patients: safety, antiviral activity - (01/13/09)
     
  329. Telaprevir Phase 3 Studies Update - (01/12/09)
     
  330. Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C - (01/12/09)
     
  331. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients - (01/12/09)
     
  332. ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection - (01/08/09)
     
  333. Hepatitis C Drug From Anadys Shows Quick Virus-Killing Punch: potent antiviral activity displayed -2.5 log reduction in 72 hours - (01/08/09)
     
  334. New Therapies for Hepatitis C Virus Infection: REVIEW ARTICLE - (01/08/09)
     
  335. Influence of aminotransferase values on liver stiffness measurement: the case of HIV-infected patients with acute viral hepatitis B or C - (01/02/09)
     
  336. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre-Clinical NS5A Program in Hepatitis C to Presidio Pharmaceuticals - (12/30/08)
     
  337. Is there disease progression in patients who are hepatitis C virus antibody-positive and hepatitis C virus RNA-seronegative? - (12/22/08)
     
  338. Histological changes in HCV antibody-positive, HCV RNA-negative subjects suggest persistent virus infection - (12/22/08)
     
  339. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV - (12/19/08)
     
  340. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial - (12/19/08)
     
  341. Liver biopsy: The best, not the gold standard EDITORIAL vs surrogate markers - (12/19/08)
     
  342. AASLD: REVIEW OF SELECTED LIVER CANCER ABSTRACTS FROM THE AASLD MEETING IN SF 2008 FOR NATAP - written by Robert Gish MD and Catherine Frenette MD CPMC (12/19/08)
     
  343. Next-Generation HCV Protease Inhibitor SCH 900518 - (12/16/08)
     
  344. Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C - (12/12/08)
     
  345. AASLD: Evaluation of a 4 Week Lead-in Phase with Nitazoxanide (NTZ) prior to Peginterferon (PegIFN) plus NTZ for Treatment of Chronic Hepatitis C: Final Report - (12/10/08)
     
  346. Pegasys EMEA Approval for Retreatment for 72 Weeks in Nonresponders - (12/09/08)
     
  347. HCV Research Done Poorly and Misreported Results in NEJM on Maintenance Therapy in HALT-C Study - (12/09/08)
     
  348. HUMAN GENOME SCIENCES ANNOUNCES ALBUFERON MEETS PRIMARY ENDPOINT IN PHASE 3 TRIAL IN CHRONIC HEPATITIS C - (12/09/08)
     
  349. ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection - (12/03/08)
     
  350. AASLD: Treatment-Related Anemia Is Associated With Higher SVR Rates Among Persons Treated With Peginterferon (PEG)/Ribavirin (RBV): Results From the IDEAL Study - (12/01/08)
     
  351. AASLD: A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of the NS3/4A Protease Inhibitor ITMN-191 in Healthy Subjects - (12/01/08)
     
  352. AASLD: Pharmacokinetic-Pharmacodynamic (PK-PD) Relationships for ITMN-191 in a Phase 1 Multiple Ascending Dose (MAD) Trial in Patients with Genotype 1 Chronic Hepatitis C Infection - (12/01/08)
     
  353. AASLD: In Vitro activity and pharmacological properties of IDX375, a novel HCV non-nucleoside inhibitor - (12/01/08)
     
  354. AASLD: A 72-week treatment duration with peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) has a favorable risk:benefit ratio in non-responders to pegylated interferon alfa-2b (12KD) plus ribavirin: findings of the multinational REPEAT study - (11/26/08)
     
  355. AASLD: Probability of virologic relapse during follow-up varies with the rapidity of the on-treatment virologic response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin - (11/26/08)
     
  356. AASLD: Prediction of SVR in HCV genotype 1 patients co-infected with HIV based on virologic responses at week 4 and 12 of treatment with peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS): Retrospective analysis of APRICOT - (11/26/08)
     
  357. AASLD: Phase 2 Study of Telaprevir Administered q8h or q12h with Peginterferon Alfa-2a or Alfa-2b and Ribavirin in Treatment-naïve Patients with Genotype 1 Hepatitis C: Week 12 Interim Results - (11/26/08)
     
  358. AASLD: Randomized study comparing Peginterferon alfa2a plus Ribavirin and Peginterferon alfa2b plus Ribavirin in naïve patients with chronic hepatitis C: Final results of the MiIan Safety and Tolerability (MIST) Study - (11/24/08)
     
  359. AASLD: Metformin with Peginterferon Alfa-2a and Ribavirin in the Treatment of Naive Genotype 1 Chronic Hepatitis C Patients with Insulin Resistance (TRIC-1): Final Results of a Randomized and Double-Blinded Trial - (11/21/08)
     
  360. AASLD: SVR in African American Patients: Results of the IDEAL Study (Individualized Dosing Efficacy vs Flat Dosing to Assess OptimaL Pegylated Interferon Therapy) - (11/21/08)
     
  361. AASLD: A Study of Telaprevir Combined with Peginterferon Alfa-2a and Ribavirin in Patients with Well-documented Non-response or Relapse After Previous Peginterferon Alfa-2a and Ribavirin Treatment: Interim Analysis - (11/20/08)
     
  362. Albuferon Pulmonary Adverse Events - (11/18/08)
     
  363. Hepatitis C Therapeutic DNA Vaccine Delivered by Inovio Biomedical's Electroporation Technology Reduces Viral Load by Up to 99.7% Clinical Data Presented at Annual Scientific Meeting of the American Association for the Study of Liver Diseases - (11/18/08)
     
  364. AASLD: Safety and antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in combination therapy with peginterferon alfa-2a (P) and ribavirin (R) for 28 days in P+R treatment-experienced patients with chronic hepatitis C genotype 1 infection - (11/14/08)
     
  365. AASLD: Safety, Tolerability, and Pharmacokinetic Data Following Single- and Multiple-Dose Administration of MK-7009, a Hepatitis C Virus Non-structural 3/4a Protease Inhibitor, to Healthy Male Subjects (1910) - (11/14/08)
     
  366. AASLD: Combination of the NS3/4A Protease Inhibitor ITMN-191 (R7227) with the Active Moiety of the NS5B Inhibitors R1626 or R7128 Enhances Replicon Clearance and Reduces the Emergence of Drug Resistant Variants - (11/12/08)
     
  367. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C - (11/12/08)
     
  368. AASLD: Safety, Tolerability, and Pharmacokinetic Data Following Single- and Multiple-Dose Administration of MK-7009, a Hepatitis C Virus Non-structural 3/4a Protease Inhibitor, to Healthy Male Subjects (1910) - (11/11/08)
     
  369. AASLD: Pharmacokinetics of once-daily regimens of the novel HCV NS3/4A-protease inhibitor TMC435350, with and without peg-IFN and ribavirin, in HCV-infected individuals - (11/11/08)
     
  370. AASLD: Inhibitory activity of TMC435350 on HCV NS3/4A proteases from genotypes 1 to 6 - (11/11/08)
     
  371. AASLD: Potent Antiviral Response To The HCV Nucleoside Polymerase Inhibitor R7128 For 28 Days With Peg-IFN And Ribavirin: Subanalysis by Race/Ethnicity, Weight and HCV Genotype - (11/07/08)
     
  372. AASLD: New HCV Drugs at AASLD: Vertex is Focus at Hepatitis C Meeting - (11/07/08)
     
  373. AASLD: Antiviral Activity Of The HCV Nucleoside Polymerase Inhibitor R7128 In HCV Genotype 2 and 3 Prior Non-Responders: Results Of R7128 1500mg BID With PEG-IFN And Ribavirin For 28 Days - (11/07/08)
     
  374. AASLD: Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers Phase I Clinical Data and Additional Preclinical Results for Non-Nucleoside HCV Polymerase Inhibitor Being Presented at AASLD - (11/07/08)
     
  375. AASLD: Antiviral Activity of the HCV Polymerase Inhibitor PF-00868554 Administered as Monotherapy in HCV Genotype 1 Infected Subjects - (11/07/08)
     
  376. AASLD: Telaprevir in Combination with Peginterferon-a-2a With or Without Ribavirin in the Treatment of Chronic Hepatitis C Treatment-Naive Genotype 1: Final Results of the PROVE2 Study (conducted in Europe) - (11/06/08)
     
  377. AASLD: A Phase 2b Study of Telaprevir with Peginterferon-Alfa-2a and Ribavirin in Hepatitis C Genotype 1 Null and Partial Responders and Relapsers Following a Prior Course of Peginterferon-Alfa-2a/b and Ribavirin Therapy: PROVE3 Interim Results - (11/06/08)
     
  378. AASLD: Safety and antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in treatment-naive patients with chronic hepatitis C genotype 1 infection given as monotherapy and in combination with peginterferon alfa-2a (P) and ribavirin (R) - (11/06/08)
     
  379. AASLD: Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Patients with the NS3/4A Protease Inhibitor ITMN-191 Leads to Rapid Reductions in Plasma HCV RNA: Results of a Phase 1b Multiple Ascending Dose (MAD) Study - (11/05/08)
     
  380. AASLD: Intravenous silibinin for treatment of nonresponders to peginterferon/ribavirin therapy in chronic hepatitis C - (11/05/08)
     
  381. Bristol-Myers Squibb Foundation to Award $1.4 Million in Grants to Bridge Gaps in Hepatitis C Awareness, Prevention and Care in Asia - (11/04/08)
     
  382. AASLD: Safety and antiviral activity of TMC435350 in treatment-naive genotype 1 HCV-infected patients - (11/04/08)
     
  383. AASLD: Safety, Tolerability and Antiviral Activity of MK-7009, a Novel Inhibitor of the Hepatitis C Virus NS3/4A Protease, in Patients with Chronic HCV Genotype 1 Infection - (11/04/08)
     
  384. AASLD: GlobeImmune Hepatitis C Therapeutic Vaccine, GI-5005, Doubles Viral Clearance And Increases RVR Rates In Phase 2 Clinical Trial - (11/04/08)
     
  385. AASLD: Boceprevir Plus Peginterferon alfa-2b/Ribavirin for Treatment of Genotype 1 Chronic Hepatitis C in Previously Untreated Patients: Interim Results from the HCV SPRINT-1 Study - (11/04/08)
     
  386. AASLD: BMS-790052 is a First-in-class Potent Hepatitis C Virus (HCV) NS5A Inhibitor for Patients with Chronic HCV Infection: Results from a Proof-of-concept Study - (11/04/08)
     
  387. AASLD: An On-going Outbreak of Acute HCV in HIV-infected Men in New York City: Rates of Spontaneous Clearance, Treatment Responses, and Liver Fibrosis - (11/3/08)
     
  388. AASLD: New Clinical Data Support Broad Profile for Telaprevir in Patients with Genotype 1 Hepatitis C Virus (HCV) Infection - (11/3/08)
     
  389. AASLD: Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients - (11/3/08)
     
  390. AASLD: TIBOTEC PRESENTS INTERIM FINDINGS FOR TMC435, AN INVESTIGATIONAL GENOTYPE 1 HEPATITIS C TREATMENT, AT THE AASLD LIVER MEETING 2008 - (11/3/08)
     
  391. AASLD: GILEAD ANNOUNCES TWO-YEAR DATA FROM PIVOTAL PHASE III STUDIES EVALUATING VIREAD FOR CHRONIC HEPATITIS B - (11/3/08)
     
  392. GSK boosts HCV presence with Genelabs purchase - (10/31/08)
     
  393. Roche Receives FDA Approval for Hepatitis C Viral Load Test on Its Fully Automated Real-Time PCR Platform Improved laboratory efficiencies and standardization to personalize patient care - (10/31/08)
     
  394. Roche HCV Drug R1626 Terminated - (10/21/08)
     
  395. Validation of a Hepatitis C Screening Tool in Primary Care - (10/20/08)
     
  396. Tibotec Begins Enrollment for Phase III Study of Telaprevir, an Investigational Agent, in HCV Patients Who Failed Prior Treatment - (10/15/08)
     
  397. New BMS HCV NS5A Inhibitor: From Screen Hit to Clinic - (10/14/08)
     
  398. Hepatocellular carcinoma in long-term sustained virological responders following antiviral combination therapy for chronic hepatitis C - (10/10/08)
     
  399. Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin - (10/10/08)
     
  400. Treatment of the hepatitis B virus and hepatitis C virus co-infection: Still a challenge for the hepatologist - (10/10/08)
     
  401. High relapse rate seen at week 72 for patients treated with R1626 combination therapy - (10/09/08)
     
  402. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: Randomized study of higher doses of peginterferon a-2a and ribavirin - (10/09/08)
     
  403. Fatigue Associated with Degree of Fibrosis: fatigue level may predict severity of fibrosis - (09/26/08)
     
  404. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C - (09/23/08)
     
  405. Subclinical Glucose Abnormalities & Undiagnosed Diabetes Noted in HCV+ - (09/18/08)
     
  406. Inaugural Conference of the BHIVA Hepatitis Working Group (BHWG) - Oct 8 2008 London - (09/18/08)
     
  407. GENOVAC starts a project to develop blocking antibodies for the therapy of hepatitis C infections (AntiHepaC) - (09/18/08)
     
  408. R7128, a prodrug of PSI-6130 - (09/18/08)
     
  409. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders - (09/12/08)
     
  410. Intranasal Transmission of Hepatitis C Virus: Virological and Clinical Evidence - (09/12/08)
     
  411. Silibinin Is a Potent Antiviral Agent in Patients With Chronic HCV not Responding to Pegylated Interferon/Ribavirin Therapy - (09/08/08)
     
  412. Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors (Vertex's telaprevir) in Treatment-Naive Subjects - (09/04/08)
     
  413. HCV Coinfection Increases Risk for HIV-Related Kidney Disease - (08/29/08)
     
  414. Insulin Resistance Among Patients With Chronic Hepatitis C: Etiology and Impact on Treatment - (08/27/08)
     
  415. Vertex Pharmaceuticals to Start Phase 3 'REALIZE' Trial with Telaprevir in Treatment-Failure HCV Patients - (08/20/08)
     
  416. IAS: HCV Increased Risk for MI and Stroke in HIV+, Study Reported at IAC - (08/13/08) -
     
  417. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C - (08/05/08)
     
  418. Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients - (08/05/08)
     
  419. Erythropoiesis Stimulating Agents (ESAs) - Epoetin alfa (marketed as Procrit, Epogen), Darbepoetin alfa (marketed as Aranesp) - (08/04/08)
     
  420. Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C - (08/04/08)
     
  421. Liver Fibrosis (accelerated) during an Outbreak of Acute Hepatitis C Virus Infection in HIV-Infected Men: A Prospective Cohort Study - (08/04/08)
     
  422. HCV Protease Vertex/Tibotec Telaprevir Update - (08/01/08)
     
  423. Liver Fibrosis during an Outbreak of Acute Hepatitis C Virus Infection in HIV-Infected Men: A Prospective Cohort Study - (07/30/08)
     
  424. Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort - (07/29/08)
     
  425. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic: several new HCV drugs in development - (07/29/08)
     
  426. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis (increased 13% risk): A systematic review - (07/02/08)
     
  427. Role of week 4-rapid virological response (RVR) in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals - (06/30/08)
     
  428. Two New HCV Drugs - NS5b and NS4b NNRTI Inhibitors- in Early Research by Genelabs/Novartis - (06/26/08)
     
  429. Vertex CEO preparing for '09 early telaprevir hepatitis C drug launch - (06/20/08)
     
  430. Vertex Reports 52% SVR 12 Rate for a 24-week Telaprevir-based Regimen in Genotype 1 Hepatitis C Patients Who Failed Prior Treatment - (06/10/08)
     
  431. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus - (06/02/08)
     
  432. Market uptake of new antiviral drugs (Peginterferon + Ribavirin) for the treatment of hepatitis C - (06/02/08)
     
  433. A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3 - (06/02/08)
     
  434. Randomized comparison of 12 or 24 weeks of peginterferon a-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection - (06/02/08)
     
  435. Santaris Pharma Begins Human Clinical Testing of the World's First Medicine Targeted at a Human microRNA - (05/29/08)
     
  436. DDW: Alcohol Abuse & Dependence Has Big Impact on Cirrhosis in HIV/HCV Coinfection - (05/28/08)
     
  437. DDW: Despite Mucosal CD4+ T Cell Depletion, the Prevalence of GI Symptoms Is Low During Acute and Early HIV-1 Infection - (05/28/08)
     
  438. Pioglitazone in chronic hepatitis C with Insulin Resistance not responding to pegylated interferon-β and ribavirin - (05/27/08)
     
  439. Liver and heart: A new link? - ALT Predicts Heart Disease - (05/27/08)
     
  440. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-β2b and ribavirin in patients with HBV/HCV co-infection - (05/27/08)
     
  441. Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients EDITORIAL - (05/27/08)
     
  442. Cerebral immune activation in chronic hepatitis C infection: A magnetic resonance spectroscopy study - (05/27/08)
     
  443. Schering starts hepatitis C trials, Vertex falls - (05/27/08)
     
  444. Beach Boys Guitarist Cured of HCV with Peg/RBV - (05/27/08)
     
  445. Discovery of TMC435350, HCV Protease Inhibitor - (05/27/08)
     
  446. DDW: Effects of Eltrombopag On Thrombopietin Levels During Antiviral Therapy in HCV Patients with Cirrhosis - (05/21/08)
     
  447. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment - (05/21/08)
     
  448. DDW: The Role of Cholesterol On Sustained Virological Response (SVR) in the Treatment of Genotype-1 Infected Hepatitis C (cHC) Patients with Peginterferon Alfa-2a (PEG) and Ribavirin (RBV) - (05/21/08)
     
  449. DDW: Telaprevir, HCV Protease Inhibitor: results from PROVE1 and PROVE2 Studies at DDW - (05/20/08)
     
  450. DDW: A Dramatic Alteration in the Cholesterol Metabolism in An HCV Infected-Liver: the Implications for HCV Infection and Treatment - (05/20/08)
     
  451. DDW: Utility of Serum Biomarker Profiles in Predicting the Treatment Outcome in Chronic Hepatitis C Virus Patients - (05/20/08)
     
  452. DDW: Very Early Viral Response to Treatment of Hepatitis C Virus (HCV) with Pegylated Interferon and Ribavirin: the First 24 Hours - (05/20/08)
     
  453. DDW: A Randomized Trial of Standard vs. Dose-Escalation Dosing of Ribavirin in Combination Therapy for Chronic Hepatitis C Patients with Genotype 1 and High Viral Load - (05/20/08)
     
  454. DDW: Metabolic Factors and Inflammatory Changes Are Responsible for Increased Gamma-Glutamyltranspeptidase Level in Chronic Hepatitis C - (05/20/08)
     
  455. DDW: Effect of Nicotine On Innate Antiviral Pathways and HCV Replication - (05/20/08)
     
  456. DDW: African-American Peg/RBV Response May Be Genetically Impaired: Polymorphism in the Human MHC and the Early Viral Decline During Treatment of HCV - (05/20/08)
     
  457. DDW: Explosion Disrupts Digestive Disease Week Meeting - (05/20/08)
     
  458. DDW: Racial/Ethnic Minorities with Chronic Hepatitis C Virus Infection Have More Severe Fatigue Than White Patients with Chronic Hepatitis C Virus Infection - (05/20/08)
     
  459. DDW: A Dramatic Alteration in the Cholesterol Metabolism in An HCV Infected-Liver: the Implications for HCV Infection and Treatment - (05/20/08)
     
  460. DDW: African-American Peg/RBV Response May Be Genetically Impaired: Polymorphism in the Human MHC and the Early Viral Decline During Treatment of HCV - (05/20/08)
     
  461. DDW: Variants in Interferon-Α Pathway Genes and Response to Treatment of Chronic Hepatitis C - (05/20/08)
     
  462. DDW: Response to Therapy with Pegylated Interferon and Ribavirin in Hispanics with Hepatitis C Compared to Non-Hispanic Whites - (05/20/08)
     
  463. New theory suggests how hepatitis C may cause rare immune disease, mixed cryoglobulinemia - (05/19/08)
     
  464. New York State Proposes Hepatitis-Doctor Safety-Oversight Law - (05/19/08)
     
  465. A dozen good ideas to battle hepatitis Editorial - (05/19/08)
     
  466. Latinos and Chronic Hepatitis C: A Singular Population - (05/19/08)
     
  467. Correlation of FIBROSpect II With Histologic and Morphometric Evaluation of Liver Fibrosis in Chronic Hepatitis C - (05/19/08)
     
  468. Considerations Regarding the Present and Future Roles of Colonoscopy in Colorectal Cancer Prevention - (05/19/08)
     
  469. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C - (05/19/08)
     
  470. World Hepatitis Alliance calls for urgent action on epidemic - (05/19/08)
     
  471. EASL: Virologic Responses to Peginterferon Alfa-2a/Ribavirin in Treatment-Naive Latino vs Non-Latino Whites Infected With HCV Genotype 1: The LATINO Study - (05/19/08)
     
  472. EASL: Comparing Pegasys and PegIntron at EASL 2008 Milan - (05/16/08)
     
  473. EASL: Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication... - (05/16/08)
     
  474. EASL: Studies of the Potential for Resistance to Nitazoxanide or Tizoxanide in HCV Replicon-Containing Cell Lines - (05/16/08)
     
  475. EASL: RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED TRIAL OF NITAZOXANIDE IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 4 - (05/16/08)
     
  476. EASL: EVALUATION OF A 4 WEEK LEAD-IN PHASE WITH NITAZOXANIDE PRIOR TO NITAZOXANIDE+PEGINTERFERON IN TREATING CHRONIC HEPATITIS C - (05/16/08)
     
  477. EASL: Randomized Controlled Trial of Nitazoxanide-Peginterferon-Ribavirin, Nitazoxanide-Peginterferon and Peginterferon-Ribavirin in the Treatment of Patients with Chronic Hepatitis C Genotype 4 - (05/16/08)
     
  478. EASL: Estimating the Likelihood of Sustained Virological Response in Chronic Hepatitis C (CHC) Therapy - (05/16/08)
     
  479. EASL: R1626* (Prodrug of R1479) Demonstrates Potent Antiviral Activity Across HCV Genotypes 1-6 In Vitro - (05/16/08)
     
  480. EASL: Regression of Cirrhosis Occurs & Prevents Death/Events - (05/16/08)
     
  481. EASL: SVR Eradicates HCV - (05/16/08)
     
  482. EASL: SVR Can Prevent HCC & Other Complications - (05/16/08)
     
  483. EASL: SVR Reversed Cirrhosis in 21% - (05/16/08)
     
  484. EASL: Locteron Viral Kinetics and Anti-Viral Activity during Treatment with a Controlled-Release Interferon Alfa-2b in Genotype 1 Chronic Hepatitis C Patients - (05/06/08)
     
  485. EASL: POTENT ANTIVIRAL ACTIVITY OF THE HCV NUCLEOSIDE POLYMERASE INHIBITOR, R7128, IN COMBINATION WITH PEG-IFN a-2a AND RIBAVIRIN - (05/06/08)
     
  486. EASL: High end-of-treatment response (84%) after 4 weeks of R1626, peginterferon alfa-2a (40KD) and ribavirin followed by a further 44 weeks of peginterferon alfa-2a and ribavirin - (05/06/08)
     
  487. EASL: RVR & Ribavirin Dose Predict SVR - (05/05/08)
     
  488. EASL: Biolex Therapeutics Researchers Present Locteron (controlled-release interferon alpha) Phase 2a Hepatitis C Trial Results at EASL Conference - (05/05/08)
     
  489. EASL: EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2a OR -2b PLUS RIBAVIRIN IN THE ROUTINE DAILY TREATMENT OF CHRONIC HEPATITIS C PATIENTS IN GERMANY: THE PRACTICE STUDY - (05/05/08)
     
  490. EASL: Several Key Pegasys Studies at EASL 2008 - (05/05/08)
     
  491. EASL: Association of Pre-Treatment and On-Treatment Factors With Null Response in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin - (05/05/08)
     
  492. EASL: Sustained Virologic Response After Peginterferon alfa-2b and Ribavirin Treatment Predicts 99% Long-term Clearance of HCV at 5-Year Follow-up - (05/05/08)
     
  493. EASL: Platelet Count (and fibrosis stage) Predicts Sustained Viral Response (SVR) in the Re-Treatment of Previous Interferon/Ribavirin (I/R) Non-Responders (NR): Results from the EPIC3 Program - (05/05/08)
     
  494. EASL: Treatment of Chronic Hepatitis C with Telaprevir (TVR) in Combination with Peginterferon Alfa-2a with or without Ribavirin: Interim Results of the PROVE2 Study - (05/02/08)
     
  495. EASL: SILIBININ IS A POTENT ANTIVIRAL AGENT IN CHRONIC HEPATITIS C NOT RESPONDING TO ANTIVIRAL COMBINATION THERAPY - (05/02/08)
     
  496. EASL: Results of a Safety, Tolerability and Pharmacokinetic Phase I Study of VCH-916, a Novel Polymerase Inhibitor for HCV, Following Single Ascending Doses in Healthy Volunteers - (05/02/08)
     
  497. EASL: Preclinical Pharmacokinetic and ADME Characterization of VCH-916, a Novel Non-Nuclesoside HCV NS5B Polymerase Inhibitor - (05/02/08)
     
  498. EASL: Genotypic analysis of HCV NS5B variants selected from patients treated with VCH-759, and Viral Load Declines - (05/02/08)
     
  499. EASL: Important Progress Toward Control of Hepatitis B and C - (05/01/08)
     
  500. EASL: Incidence Rates and Risk Factors Associated with Hepatocellular Carcinoma (HCC) in Patients with Advanced Liver Disease Due to Hepatitis C: Results of the HALTC Trial; Is the HALT-C Study Design Flawed??? - (05/01/08)
     
  501. EASL: Interim Results from HCV SPRINT-1: RVR/EVR from Phase 2 Study of Boceprevir Plus Peginterferon alfa-2b/Ribavirin in Treatment-Naive Subjects with Genotype-1 CHC - (04/30/08)
     
  502. EASL: DEVELOPMENT OF NOVEL HYPERGLYGOSYLATED TYPE 1 INTERFERONS: A STRATEGY TO IMPROVE PK PERFORMANCE WITHOUT LOSS OF BIOLOGICAL POTENCY - (04/30/08)
     
  503. EASL: New HCV Drugs Panel Discussion at EASL 2008 - (04/30/08)
     
  504. EASL: Boceprevir (NS3 Protease Inhibitor) Combination Therapy in Non Responders: Phase II Dose Finding Study - (04/30/08)
     
  505. EASL: Sustained Viral Response Is Dependent On Baseline Characteristics In The Re-treatment Of Previous Interferon/Ribavirin Non-responders: Final Results From The EPIC3 Program - (04/30/08)
     
  506. EASL: Romark Announces Presentation of New Data For Nitazoxanide in Chronic Hepatitis C at EASL 2008 - (04/29/08)
     
  507. EASL: Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C - (04/28/08)
     
  508. EASL: Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study - (04/28/08)
     
  509. EASL: Potent Antiviral Activity of 2nd Generation HCV Nucleotide Inhibitors, IDX102 and IDX184, in HCV-infected Chimps - (04/28/08)
     
  510. EASL: In Vitro Activity and Pharmacologic Properties of Two Novel Series of HCV Protease Inhibitors - (04/28/08)
     
  511. EASL: HALT-C Study Design Flawed - (04/28/08)
     
  512. EASL: Efficacy and safety of increasing doses of the cyclophilin inhibitor Debio 025 in combination with pegylated interferon alpha-2a in treatment naive chronic HCV patients - (04/28/08)
     
  513. EASL: Peginterferon Alfa-2a (Pegasys) plus Ribavirin versus Peginterferon alfa-2b (Pegintron) Plus Ribavirin in Naive Patients with Chronic HHCV Infection: Results of a Prospective Randomized Trial - (04/28/08)
     
  514. EASL: Final Results of the Phase IIIb IDEAL Study (Individualized Dosing Efficacy vs. Flat Dosing to Assess OptimaL PegInterferon Therapy) - (04/28/08)
     
  515. EASL: ONCE-DAILY REGIMENS OF THE HCV NS3/4A-PROTEASE INHIBITOR TMC435350 ARE PREDICTED TO PROVIDE THERAPEUTIC EXPOSURE IN PLASMA AND LIVER - (04/25/08)
     
  516. EASL: Safety of the HCV Protease Inhibitor TMC435350 in Healthy Volunteers and Safety and Activity in Chronic Hepatitis C Infected Individuals: A Phase I Study - (04/25/08)
     
  517. EASL: HCV Protease Inhibitor Telaprevir, PROVE1 Study: final results of a phase 2 study with peginterferon plus ribaviron in treatment-naive patients with hepatitis C - (04/25/08)
     
  518. EASL: A Study of Telaprevir (TVR) with Peginterferon Alfa-2a (P) and Ribavirin (R) in Subjects with Well-Documented Prior PR Null Response, Non-Response or Relapse: Preliminary Results - (04/25/08)
     
  519. EASL: Study shows positive findings in treating patients with advanced hepatitis C - (04/25/08)
     
  520. EASL: COLCHICINE VERSUS PEG-INTERFERON ALFA 2B LONG TERM THERAPY: RESULTS OF THE 4 YEAR COPILOT TRIAL - (04/25/08)
     
  521. EASL: FACTORS PREDICTIVE OF RELAPSE IN GENOTYPE 2 AND 3 PTS TREATED FOR 12 WEEKS WITH PEGIFN ALFA 2B AND WEIGHT BASED RIBAVIRIN COMBINATION - (04/25/08)
     
  522. EASL: RIBAVIRIN CONCENTRATION AT WEEK FOUR IS AN INDEPENDEND PREDICTOR FOR SUSTAINED VIROLOGICAL RESPONSE AFTER TREATMENT OF HEPATITIS C GENOTYPE 2/3 (NORDYNAMIC TRIAL) - (04/25/08)
     
  523. EASL: Vertex Announces Positive Interim Results with Telaprevir-based Therapy in Genotype 1 Chronic Hepatitis C Patients who Failed to Achieve SVR with Previous Pegylated Interferon & Ribavirin Treatment - (04/24/08)
     
  524. Telaprevir-Based PROVE Studies Show Significantly Higher SVR Rates in Treatment-Naive Genotype 1 Hepatitis C Patients in Half the Time of Current Treatments - (04/24/08)
     
  525. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results - (04/23/08)
     
  526. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update - (04/23/08)
     
  527. High Prevalence of Hepatitis C Virus Infection Among Immigrants From the Former Soviet Union in the New York City Metropolitan Area: Results of a Community-Based Screening Program - (04/22/08)
     
  528. Vertex Telaprevir HCV Protease Inhibitor Could Be A Winner; 2.5 million untreated/undiagnosed - (04/21/08)
     
  529. Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-Analysis - (04/21/08)
     
  530. HCV & increased risk non-Hodgkin's Lymphoma: Hepatitis C and Non-Hodgkin Lymphoma Among 4784 Cases and 6269 Controls From the International Lymphoma Epidemiology Consortium - (04/21/08)
     
  531. Hepatic steatosis in HIV/HCV co-infected patients: Correlates, efficacy and outcomes of anti-HCV therapy: A paired liver biopsy study - (04/21/08)
     
  532. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 - (04/18/08)
     
  533. Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients; And New HCV Drugs in development - (04/17/08)
     
  534. ViroPharma, Wyeth stop development of hepatitus C drug HCV-796 - (04/17/08)
     
  535. How does interferon inhibit HCV cell entry? Commentaries - (04/16/08)
     
  536. Targeting siRNA to arrest fibrosis - (04/16/08)
     
  537. Fluvastatin Inhibits Hepatitis C Replication in Humans- But Not Much - (04/16/08)
     
  538. Hepatitis C : Identification Of A Protein That Inhibits The Virus - (04/15/08)
     
  539. Building a liver disease policy in the European Union - (04/04/08)
     
  540. ALT Predicts Mortality & General Health - (04/04/08)
     
  541. Positive New Info on HCV Protease Inhibitor ITMN-191 - (04/02/08)
     
  542. New HCV Protease Inhibitor Telaprevir: 80% of Treatment-Experienced Patients Achieve Early Viral Response - (04/02/08)
     
  543. Hepatitis C cases in New York expected to soar in a decade; 1 in 24 New Yorkers have hepatitis C: 340,000 in NYS - (03/31/08)
     
  544. FDA Approves Label Revisions Recommending New Robetol (ribavirin) Weight-Based Dosing Regimen: PEGINTRON PLUS WEIGHT-BASED REBETOL (ribavirin) RESULTED IN HIGHER SVR THAN FLAT DOSING; LOW RELAPSE RATES IN PATIENTS WITH CHRONIC HEPATITIS C. Schering Plough press release - (03/28/08)
     
  545. New HCV Therapy Approach - Nature Publishes Study by Santaris Pharma Scientists and Collaborators: LNA-Mediated MicroRNA Silencing in Non-Human Primates - (03/28/08)
     
  546. U.S. hepatitis C soars in those over 45 - (03/26/08)
     
  547. HCV Death Rates 50% Underestimated - (03/26/08)
     
  548. UNOS Liver Transplant Waiting List: Is it a Scandal?? - (03/24/08)
     
  549. HCV Therapy: TT-033, novel RNA interference product Oncolys and Tacere partner in hepatitis C drug development - (03/17/08)
     
  550. HIV Proteins Accelerate Liver Disease; HIV Increases HCV Replication in a TGF-ß1-Dependent Manner - (03/14/08)
     
  551. CROI: Hepatitis C Viremia following Sustained Virological Response to Pegylated Interferon and Ribavarin in HIV+ Men Who Have Sex with Men-Re-infection or Late Relapse? (03/13/08)
     
  552. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus - (03/12/08)
     
  553. Worse Survival & HCV Recurrence in Coinfected After Transplantation - (03/12/08)
     
  554. Glucose >100 mg/dl Reduces Interferon/RBV SVR - (03/10/08)
     
  555. PBMC Not A Reservoir for HCV for Patients Who Clear HCV RNA, Study Reports - (03/07/08)
     
  556. CROI: Liver histology and hepatic mitochondrial function in HIV-1-infected patients on antiretroviral therapy with chronic transaminase elevation - (03/07/08)
     
  557. Changing trends in hepatitis C-related mortality in the United States, 1995-2004 - (03/06/08)
     
  558. FDA Grants Priority Review to GSKs ITP Drug Promacta: the drug increases platelet counts; phase III studies for use in HCV are still ongoing - (03/03/08)
     
  559. Team Identifies Human Antibodies that Prevent Hepatitis C Virus Infection in Mouse Model - (02/28/08)
     
  560. HCV May Directly Cause Insulin resistance - (02/28/08)
     
  561. CROI: On-treatment responses at weeks 4 and 12 can be used to predict sustained virologic response rates in HIV HCV co-infected patients treated with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) - (02/22/08)
     
  562. CROI: Week 4 or 12 Response to PegIFN Predicts Sustained Response With HCV/HIV - Written by Mark Mascolini (02/28/08)
     
  563. The way forward in HCV treatment - finding the right path: New HCV Drugs, resistance - (02/27/08)
     
  564. Nothing new in anaemia drug EPO meta-analysis, say Amgen and J&J - (02/27/08)
     
  565. Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C - (02/22/08)
     
  566. Proteomic profiling shown more accurate than traditional biomarkers in identifying liver cancer - (02/20/08)
     
  567. Influence of Cannabis Use on Severity of Hepatitis C Disease - (01/29/08)
     
  568. Treatment of Hepatitis C Reduces Incidence of Non-Hodgkin's Lymphoma - (01/23/08)
     
  569. Vertex Pharmaceuticals to Begin Phase 3 Development of Telaprevir, Investigational Hepatitis C Protease Inhibitor - (01/23/08)
     
  570. Roche responds to announcement of 'IDEAL' hepatitis C trial results - (01/14/08)
     
  571. SCHERING-PLOUGH REPORTS TOP-LINE RESULTS OF THE IDEAL STUDY First Large Study Comparing Leading Hepatitis C Therapies Shows Similar Sustained Response Rates; Fewer Patients Relapsed Following PEGINTRON Combination Therapy - (01/14/08)
     
  572. IDEAL Study COMMENTARY- Doug Dieterich MD A Healthy Dose of Curiosity Clinical trial results require careful interpretation - (01/14/08)
     
  573. Stem cell therapy for chronic liver disease-choosing the right tools for the job Commentaries - (01/14/08)
     
  574. InterMune Announces Continuing Progress on HCV Protease Inhibitor ITMN-191 (R7227) - (01/08/08)
     
  575. Pfizer/Benitec to develop Hepatitis C drug - (01/08/08)
     
  576. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3 - (01/07/08)
     
  577. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C - (01/07/08)
     
  578. Genetic Variation May Double Risk of Liver Cancer - (01/04/08)
     
  579. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial - (01/03/08)
     
  580. Genetic Variation May Double Risk of Liver Cancer - (01/02/08)
     
  581. HCV Coinfection Problem in India, Despite HAART - (12/27/07)
     
  582. HCV Coinfection Biggest Problem in India - (12/27/07)
     
  583. GSK files eltrombopag for chronic ITP (thrombocytopenia) with the FDA - (12/21/07)
     
  584. Valeant Pharmaceuticals Sells Hep-C Drug Infergen to Three Rivers Pharmaceuticals, LLC for $91 Million - (12/21/07)
     
  585. GB Virus C Reduced HCV-Liver Disease in HIV/HCV Coinfected - (12/18/07)
     
  586. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis - (12/12/07)
     
  587. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART - (12/12/07)
     
  588. Liver cancer set to soar in UK - (12/04/07)
     
  589. AASLD: Multiple dose safety and pharmacokinetic study of bavituximab in patients with chronic hepatitis C virus (HCV) infection - (11/30/07)
     
  590. Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C - (11/29/07)
     
  591. Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura - (11/29/07)
     
  592. Inovio Biomedical Partner Tripep Treats First Subject in Phase I/II Study of Novel Hepatitis C DNA Vaccine - (11/28/07)
     
  593. Medivir: Initiation of a Phase IIa Clinical Trial with Investigational Hepatitis C Protease Inhibitor TMC435350 - (11/27/07)
     
  594. Report: about 38 million Chinese carry hepatitis C virus - (11/27/07)
     
  595. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response - (11/27/07)
     
  596. Inhibitex Obtains License To HCV Polymerase Inhibitors - (11/27/07)
     
  597. Roche and Maxygen terminates hepatitis drug project - (11/27/07)
     
  598. Pfizer snaps up Coley Pharmaceutical for $164 million - (11/19/07)
     
  599. New HCV Gene microRNA Therapy Research - (11/19/07)
     
  600. AASLD: Higher Caffeine Consumption is associated with Milder Fibrosis in patients with Chronic Liver Diseases - (11/16/07)
     
  601. AASLD: Hepatitis D Virus; Triply Infected HIV/HBV/HCV Progress More Quickly - (11/16/07)
     
  602. PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy - (11/15/07)
     
  603. Improved cognitive function as a consequence of hepatitis C virus treatment - (11/15/07)
     
  604. AASLD: MAINTENANCE THERAPY FOUND INEFFECTIVE HALT-C STUDY - (11/14/07)
     
  605. AASLD: Rapid Virological Response at Week 4 Is the Best Predictor of Treatment Outcome in Patients With Chronic Hepatitis C: A Multivariate Analysis - (11/14/07)
     
  606. AASLD: Predictability of Response: Positive and Negative Predictive Values of Rapid and Early Virologic Responses to Peginterferon alfa-2b and Ribavirin in the Treatment of Chronic Hepatitis C - (11/14/07)
     
  607. AASLD: Final Results of the Canadian POWeR (Pegetron Prospective Optimal Weight-Based Dosing Response) Program. Sustained Virologic Response (SVR) to Weight-Based Peginterferon alfa-2b + Ribavirin in a Large, Mixed, Community and Academic Observational Study - (11/14/07)
     
  608. AASLD: Clinical Relevance of Rapid Virological Response (RVR) in Decompensated HCV-Related Cirrhosis Treated With Peginterferon and Ribavirin - (11/14/07)
     
  609. AASLD: Assessment of Virological Response at Week 4 and at Week 12 Optimizes Prediction of Treatment Outcome in Patients With Chronic Hepatitis C Treated With Peginterferon alfa-2b Plus Ribavirin - (11/14/07)
     
  610. AASLD: Patients co-infected with HCV and HIV who achieve an RVR (HCV RNA <50 IU/mL at week 4) or cEVR (HCV RNA <50 IU/mL at week 12) have similar rates of SVR to mono-infected patients treated with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) - (11/13/07)
     
  611. AASLD: Differentiation of early virologic response (EVR) into RVR, complete EVR (cEVR) and partial EVR (pEVR) allows for a more precise prediction of SVR in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) - (11/13/07)
     
  612. AASLD: Response-guided therapy in a prospective trial of peginterferon alfa-2a (40KD)/ribavirin treatment in patients with HCV genotype 1 or 4 - (11/13/07)
     
  613. AASLD: What is the impact of higher sensitivity assay on response-guided therapy in hepatitis C virus (HCV)? Comparative analysis between COBAS TaqMan™ and COBAS Amplicor™ tests from two large, randomized, international trials of PEGASYS plus COPEGUS - (11/13/07)
     
  614. AASLD: Outcomes in HIV-HCV co-infected genotype 1 patients treated with peginterferon alfa-2a (40KD) plus ribavirin 1000 or 1200 mg/day: predictions based on generalized additive models - (11/13/07)
     
  615. AASLD: Results of a Phase I Placebo-Controlled Trial in Healthy Volunteers to Examine the Safety, Tolerability and PK of the HCV Protease Inhibitor TMC435350 after Single and Repeated Dosing in healthy volunteers - (11/13/07)
     
  616. AASLD: In vitro activity and preclinical pharmacokinetics of the HCV protease inhibitor TMC435350 - (11/13/07)
     
  617. AASLD: Insulin Resistance Predicts HCV Progression in Genotype 1 - (11/13/07)
     
  618. AASLD: Pioglitazone Improved Metabolics & Liver Injury in Non-diabetics with NASH - (11/13/07)
     
  619. AASLD: Chronic hepatitis C virus infection and risk of hepatocellular carcinoma: a community-based prospective study on 19,565 residents in Taiwan - (11/13/07)
     
  620. AASLD: What is the best non invasive method for early prediction of cirrhosis in chronic hepatitis C? Prospective comparison between Fibroscan and serum markers (Lok index, APRI, AST/ALT ratio, platelet count and Fibrotest) - (11/13/07)
     
  621. AASLD: HCV patients with genotype 2 or 3 who do not achieve a rapid virologic response (RVR) with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) are not easy to treat: an analysis of non-RVR patients from the ACCELERATE study - (11/13/07)
     
  622. AASLD: High rates of sustained virologic response (SVR) in patients >50 years infected with HCV genotype 1 with positive prognostic factors treated with peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®) - (11/13/07)
     
  623. AASLD: High chance of cure in HCV genotype 1 patients with a low viral load achieving an RVR treated for 24 weeks with pegylated interferon alfa-2a (PEGASYS) plus ribavirin (COPEGUS): prospective, randomized, controlled study comparing 24 & 48 weeks of treatment - (11/13/07)
     
  624. AASLD: The DIRECT Trial (Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy): treatment of non-responders to previous pegylated interferon plus ribavirin: sustained virologic response data - (11/9/07)
     
  625. Positive results for GlobeImmune's hepatitis C drug in Phase I - (11/09/07)
     
  626. AASLD: Tibotec HCV Protease Inhibitor - (11/9/07)
     
  627. AASLD: Antiviral activity of the non-nucleoside polymerase inhibitor, VCH-759, in chronic Hepatitis C patients:Results from a randomized, double-blind, placebo -controlled, ascending multiple dose study - (11/9/07)
     
  628. AASLD: Vital Therapies Announces Presentation of ELAD "Artificial Liver" Data at American Association for the Study of Liver Diseases 2007 Annual Meeting - (11/9/07)
     
  629. AASLD: Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected patients - (11/9/07)
     
  630. AASLD: Pegylated interferon alfa-2a (40KD) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2b (12KD)/RBV: final efficacy and safety outcomes of the REPEAT study - (11/8/07)
     
  631. AASLD: Rapid and early virological response rates are increased with 12 week 360 μg/wk peginterferon alfa-2a (40KD) and standard ribavirin in HCV genotype 1 treatment naive patients: efficacy and safety analysis of the induction phase of the CHARIOT study - (11/7/07)
     
  632. AASLD: Evaluation of Viral Variants During a Phase 2 Study (PROVE2) of Telaprevir with Peg-interferon alfa-2a and Ribavirin in Treatment-naïve HCV Genotype 1-Infected Patients - (11/7/07)
     
  633. AASLD: Phase 2a study to evaluate the safety and tolerability and anti-viral of 4 doses of a novel, controlled-release interferon-alfa 2b (Locteron) given every 2 weeks for 12 weeks in treatment-naive patients with chronic hepatitis C (genotype 1) - (11/7/07)
     
  634. AASLD: Antiviral Activity, Pharmacokinetics, Safety, and Tolerability of R7128, a Novel Nucleoside HCV RNA Polymerase Inhibitor, Following Multiple, Ascending, Oral Doses in Patients with HCV Genotype 1 Infection Who have Failed Prior Interferon Therapy - (11/7/07)
     
  635. GSK launches new Phase III trials of Revolade, new drug that boosts platelet counts in patients with HCV - (11/06/07)
     
  636. GlaxoSmithKline initiates trials of Promacta/Revolade (eltrombopag) for Increasing Plateket Count in HCV+ Individuals - (11/06/07)
     
  637. AASLD: Interim analysis: results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C: Prove 1 - (11/7/07)
     
  638. AASLD: A high barrier to resistance may contribute to the robust antiviral effect demonstrated by R1626 in HCV genotype 1-infected treatment-naive patients - (11/7/07)
     
  639. AASLD: Robust Synergistic Antiviral Effect of R1626 in Combination with Peginterferon alfa-2a (40KD), with or without Ribavirin, Interim Analysis Results of Phase 2a Study - (11/7/07)
     
  640. AASLD: Rapid and early virological response rates are increased with 12 week 360 μg/wk peginterferon alfa-2a (40KD) and standard ribavirin in HCV genotype 1 treatment naive patients: efficacy and safety analysis of the induction phase of the CHARIOT study - (11/7/07)
     
  641. AASLD: Danazol Increases Platelet Counts in Thrombocytopenia Patients with Chronic Hepatitis C or Cirrhosis - (11/7/07)
     
  642. AASLD: Hepatitis C Associated Systemic Cryoglobulinemia: Successful Treatment With Plasma Exchange - (11/7/07)
     
  643. AASLD: Long-Term, Low-Dose Treatment With Pegylated Interferon alfa-2b Leads to a Significant Reduction in Fibrosis and Inflammatory Scores in Chronic Hepatitis C Nonresponder Patients With Fibrosis or Cirrhosis - (11/7/07)
     
  644. AASLD: Gilead hepatitis C drug may have heart issue-study - (11/5/07)
     
  645. AASLD: Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C - (11/5/07)
     
  646. AASLD: PROVE2: phase II study of telapravir (VX-950) in combination with peginterferon alfa-2 with or without ribavirin in subjects with chronic hepatitis C, an interim analysis - (11/5/07)
     
  647. EACS: Insulin Resistance Imperils Response to Interferon in People With HCV/HIV - (11/04/06)
     
  648. AASLD: Roche's Oral Polymerase Inhibitor Shows Robust Antiviral Efficacy in Treatment of Chronic Hepatitis C - (11/2/07)
     
  649. AASLD: Pegasys High Dose Induction for PegIntron Nonresponders: REPEAT Study - (11/2/07)
     
  650. AASLD: GILEAD ANNOUNCES 48-WEEK DATA FROM TWO PIVOTAL PHASE III STUDIES EVALUATING VIREAD FOR THE TREATMENT OF CHRONIC HEPATITIS B - (11/2/07)
     
  651. AASLD: 91% OF BARACLUDE (ENTECAVIR) TREATED PATIENTS IN A FOUR-YEAR COHORT DEMONSTRATED VIROLOGIC SUPPRESSION TO UNDETECTABLE LEVELS - (11/2/07)
     
  652. AASLD: Roche Polymerase Inhibitor Shows Promise In Phase II - (11/2/07)
     
  653. Potent Abbott Hepatitis C Virus Protease Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies - (11/02/07)
     
  654. AASLD: First Studies Demonstrating Greater than 60% Sustained Viral Response Rates with Half the Standard Treatment Duration in Genotype 1 Chronic Hepatitis C Patients (Vertex press release) - (11/2/07)
     
  655. AASLD: Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C - (11/2/07)
     
  656. AASLD: Vertex feeling growing pains Firm scrambles for workers, space as drug shows promise - (11/2/07)
     
  657. AASLD: Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C - (11/2/07)
     
  658. AASLD: 2 New HCV Drugs at AASLD - (11/2/07)
     
  659. New Hepatitis C Antiviral CB5300 Identified by Canopus BioPharma Researchers to Enter Clinical Trial Assessment - (11/01/07)
     
  660. Human Genome Sciences Completes Enrollment Ahead of Schedule in Second Phase 3 Albuferon(R) Trial - (11/01/07)
     
  661. New Drug CF-102 for Liver Cancer Enters Phase 1 Clinical Trials - (10/31/07)
     
  662. Bayer and Onyx get liver cancer approval for Nexavar in EU - (10/31/07)
     
  663. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody - (10/30/07)
     
  664. R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection - (10/24/07)
     
  665. INITIAL RESULTS OF PHASE II STUDY WITH HCV PROTEASE INHIBITOR BOCEPREVIR IN TREATMENT-NAIVE HEPATITIS C PATIENTS SHOW A HIGH RATE OF EARLY VIROLOGIC RESPONSE - (10/19/07)
     
  666. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus - (10/17/07)
     
  667. Marianne Faithfull Has Hepatitis C - (10/16/07)
     
  668. Glucose Abnormalities Are an Independent Risk Factor for Nonresponse to Antiviral Treatment in Chronic Hepatitis C - (10/16/07)
     
  669. Low-Dose Interferon Lozenges HCV & HIV/oral warts Study - (10/10/07)
     
  670. Discovery of a novel class of Hepatitis C Polymerase Inhibitors - (10/10/07)
     
  671. The Antiviral Efficacy of the Nonnucleoside HCV Polymerase Inhibitor A-848837 in the HCV Infected Chimpanzee - (10/05/07)
     
  672. Ultrasound-Based Transient Elastography for the Detection of Hepatic Fibrosis: Systematic Review and Meta-analysis - (10/05/07)
     
  673. Stiffness and Impedance: The New Liver Biomarkers Editorial - (10/05/07)
     
  674. Noninvasive Diagnosis of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Splenic Doppler Impedance Index - (10/05/07)
     
  675. Assessment of Hepatic Fibrosis With Magnetic Resonance Elastography - (10/05/07)
     
  676. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C - (10/03/07)
     
  677. "True" weight-based dosing versus "flat' dosing of ribavirin: Will the WIN-R please come forward? Editorial - (10/03/07)
     
  678. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial - (10/03/07)
     
  679. Impact of weight-based ribavirin with peginterferon alfa-2b in african americans with hepatitis C virus genotype - (10/03/07)
     
  680. Intermune HCV Protease Trials Timeline - (10/01/07)
     
  681. VX950+Peg Data Without RBV at AASLD Nov - (10/01/07)
     
  682. Pharmasset HCV & HBV Drugs - (09/27/07)
     
  683. Maxygen Announces Hold on MAXY-alpha Development Program - (09/24/07)
     
  684. Preclinical Characterization of TMC435350, a novel macrocyclic inhibitor of the HCV NS3/4A serine protease - (09/24/07)
     
  685. European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy - (09/24/07)
     
  686. Helicase Target for HCV Therapy - (09/18/07)
     
  687. Idera Pharmaceuticals Initiates Phase 1 Trial of IMO-2125 in Hepatitis C - (09/18/07)
     
  688. XTL Biopharmaceuticals Presents a New Class of Highly Potent Small Molecule Inhibitors of Hepatitis C Affecting the NS5A Target at an International Scientific Conference - (09/18/07)
     
  689. New Treatment for Liver Cancer 'Burns Tumors Off' N&N makes cancer breakthrough - (09/13/07)
     
  690. The Use of Transient Elastometry for Assessing Liver Fibrosis in Patients with HIV and Hepatitis C Virus Coinfection: only detects cirrhosis - (09/13/07)
     
  691. New therapies for hepatitis C: VX-950 (telaprevir) - (09/11/07)
     
  692. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C - (09/11/07)
     
  693. Possible Hepatitis C vaccine - (09/05/07)
     
  694. Human Genome Sciences gets 40 mln usd Albuferon milestone payment from Novartis - (08/28/07)
     
  695. HCV Care by Liver Specialists or Community-Based Practices: Pro & Con - (08/27/07)
     
  696. Hep C vaccine shows promise - (08/21/07)
     
  697. Intercell's therapeutic Hepatitis C vaccine meets primary endpoints in Phase II interim analysis - (08/21/07)
     
  698. Incidence and Predictors of Hepatocellular Carcinoma in Patients With Cirrhosis - (08/20/07)
     
  699. Risk factors (AZT) for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin - (08/17/07)
     
  700. Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients - (08/17/07)
     
  701. Twelve-Week Treatment of Acute Hepatitis C Virus with Pegylated Interferon-a-2b in Injection Drug Users is Effective - (08/17/07)
     
  702. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients - (08/16/07)
     
  703. Coffee drinking and hepatocellular carcinoma risk: A meta-analysis - (08/16/07)
     
  704. Inovio Biomedical Partner Tripep Receives Approval to Initiate Phase I/II Study of Novel Vaccine for Hepatitis C Virus - (08/16/07)
     
  705. HCV/HIV co-infection, HCV viral load and mode of delivery: risk factors for mother-to-child transmission of hepatitis C virus? - (08/16/07)
     
  706. Nitazoxanide+Pegasys/RBV Study for HCV - (08/15/07)
     
  707. IAS: Hepatitis C Viral Kinetics During Treatment With Weekly Versus Twice Weekly Peg IFN-alpha-2a in HIV/HCV Co-infected Patients - (08/10/06)
     
  708. Peregrine's Bavituximab HCV Phase Ib Study Results Selected for Oral Presentation at Upcoming AASLD Annual Meeting - (08/09/07)
     
  709. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy: Virahep-C Study - (08/06/07)
     
  710. Coffee Consumption and Risk of Liver Cancer: A Meta-Analysis. Coffee, 2 Cups Daily, May Reduce Risk for Liver Disease, ALT Elevations - (08/06/07)
     
  711. Hepatitis C strongly linked to type 2 diabetes - (08/02/07)
     
  712. InterMune Submits CTA Amendment for HCV Protease Inhibitor ITMN-191 and Provides Update on Clinical Development Program - (08/02/07)
     
  713. VX-950 HCV Protease inhibitor at AASLD - (08/02/07)
     
  714. Development Discontinued for ANA975, an Early Stage Compound for Treatment of Hepatitis C Virus Infection - (08/02/07)
     
  715. Hepatitis C helicase unwinds DNA in a spring-loaded, 3-step process - (08/02/07)
     
  716. Roche/Pharmasset HCV Polymerase Drug New Patient Study Results Expected in September - (08/02/07)
     
  717. OraSure Technologies Announces Pre-Clinical Study Results for Prototype Rapid HCV Antibody Test at AACC Annual Meeting - (07/20/07)
     
  718. Hepatitis C Viremia Increases the Association With Type 2 Diabetes Mellitus in a Hepatitis B and C Endemic Area: An Epidemiological Link With Virological Implication - (07/17/07)
     
  719. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha - (07/16/07)
     
  720. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis - (07/16/07)
     
  721. Novartis, Idenix Suspend Tests on Hepatitis C Drug NM283 - (07/16/07)
     
  722. Atorvastatin (Lipitor) lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase - (07/16/07)
     
  723. Opportunities for treating chronic hepatitis B and C virus infection using RNA interference - (07/16/07)
     
  724. Predictors of response to Pegasys/RBV of U.S. veterans to treatment for the hepatitis C virus - (07/13/07)
     
  725. Shortened Therapy for Hepatitis C Virus Genotype 2 or 3 - Is Less More? EDITORIAL - (07/12/07)
     
  726. Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3 (NEJM) - (07/12/07)
     
  727. Do high lipids help clearance of hepatitis C? - (07/12/07)
     
  728. Pharmasset and Roche Initiate Studies to Advance R7128 Polymerase Inhibitor for HCV - (07/12/07)
     
  729. HCV/HIV Coinfection in Asia - (07/05/07)
     
  730. HCV Replication Found in CNS in HIV+ - (07/03/07)
     
  731. Schering Plough Ends Celgosivir Deal - (06/28/07)
     
  732. Pakistan to launch survey on hepatitis B & C Prevalence - (06/27/07)
     
  733. New RNAi HCV Drug - (06/22/07)
     
  734. Inhibition of T-Cell Inflammatory Cytokines, Hepatocyte NF-κB Signaling, and HCV Infection by Standardized Silymarin (Milk thistle) - (06/20/07)
     
  735. 67% Steatosis in HCV/HIV Coinfected: : Liver inflammation, HCV genotype 3, and BMI are associated with steatosis, a common finding in HCV-HIV-coinfected patients. - (06/20/07)
     
  736. Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial: no ribavirin-Valopicitabine drug interaction - (06/13/07)
     
  737. ViroPharma Announces Completion of Enrollment in 500mg BID Arms of HCV-796 Phase 2 Study - (06/13/07)
     
  738. Roche's Hepatitis C drug Pegasys patent challenged - (06/13/07)
     
  739. Phase III data looks promising for GSK's eltrombopag - (06/11/07)
     
  740. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon - (06/08/07)
     
  741. XTL-2125 Hep C Drug Fails - (06/07/07)
     
  742. Medical Resource Utilization in Chronic Liver Disease Patients with Thrombocytopenia - (06/06/07)
     
  743. DDW: Eltrombopag Maintains Platelet Counts During Myelosuppressive Pegylated Interferon Alpha Treatment of Chronic Hepatitis C Virus Infection - (06/05/07)
     
  744. New HCV Therapy PYN17 - (06/04/07)
     
  745. Cytheris to start two phase I/IIa clinical trials of CYT107, its new recombinant Interleukin-7, in Hepatitis C and oncology - (06/04/07)
     
  746. 5% in Pakistan have HCV, 7-8 Million People - (06/04/07)
     
  747. Free IFN/RBV in Pakistan - (06/04/07)
     
  748. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients - (06/04/07)
     
  749. HCV Increased NHL Risk & Appears to Drive Immunological Stimulus for Progression to Hematological Malignancy; Interferon Can Regress NHL - (06/04/07)
     
  750. DDW: 12 weeks VX-950 Therapy - (06/04/07)
     
  751. HCV Increased NHL Risk & Appears to Drive Immunological Stimulus for Progression to Hematological Malignancy; Interferon Can Regress NHL - (05/31/07)
     
  752. Body composition, muscle function, and energy expenditure in patients with liver cirrhosis: a comprehensive study - (05/31/07)
     
  753. Acute HCV in MSM in London - (05/31/07)
     
  754. UK and Wales Fail on HCV Policy - (05/31/07)
     
  755. Controlled Release Interferon - (05/31/07)
     
  756. Reversibility of hepatic fibrosis and cirrhosis-is it all hype? Editorial - (05/31/07)
     
  757. Hepatitis D virus infection - Not a vanishing disease in Europe! - (05/31/07)
     
  758. DDW: NY Montefiore Hospital Coinfection Program Reports Success With a Multi-Disciplinary Program: Model of Care - (05/31/07)
     
  759. CROI: HOMA-IR Is a Strong Predictor of Rapid Virologic Response in HIV/HCV-co-infected Patients Treated with Pegylated Interferon-alpha 2a and Ribavirin (05/29/07)
     
  760. CROI: Glucose Intolerance Associated with Advancing Liver Disease (Fibrosis) (05/29/07)
     
  761. CROI: Non-Invasive Liver Tests Studies Disappoint at CROI in Coinfection Studies (05/29/07)
     
  762. DDW: Patterns of fat distribution and its relationship to liver histology in nonalcoholic fatty liver disease (NAFLD): does fatty liver cause lipodystrophy? - (05/25/07)
     
  763. DDW: Diabetes Therapy Improves Peg/RBV Response - (05/25/07)
     
  764. DDW: Early Pegasys/RBV Therapy is Cost Effective, Improves Survival & Reduces Risk for Cirrhosis - (05/25/07)
     
  765. DDW: Efficacy and Safety of Peginterferon Alfa-2a/Ribavirin in Methadone Maintenance Patients: Randomized Comparison of Direct Observed Therapy and Self-Administration - (05/25/07)
     
  766. DDW: Patterns of fat distribution and its relationship to liver histology in nonalcoholic fatty liver disease (NAFLD) - (05/24/07)
     
  767. DDW: Cost-effectiveness, Survival, and Prevention of Cirrhosis with Early Treatment of Chronic Hepatitis C with Peginterferon Alfa-2a (40KD) plus Ribavirin before Progression to Advanced Liver Disease - (05/24/07)
     
  768. DDW: HCV Can Be Cured - (05/24/07)
     
  769. DDW: Treatment Duration and Histological Response to Peginterferon Alfa-2a/Ribavirin: 48 weeks improves liver disease in Non-SVRs better than 24 weeks - (05/24/07)
     
  770. DDW: Safety and Tolerability of Peginterferon Alfa-2a Plus Ribavirin in HCV Patients Nontolerant or Nonresponsive to Peginterferon Alfa-2b Plus Ribavirin - (05/23/07)
     
  771. DDW: Celgosivir with Peginterferon and Ribavirin in Chronic Hepatitis C - (05/23/07)
     
  772. DDW: Pharmacodynamic Analysis of the Antiviral Activity of the Non-Nucleoside Polymerase Inhibitor, HCV-796, in Combination With Pegylated Interferon Alfa-2b in Treatment-Naive Patients With Chronic HCV - (05/23/07)
     
  773. EASL: Safety, Pharmacokinetics and Antiviral effects of Boehringer Ingelheim BILB 1941, a Novel HCV RNA Polymerase, After 5 days Oral treatment in Patients with Chronic Hepatitis C - (05/21/07)
     
  774. EASL: Phase II Proof of Concept Study of celgosivir in combination woth peginterferon alfa-2a and ribavirin in chronic hepatitis C genotype-1 non responder patients - (05/21/07)
     
  775. DDW: HCV-Infected Liver Donors for Liver Transplantation Are Recommended Instead of Uninfected HCV-Donated Livers, from a new study presented at DDW 2007 - (05/22/07)
     
  776. DDW: HCV-796, Polymerase Inhibitor - (05/22/07)
     
  777. DDW: Eltrombopag Maintains Platelet Counts During Myelosuppressive Pegylated Interferon Alpha Treatment of Chronic Hepatitis C Virus Infection - (05/22/07)
     
  778. DDW: Increased SVR rate with 48 weeks' treatment and higher RBV dose in HCV genotype 2/3 patients without a rapid virologic response (RVR) treated with peginterferon alfa-2a (40KD) (PEGASYS) plus RBV (COPEGUS) - (05/22/07)
     
  779. DDW: Peginterferon Alfa-2a (40KD) Plus Ribavirin for 16 or 24 Wks in Pts With HCV Genotype 2/3 Infection and Advanced Fibrosis/Cirrhosis - (05/22/07)
     
  780. DDW: Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered ''Cured''; Mitch Shiffman says 'you can cure HCV', Eugene Schiff says 'get treated'. - (05/22/07)
     
  781. DDW: 16 vs 24 wks Pegasys/RBV in Cirrhotics & Non-Cirrhotics Genotype 2/3 from ACCELERATE Study - (05/22/07)
     
  782. DDW: Increased SVR Rate with 48 Wks' Treatment and Higher RBV Dose in HCV Genotype 2/3 Pts Without a Rapid Virologic Response (RVR) Treated with Peginterferon Alfa-2a (40KD) (PEGASYS) Plus RBV (COPEGUS) - (05/21/07)
     
  783. DDW: Statin Improved PegIFN/RBV SVR Rate, Improve ALTs in HCV+ - (05/21/07)
     
  784. DDW: InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting - (05/21/07)
     
  785. Hepatitis D virus infection - Not a vanishing disease in Europe! - (05/03/07)
     
  786. HCV Reinfection: is there protective effect following natural HCV clearance? - (05/03/07)
     
  787. EASL: Pegasys vs Peg/ADV for Hepatitis D Virus: Pegasys most effective - (05/03/07)
     
  788. EASL: HCV Antiviral Activity and Resistance Analysis in Chronically Infected Chimpanzees Treated with Merck NS3/4A Protease and NS5B Polymerase Inhibitors - (05/02/07)
     
  789. EASL: Low-Dose PegIFN Maintenance Therapy Successful - (05/02/07)
     
  790. European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) and REBETOL(R) Combination Therapy for Hepatitis C in Patients Coinfected With HIV - (05/01/07)
     
  791. More gay men getting hepatitis C; Increased HCV Infection Among HIV+ Gay Men - (05/01/07)
     
  792. EASL: Albuferon Once Every 2 or 4 Weeks Interferon Looks Good in Phase 2 Study - (05/01/07)
     
  793. EASL: Inherited Variants of Genes Involved in Insulin Signaling and Lipogenesis Influence The Risk of Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease - (05/01/07)
     
  794. EASL: Insulin Resistance in HBV, HCV & Non-Virus Related Chronic Hepatitis (liver enzymes) - (05/01/07)
     
  795. EASL: Insulin Resistance Inflames The Liver in HCV - (05/01/07)
     
  796. EASL: Insulin Resistance in 424 HCV+ Patients: association with HCV replication and advanced fibrosis - (05/01/07)
     
  797. EASL: Statins May Improve Liver Fibrosis - (05/01/07)
     
  798. EASL: PegIntron + 2 HCV Nucleosides Show Synergy - (04/27/07)
     
  799. New Genetic Diagnostic Tests-Financial Impact - (04/27/07)
     
  800. EASL: R1479 (R1626), a Novel Hepatitis C Polymerase Inhibitor: Lack of Pre-Existing Resistance Mutations Supports the Observed In Vivo High Barrier to Resistance - (04/27/07)
     
  801. EASL: ITMN-191 CONCENTRATIONS ACHIEVED IN THE LIVER OF ANIMALS PROMOTE HCV REPLICON CLEARANCE IN VITRO AND THIS EFFECT IS ENHANCED BY PEG-IFN a-2a (Pegasys) - (04/27/07)
     
  802. EASL: HCV Protease Inhibitor ITMN-191 Resistance - (04/27/07)
     
  803. HCV Protease Inhibitor ITMN-191 + HCV Polymerase Inhibitor R1626 Synergy - (04/27/07)
     
  804. EASL: Lipid steatosis, metabolic variables and body composition in the setting of HIV/HCV coinfection; findings from a large randomised trial (APRICOT) - (04/26/07)
     
  805. EASL: 400,000 IU/mL Is New Cut-Off for Low vs High Viral Load in HCV - (04/26/07)
     
  806. EASL: Favorable Cross-Resistance Profile of Two Novel Hepatitis C Virus Inhibitors, SCH 503034 (Boceprevir) and HCV-796, and Enhanced Anti-Replicon Activity Mediated by the Combined Use of Both Compounds - (04/26/07)
     
  807. EASL: SCH503034 & NM283 Not Cross-Resistant - (04/26/07)
     
  808. EASL: An open label, comparative, multi-center study of peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin in the treatment of patients with chronic hepatitis C/hepatitis B dual infection versus with mono-infected chronic hepatitis C: An interim report - (04/25/07)
     
  809. EASL: Virological response at 4 and 12 weeks predict high rates of sustained virological response in genotype 1 patients treated with peginterferon alfa-2a (40KD) plus ribavirin - (04/25/07)
     
  810. EASL: 14 Weeks vs 24 Weeks Peg/RBV for Genotypes 2/3 - (04/20/07)
     
  811. EASL: In vitro Resistance Selection to the HCV Nucleoside Polymerase Inhibitor R1479 (R1626) and to the Protease Inhibitor VX-950 - (04/23/07)
     
  812. EASL: SVR Durable (99%) After 5 Years of Followup - (04/23/07)
     
  813. EASL: 48 Weeks & High Ribavirin Dose May Improve SVR Rates for Genotype 2/3, French study by Bernard Willems - (04/23/07)
     
  814. EASL: In Patients Who Clear HCV RNA At Week 12 (between week 8 and 12): SVR is Higher After 72 Weeks Than After 48 Weeks Treatment: Results of a Randomized Controlled Trial - (04/23/07)
     
  815. EASL: New HCV Drug Target NS4A Antagonists - (04/23/07)
     
  816. EASL: 3 YEARS OF ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY MINIMIZES THE RISK OF GENOTYPIC RESISTANCE TO ADV IN LAM RESISTANT PATIENTS - (04/20/07)
     
  817. EASL: Abbott HCV Polymerase Inhibitor - (04/18/07)
     
  818. EASL: CANNABIS USE AS AN INDEPENDENT PREDICTOR OF SEVERE STEATOSIS DURING CHRONIC HEPATITIS C - (04/19/07)
     
  819. EASL:3-Drug HCV therapy for 12 weeks: VX950+pegIFN+RBV, interim results from phase II PROVE 1 Trial - (04/17/07)
     
  820. EASL: HCV-796 Polymerase Inhibitor Shows 1.5 log Viral Load Reduction - (04/17/07)
     
  821. EASL: GSK625433: A Novel and Highly potent Inhibitor of the HCV NS5B Polymerase - (04/17/07)
     
  822. EASL: Merck HCV Protease & Polymerase Inhibitor Viral Load Reduction & Resistance in Chimps - (04/17/07)
     
  823. EASL: GSK625433: A Novel and Highly Potent Inhibitor of the HCV NS5B Polymerase - (04/17/07)
     
  824. EASL: Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigational Drug Telaprevir in Patients with Genotype 1 Hepatitis C - (04/17/07)
     
  825. EASL: New HCV Drug Target NS4A Antagonists - (04/17/07)
     
  826. EASL: NM283 in Treatment-Naives Looks Better - (04/13/07)
     
  827. EASL: NM283, HCV Polymerase Inhibitor in Non-Responders - (04/13/07)
     
  828. Omega-3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines - (04/12/07)
     
  829. EASL: Resistance to New HCV Antivirals - (04/12/07)
     
  830. EASL: Vertex Pharmaceuticals Announces New Data for Investigational HCV Protease Inhibitor Telaprevir to be Presented at 42nd Annual Meeting of the European Association for the Study of the Liver (EASL) - (04/12/07)
     
  831. EASL: New Clinical Study Results Indicate Higher Early Virologic Response with Celgosivir Combination Therapy in HCV Non-Responders - (04/12/07)
     
  832. New Once Weekly Oral Interferon Belerofon in Phase 1 - (04/09/07)
     
  833. Viral Hepatitis (HCV, HBV) in HIV Infection REVIEW by Margaret Koziel, Marion Peters - (04/09/07)
     
  834. 33% HCV/HIV Coinfected in Milan, Italy - (04/09/07)
     
  835. Viral Hepatitis (HCV, HBV) in HIV Infection REVIEW by Margaret Koziel, Marion Peters - (04/05/07)
     
  836. Liver Iron Levels NOT Directly Linked to Fibrosis - (04/03/07)
     
  837. UK Parliament adopts written declaration on Hepatitis C - (03/29/07)
     
  838. Treatment of Chronic Hepatitis C Virus in African Americans With Genotypes 2 and 3 - (03/27/07)
     
  839. Improved Outcomes After SVR, Interferon Therapy - (03/27/07)
     
  840. CROI: In NYC: Liver Fibrosis During Acute HCV Infection of HIV-infected Men (03/21/07)
     
  841. Hepatitis C virus infection is associated with insulin resistance among older adults with or at risk of HIV infection - (03/21/07)
     
  842. U.S. sees sharp decline in hepatitis cases: CDC - (03/21/07)
     
  843. Hepatitis C in Prison & After Release: 40% infected - (03/21/07)
     
  844. Roche Driving PROGRESS in Treatment of Difficult-to-Cure Hepatitis C Patients With New PEGASYS (R) (peginterferon alfa-2a (40KD)) and COPEGUS(R) (ribavirin) Trial - (03/16/07)
     
  845. Procrit/Epogen FDA Safety Warning - (03/12/07)
     
  846. PEGASYS(R) Gets European Approval for a Shorter Treatment Duration for Some Genotype 1 and 4 Hepatitis C Patients who Show a Rapid Response to Therapy - (03/06/07)
     
  847. Human Genome Sciences Initiates Phase 3 Clinical Trial of Albuferon(R) With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C Genotypes 2 and 3 - (02/29/07)
     
  848. New HCV Drug R7128 Polymerase Inhibitor - (02/29/07)
     
  849. SVR Improved Quality of Life & Sexual Function in Patients with Advanced Fibrosis in HALT-C Study - (02/20/07)
     
  850. Hepatic Steatosis in Hepatitis C: Comparison of Diabetic and Nondiabetic Patients in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial (HALT-C Study) - (02/16/07)
     
  851. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients - (02/15/07)
     
  852. Non-invasive markers of liver fibrosis: How to use them in clinical practice? - (02/15/07)
     
  853. Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C (HALT-C Study) - (02/12/07)
     
  854. Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients Completing Peginterferon Alfa-2a/Ribavirin Treatment - (01/26/07)
     
  855. Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients - (02/12/07)
     
  856. Short-duration therapy for hepatitis C & RVR: suitable for all? - (02/12/07)
     
  857. Liver Stiffness Measurement Versus Clinicians' Prediction or Both for the Assessment of Liver Fibrosis in Patients with Chronic Hepatitis C - (02/09/07)
     
  858. Are Noninvasive Liver Fibrosis Tests Ready for Use? There are lots of questions. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C - (02/09/07)
     
  859. Medivir: Clinical Phase I Trial with Hepatitis C Virus Protease Inhibitor Initiated - (02/09/07)
     
  860. Gilead and Achillion Announce Positive Antiviral Activity of NS4A Antagonist in HCV, But Discontinue GS 9132 (ACH-806) Development - (02/09/07)
     
  861. Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients - (02/01/07)
     
  862. Combination Therapy With Telaprevir and Pegylated Interferon Suppresses Both Wild-Type and Resistant Hepatitis C Virus - (02/01/07)
     
  863. Time-Released Interferon Drug: OctoPlus initiates Locteron Phase II clinical study in chronic hepatitis C - (01/30/07)
     
  864. Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients Completing Peginterferon Alfa-2a/Ribavirin Treatment - (01/26/07)
     
  865. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: A controlled study - (01/26/07)
     
  866. New Hepatitis C Culture System for Study of Virus - (01/24/07)
     
  867. Coley Suspends Development of HCV Toll-Receptor Drug - (01/23/07)
     
  868. Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia - (01/22/07)
     
  869. Diabetes, HCV and Liver Transplanation - (01/22/07)
     
  870. Arrow Therapeutics Selects a 2nd Hepatitis C Clinical Candidate - (01/22/07)
     
  871. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis - (01/22/07)
     
  872. Noninvasive Markers of Liver Fibrosis - (01/19/07)
     
  873. Negative-Strand Hepatitis C Virus (HCV) RNA in Peripheral Blood Mononuclear Cells from Anti-HCV-Positive/HIV-Infected Women - (01/11/07)
     
  874. Detection of Hepatitis C Virus (HCV) in Serum and Peripheral-Blood Mononuclear Cells from HCV-Monoinfected and HIV/HCV- Coinfected Persons - (01/11/07)
     
  875. Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C - (01/09/07)
     
  876. Schering and Orasure in pact to develop oral hepatitis C test - (01/09/07)
     
  877. Successful IFN Therapy in IVDUs on Naltraxone - (01/09/07)
     
  878. Enhancing hepatitis C treatment uptake and outcomes for injection drug users EDITORIAL - (01/09/07)
     
  879. Diet (Food groups) and risk of hepatocellular carcinoma: A multicenter case-control study in Italy - (01/09/07)
     
  880. Phynova Obtains FDA Approval of its IND to Enter Into a Clinical Trial of PYN17 for the Treatment of Chronic Hepatitis C - (01/09/07)
     
  881. VX-950 Phase 2b PROVE 1 Study Interim Safety & Antiviral Activity at Week 12 - (12/20/06)
     
  882. New HCV Drug Celgosivir/MX-3253, oral alpha-glucosidase I inhibitor - (12/20/06)
     
  883. Vertex Pharmaceuticals Announces Results of First Interim Safety and Antiviral Analysis of the PROVE 1 Clinical Trial of Investigational HCV Protease Inhibitor Telaprevir (VX-950) - (12/20/06)
     
  884. Human Genome Sciences Initiates Phase 3 Clinical Trial of Albuferon(R) in Combination With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C - (12/20/06)
     
  885. Pevion Biotech Announces Its Hepatitis C Therapeutic Vaccine Enters Clinical Phase I - (12/20/06)
     
  886. InterMune Initiates Phase 1a Clinical Trial Evaluating Hepatitis C Protease Inhibitor ITMN-191 in Collaboration with Roche - (12/20/06)
     
  887. InterMune Initiates Phase 1a Clinical Trial Evaluating Hepatitis C Protease Inhibitor ITMN-191 in Collaboration with Roche - (12/20/06)
     
  888. Procrit/EP- Safety Alert from FDA - (12/18/06)
     
  889. Epoetin Alfa and Risk for Complications - (12/18/06)
     
  890. Correction of Anemia - Payoffs and Problems EDITORIAL - (12/18/06)
     
  891. ICAAC: The PRESCO study: role of extended therapy and/or optimal doses of ribavirin in the treatment of chronic hepatitis C in HIV-infected patients (12/12/06)
     
  892. Fatty Liver Associated with Increased Mortality - (12/12/06)
     
  893. Pegasys/RBV Reverses Fibrosis in HCV/HIV-Coinfected in APRICOT Study for Viral Responders, Non-responders, and Cirrhosis - (12/12/06)
     
  894. HCV Reduces Cholesterol in Coinfected; Interferon therapy Increases Cholesterol - (12/12/06)
     
  895. Diabetes and hepatocellular carcinoma Editorial - (12/12/06)
     
  896. Abbott Acquires HCV Protease Inhibitors from Enanta Pharma - (12/12/06)
     
  897. Valeant Pharmaceuticals Initiates Infergen Phase 4 Study - (12/12/06)
     
  898. Hepatitis C Virus Replicates in the Liver of Patients Who Have a Sustained Response to Antiviral Treatment - (12/06/06)
     
  899. Hepatitis C Virus Seropositivity in Organ Donors Reduced Survival in Heart Transplant Recipients - (12/06/06)
     
  900. Poorer Outcomes for Recipients of Heart Allografts From HCV-Positive Donors EDITORIAL - (12/06/06)
     
  901. HCV Infections From a Contaminated Radiopharmaceutical Used in Myocardial Perfusion Studies - (12/06/06)
     
  902. ViroPharma and Wyeth Initiate Dosing in Phase 2 Study of HCV-796 in Treatment Naive Patients and Non-Responders - (12/06/06)
     
  903. Christopher Kennedy Lawford Urges America to Face Its Silent Epidemic - Hepatitis C - (12/06/06)
     
  904. Pharmasset Initiates Phase 1 Study of R7128 for HCV - (12/06/06)
     
  905. Patients who recover from hepatitis C have lower risk of reinfection - (12/06/06)
     
  906. Racing to The Market with New HCV Drugs Vertex May Beat Roche, Merck on Drug for Hepatitis C - (12/06/06)
     
  907. HCV Drug R7128 Makes Progress - (12/06/06)
     
  908. Arrow Therapeutics HCV Compound Enters Phase I - (12/04/06)
     
  909. Saliva-based hepatitis C test developed - (12/04/06)
     
  910. New Hepatitis C Drugs - (12/04/06)
     
  911. Inovio Biomedical Partner Tripep Files Application for Phase I Clinical Study of Hepatitis C DNA Vaccine - (12/04/06)
     
  912. China's Hepatitis C Prevalent Population is Ten Times that of the United States - (12/04/06)
     
  913. AASLD: In Vitro Synergistic Antiviral Activity of ITMN-191, an Orally Active Inhibitor of the Hepatitis C Virus (HCV) NS3/4A Protease, in Combination with PEG-Interferon Alfa-2a - (11/14/06)
     
  914. AASLD: Development of HCC in Patients who Achieve SVR to IFN-Based Therapies is Associated with Cirrhosis and Prior HBV Exposure - (11/14/06)
     
  915. AASLD: CPG10101 HCV Toll-Receptor 9 Antagonist Phase II Study results - (11/10/06)
     
  916. AASLD: New HBV Drug PMEO-DAPym Active In Vitro Against Drug Resistant Mutants of HBV - (11/10/06)
     
  917. AASLD: In Vitro Resistance Studies of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-dependent RNA Polymerase - (11/08/06)
     
  918. AASLD: Early predictors of anemia in patients with HCV genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin 1000-1200 mg/day - (11/08/06)
     
  919. AASLD: PegIntron/RBV Effective for >65 Year Olds - (11/08/06)
     
  920. AASLD: New Therapy Significantly Increases Platelet Count - (11/08/06)
     
  921. AASLD: Eltrombopag, an Oral Platelet Growth Factor, Facilitates Initiation of Interferon Therapy in Subjects with HCV Associated Thrombocytopenia - (11/08/06)
     
  922. AASLD: Merck HCV Polymerase Inhibitor - (11/08/06)
     
  923. AASLD: In Vitro Resistance Studies of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-dependent RNA Polymerase - (11/08/06)
     
  924. AASLD: Pegasys 270 ug/wk+RBV 1200/1600mg in Difficult To Treat Patients - (11/07/06)
     
  925. AASLD: Pegasys Every 5 Days in PegIntron Nonresponders - (11/07/06)
     
  926. AASLD: Hispanic Responses to PegIntron/RBV in WIN-R Study - (11/07/06)
     
  927. AASLD: LATINO Pegasys Study: early responses - (11/07/06)
     
  928. AASLD: Adefovir 3 & 5 Years Followup HBeAg+: safety & efficacy - (11/06/06)
     
  929. AASLD: 16 vs 24 weeks Pegasys/RBV for Genotype 2 HCV; Taiwan Study: Week 4 Response & Ribavirin Level/Dose Predicts SVR - (11/06/06)
     
  930. AASLD: <400,000 is New HCV RNA Cutoff In genotype 1 with Pegasys/RBV - (11/06/06)
     
  931. AASLD: 72 Weeks Pegasys/RBV in Genotype 1 Improves SVR Rate For Patients With Early Viral Response (2 log reduction at wk 12) But HCV RNA >50 IU/mL - (11/06/06)
     
  932. AASLD: 72 Weeks Peg/RBV for 'Slow-Responders' Improves SVR Rate - (11/06/06)
     
  933. AASLD: 400,000 IU/ml was the best cut-off level between Low VL and High VL - (11/06/06)
     
  934. AASLD: The cyclophilin inhibitor DEBIO-025 has a potent dual anti-HIV and anti-HCV activity in treatment-naive HIV/HCV co-infected subjects - (11/03/06)
     
  935. AASLD: Entecavir vs Adefovir in HBeAg+ Naives 24 Weeks EARLY Study - (11/03/06)
     
  936. AASLD: Ribavirin Dose/Levels Predicts Outcome in Pegasys/RBV ACCELERATE Study Comparing 16 vs 24 Weeks Therapy - (11/03/06)
     
  937. AASLD: Week 4 Response Predicts SVR in Pegasys/RBV 16 Week Therapy Study in Genotypes 2/3 - (11/03/06)
     
  938. AASLD: Win-R Study: Ribavirin Weight-Base Dosing in High Weight Patients; Treatment Responses to PegIntron/RBV for Elderly Patients and by Patient Ethnicity - (11/02/06)
     
  939. AASLD: Weight-Based Ribavirin Improves SVR Rate for Patients >125 kg (275 lbs) - (11/02/06)
     
  940. AASLD: Infergen (Consensus Interferon) Phase III DIRECT Study End of Treatment Results - (11/02/06)
     
  941. AASLD: Current status of Subjects Receiving Pegays and Ribavirin Follow-On Therapy After 28 Days Treatment with the Hepatitis C Protease Inhibitor Telaprevir (VX-950), Pegasys & RBV - (11/02/06)
     
  942. AASLD: Win-R Study: Ribavirin Weight-Base Dosing in High Weight Patients; Treatment Responses to PegIntron/RBV for Elderly Patients and by Patient Ethnicity - (11/02/06)
     
  943. AASLD: VX-950 HCV Protease Inhibitor Resistance Profile: combination therapy suppresses drug resistance - (11/01/06)
     
  944. AASLD: New Drug Lowers AST/ALT Levels in Chronic HCV - (11/01/06)
     
  945. AASLD: Albuferon Phase 2 Study Results Reported in Posters at AASLD - (11/01/06)
     
  946. AASLD: Albuferon Quality-Of-Life Reported - (11/01/06)
     
  947. 75% of College Students Report Risk Factors for Hepatitis C - (10/31/06)
     
  948. Colchicine May Delay Progression of Viral Cirrhosis to Liver Cancer - (10/31/06)
     
  949. Culturing Hepatitis C for new drugs - (10/31/06)
     
  950. HCV Alters Neurotransmission - (10/31/06)
     
  951. HCV & Neurologic Dysfunction - (10/31/06)
     
  952. Intermune/Roche HCV Protease Joins HCV Protease Battle - (10/31/06)
     
  953. Intermune Inks HCV Drug Development Agreement With Roche - (10/31/06)
     
  954. Tacere Therapeutics Secures Financing And Resumes Development Of RNAi Hepatitis C Drug - (10/31/06)
     
  955. ROCHE PROGRESSES ITS ORAL POLYMERASE INHIBITOR INTO PHASE II DEVELOPMENT STUDY IN PATIENTS WITH HEPATITIS C - (10/31/06)
     
  956. Novel Robust Hepatitis C Virus Mouse Efficacy Model - (10/31/06)
     
  957. AVI BioPharma technology ineffective against hepatitis C - (10/31/06)
     
  958. AASLD: Roche HCV Polymerase Inhibitor Shows Potency: 4 log viral load reduction - (10/31/06)
     
  959. AASLD: Valopicitabine (NM283) plus Peg-Interferon in Treatment-Naive Hepatitis C Patients with HCV Genotype-1 Infection: HCV RNA Clearance During 24 Weeks of Treatment - (10/31/06)
     
  960. AASLD: SELECTION AND CHARACTERIZATION OF HEPATITIS C VIRUS REPLICONS RESISTANT TO A POTENT POLYMERASE INHIBITOR A-837093 - (10/30/06)
     
  961. AASLD: In vitro antiviral effects of combinations of Abbott HCV polymerase inhibitors with IFN or NS3/4A protease inhibitors - (10/30/06)
     
  962. AASLD: The Antiviral Efficacy of an HCV Polymerase inhibitor in the Chimpanzee Model: Genotypic and Phenotypic Analysis - (10/30/06)
     
  963. AASLD: Coffee Appears to Reduce Risk of Fibrosis in HCV+ - (10/30/06)
     
  964. AASLD: Daily Cannabis Use by HCV+ Increased Odds of Moderate to Severe Fibrosis by 7- Fold - (10/30/06)
     
  965. AASLD: Higher Fixed Dosing with PEGASYS in Difficult-to-Treat Patients - (10/30/06)
     
  966. AASLD: Early Week 4 Response Predicts SVR in Genotype 1 - (10/30/06)
     
  967. AASLD: Roche's Oral Polymerase Inhibitor R1626 Shows Strong Antiviral Activity in Chronic Hepatitis C Patients - (10/30/06)
     
  968. AASLD: Update on NM283, HCV Polymerase Inhibitor, at New 200 mg Dose - (10/30/06)
     
  969. AASLD: New Data for Investigational Hepatitis C Drug Telaprevir (VX-950) to be Presented at AASLD Meeting - (10/30/06)
     
  970. AASLD: Valeant Pharmaceuticals Previews 24-Week Results of Direct Trial for Infergen (Consensus Interferon) - (10/30/06)
     
  971. ICAAC: Baseline viral load (400,000 IU/mL) as a predictor of SVR rate with peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in HCV/HIV Coinfected in Apricot Study - (10/16/06)
     
  972. ICAAC: HIV Antiretroviral-Related Hyperlipidemia is Mitigated by HCV Co-Infection - (10/16/06)
     
  973. HUMAN GENOME SCIENCES ANNOUNCES PHASE 3 CLINICAL DEVELOPMENT PROGRAM FOR ALBUFERON IN CHRONIC HEPATITIS C - (10/05/06)
     
  974. ICAAC: Roche HCV Polymerase Inhibitor: two preclinical studies - (10/02/06)
     
  975. ICAAC: HCV-796 Displays Potent Antiviral Activity in Replicon and in Chimeric Mice Infected with Hepatitis C Virus (HCV) - (10/02/06)
     
  976. ICAAC: The Nucleoside Inhibitor MK-0608 Mediates Suppression of HCV Replication for >30 Days in Chronically Infected Chimpanzees - (10/02/06)
     
  977. Insulin resistance and HCV: Will new knowledge modify clinical management? - (09/21/06)
     
  978. GAY MEN AND HEP C - (09/21/06)
     
  979. 28 Days of the Hepatitis C Protease Inhibitor VX-950, in Combination With PEG-Interferon-ALFA-2a and Ribavirin, Is Well-Tolerated and Demonstrates Robust Antiviral Effects - (09/18/06)
     
  980. Viramidine Did Not Meet Efficacy Endpoint in Viser2 - (09/15/06)
     
  981. Treatment for hepatitis C virus and cannabis use in illicit drug user patients: implications and questions - (09/15/06)
     
  982. Cannabis use improves retention and virological outcomes in patients treated for hepatitis C - (09/15/06)
     
  983. Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-α2b plus ribavirin treatment in a patient with hepatitis B and C coinfection - (09/15/06)
     
  984. New Compound Protects Against Liver Cancer - (09/11/06)
     
  985. Hepatitis C virus therapies - (09/08/06)
     
  986. Prevention of mortality from hepatitis B and hepatitis C - (09/08/06)
     
  987. Treating viral hepatitis C: efficacy, side effects, and complications - (09/07/06)
     
  988. FDA Hepatitis C Public Hearing on Study Design Issues for New Hep C Drugs - (09/07/06)
     
  989. NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon - (08/31/06)
     
  990. ViroPharma Announces Positive Data From Phase 1b Combination Study Of HCV-796 And Pegylated Interferon In Hepatitis C Patients - (08/31/06)
     
  991. Hispanics Have More Aggressive Liver Disease in LA County Hepatitis Clinic - (08/31/06)
     
  992. IAC: HCV Death Rate Doubles Among IDUs in Last 5 Years - (08/24/06)
     
  993. Peregrine's Final HCV Phase 1a Study Results Accepted for Oral Presentation at AASLD Annual Meeting - (08/16/06)
     
  994. Cost effectiveness of interferon or peginterferon with ribavirin for histologically mild chronic hepatitis C - (08/14/06)
     
  995. 72 Weeks Pegasys/RBV Improves SVR for When HCV-RNA is Detectable at Week 4 - (08/09/06)
     
  996. Pegasys/RBV in African-Americans - (08/09/06)
     
  997. Pre-treatment LDL & T-Cholesterol Predict SVR in HCV+ - (08/08/06)
     
  998. Acute hepatitis C: Hi Dosage and compliance Predict SVR - (08/08/06)
     
  999. Interferon Enhancer Drug EMZ702 Study + PegIFN/RBV - (08/04/06)
     
  1000. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial - (08/01/06)
     
  1001. A low-carbohydrate diet rapidly and dramatically reduces intrahepatic triglyceride content - (08/01/06)
     
  1002. CDC Study on HCV Risk Transmission & Tattoos/Body Piercing, Snorting Drugs - (08/01/06)
     
  1003. Canada To Compensate HCV-Infected Tainted Blood Victims - (07/31/06)
     
  1004. Unique HIV Clinic in India - (07/31/06)
     
  1005. BMI, Waist Size, and Fitness & Central Adiposity Associated with NAFLD (nonalcoholic fatty liver disease) - (07/30/06)
     
  1006. GlaxoSmithKline announces FDA approval and the launch of Avandamet (rosiglitazone maleate and metformin HCl) as inital therapy in the treatment of type 2 diabetes - (07/30/06)
     
  1007. Cancer Incidence Much Higher in People with Hep B or C - (07/24/06)
     
  1008. What Is the Role of GB Virus C Infection in Hepatitis C Virus/HIV Coinfection? - (07/20/06)
     
  1009. Statin Drugs Inhibit HCV in vitro - (07/10/06)
     
  1010. Diagnostic and Prognostic Role of α-Fetoprotein in Hepatocellular Carcinoma: Both or Neither? - (07/10/06)
     
  1011. Extrahepatic replication of HCV: Insights into clinical manifestations and biological consequences - (07/06/06)
     
  1012. Vertex Pharmaceuticals and Janssen Pharmaceutica, a Johnson & Johnson Company, Form Collaboration to Develop and Commercialize VX-950 for Treatment of Hepatitis C - (06/30/06)
     
  1013. Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson & Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV - (06/30/06)
     
  1014. Phase 2 Study of VX-950, Pegasys, and Copegus in Hepatitis C- study sites - (06/30/06)
     
  1015. Hepatic Steatosis Is Associated with Fibrosis, Nucleoside Analogue Use, and Hepatitis C Virus Genotype 3 Infection in HIV-Seropositive Patients: Steatosis was present in 69% of patients - (06/29/06)
     
  1016. Dideoxynucleoside Analogues Should Be Used Cautiously in Patients with Hepatic Steatosis EDITORIAL - (06/29/06)
     
  1017. Anadys/Novartis HCV Toll-Receptor Drug Study Stopped for Animal Toxicity - (06/26/06)
     
  1018. A very low toxic agent induces apoptosis and reduces growth of human hepatocellular carcinoma cells - (06/23/06)
     
  1019. BREASTFEEDING & HCV TRANSMISSION - (06/23/06)
     
  1020. Drug Resistance Wksp: New HCV Polymerase Inhibitor is in Early Development; resistance at 282 is associated with polymerase drug resistance, but PSI-6130 may remain active when mutation is present - (06/20/06)
     
  1021. Drug Resistance Wksp: New achievements in hepatitis C virus research and their implications for antiviral therapy - (06/20/06)
     
  1022. Drug Resistance Wksp: Coffee, Cirrhosis, and Transaminase Enzymes - (06/14/06)
     
  1023. Drug Resistance Wksp: Selection and characterization of mutations conferring resistance to a HCV RNA dependent RNA polymerase inhibitor A-848837 in vitro - (06/14/06)
     
  1024. Drug Resistance Wksp: Merck's New HCV Polymerase Inhibitor Drug Reduces HCV Viral Load by 5.7 Log in 7 Days in Chimps - (06/14/06)
     
  1025. Coffee Consumption May Protect Liver from Alcohol - (06/13/06)
     
  1026. BMI, Insulin Resistance Contribute to Fibrosis - (06/12/06)
     
  1027. Thiazolidinediones and hepatic fibrosis: don't wait too long - (06/12/06)
     
  1028. DDW: Consensus IFN vs Pegasys for 72 Wks in Peg/RBV Relapsers - (06/12/06)
     
  1029. DDW: Consensus IFN for Peg/RBV Nonresponders in Germany - (06/12/06)
     
  1030. DDW: Hi-Dose Consensus IFN in Prior Peg/RBV Users - (06/12/06)
     
  1031. DDW: Consensus Interferon in Peg/RBV Relapsers & Nonresponders in Dallas: 48 weeks end of treatment viral response - (06/12/06)
     
  1032. HCV is Detected in Liver of HCV Antibody-Positive But HCV RNA Negative Patients, so don't assume HCV has been cleared if viral load is undetectable - (06/08/06)
     
  1033. Sexual Dysfunction is Highly Prevalent Among Men with Chronic Hepatitis C Virus Infection and Negatively Impacts Health-Related Quality of Life - (06/07/06)
     
  1034. Study Finds Diabetes is Associated with HCV & HBV, Triglycerides, Steatosis & More Severe Fibrosis - (06/07/06)
     
  1035. Novartis strengthens infectious disease portfolio by acquiring rights to Albuferon(TM), a hepatitis C interferon drug set to enter Phase III trials - (06/06/06)
     
  1036. Peginterferon alfa-2a (Pegasys) and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response - (06/06/06)
     
  1037. Study finds steatosis (fatty liver) is more common & severe in HIV coinfected compared to HCV monoinfected - (06/06/06)
     
  1038. DDW: The Impact of Growth Factors on Pegylated Interferon alfa-2b and Ribavirin Dose Reduction in Patients Treated for Genotype 1 Chronic Hepatitis C - (06/06/06)
     
  1039. DDW: Preclinical Characteristics of ITMN-191, an Orally Active Inhibitor of the HCV NS3/4A Protease Nominated for Preclinical Development - (06/06/06)
     
  1040. DDW: Pharmacokinetic Analysis and Liver Concentrations of a Series of Macrocyclic Peptidomimetic Inhibitors of HCV NS3/4A Protease: Identification of ITMN-191, a Potent NS3/4A Protease Inhibitor with High Liver Exposure Across Multiple Species - (06/06/06)
     
  1041. DDW: Growth Factors Versus Dose Reduction for Pegylated Interferon alfa-2b and Ribavirin-Associated Neutropenia and Anemia in HIV/HCV Co-Infected Patients - (06/06/06)
     
  1042. DDW: Smoking Cigarettes Reduced SVR Rates in Peg/RBV Study - (06/05/06)
     
  1043. DDW: The Effect of Liver Fibrosis and Cirrhosis on SVR in 4913 Patients With Hepatitis C: Results From The WIN-R Trial - (06/05/06)
     
  1044. DDW: Affect of Viral Load on SVR Rates to PegIntron/RBV in Genotype 1 Patients in WIN-R Study - (06/05/06)
     
  1045. DDW: Differences In Treatment Outcome To Antiviral Therapy Based On Genotype And Viral Load In Hepatitis C Genotypes 2 And 3 In The WIN-R Trial - (06/02/06)
     
  1046. Metabolics/Belly Fat Advance HCV Disease - (05/30/06)
     
  1047. EASL: A Phase 2 Dose-Escalation Study of (Albuferon) albumin interferon alfa-2b Combined with Ribavirin in Non-responders to Prior Interferon Based Therapy for Chronic Hepatitis C Infection Phase - (05/30/06)
     
  1048. EASL: Interim (Week 12) Phase 2B Virological Efficacy and Safety Results of Albuferon (albumin interferon alfa-2b) Combined with Ribavirin in Genotype 1 Treatment-naive Chronic Hepatitis C Infection - (05/30/06)
     
  1049. DDW: NM283 + Peg: differences in response between treatment naives & nonresponders; dose reductions for safety concerns - (05/26/06)
     
  1050. DDW: HCV-796, new HCV non-nucleoside- 14 day study - (05/26/06)
     
  1051. DDW: "Week 12 Antiviral Activity of Higher Doses of albumin interferon alfa-2b (Albuferon) Combined with Ribavirin in Non-responders to Prior Interferon Based Therapy for Chronic HCV-Infection" - (05/25/06)
     
  1052. DDW: Entecavir (ETV) Demonstrates Consistent Responses Throughout Baseline Disease and Demographic Subgroups for the Treatment of Lamivudine-Refractory (LVD-ref) HBeAg(+) Patients with Chronic Hepatitis B - (05/25/06)
     
  1053. DDW: Final Analysis of Virological Outcomes and Resistance During 5 Years of adefovir Dipivoxil Monotherapy in HBeAg-Negative Patients - (05/25/06)
     
  1054. DDW: 96-Week Viral Suppression Data From Two Studies Presented For BARACLUDE (entecavir) In Chronically-Infected Hepatitis B Patients - (05/24/06)
     
  1055. DDW: Results from a Cost-Effectiveness Study Demonstrate Positive Economic Impact with PEGASYS Treatment - (05/24/06)
     
  1056. DDW: G-CSF is safe and improves adherence and SVR in HCV patients with genotype 1 who develop Peg-IFNa-2b related severe neutropenia - (05/24/06)
     
  1057. DDW: African-Americans' response to Interferon: preliminary results from Virahep C Study - (05/24/06)
     
  1058. DDW: VX-950 HCV Protease Inhibitor + Pegasys/RBV: 28 days study results in treatment-naive - (05/24/06)
     
  1059. Vertex Pharmaceuticals Initiates the First of Two Major Phase II Studies of VX-950 in Treatment-Naive HCV Patients - (05/23/06)
     
  1060. DDW: ViroPharma Announces Presentation of HCV-796 Phase 1b Data at Digestive Disease Week - (05/23/06)
     
  1061. DDW: HCV Protease ITMN 191, In Vitro Resistance - - (05/23/06)
     
  1062. DDW: High Dose Albuferon -early data - (05/23/06)
     
  1063. DDW: Hepatitis Patients at Risk for Accidental Acetaminophen Toxicity - (05/23/06)
     
  1064. DDW: Reliable early prediction of viral relapse by detection of minimal residual hepatitis C viremia at treatment week 12 with Sensitive HCV Viral load Test - (05/22/06)
     
  1065. DDW: High Prevalence of Hepatitis C Virus Infection Among Russian Immigrants in the New York City Metropolitan Area: Results of A Community-Based Screening Program - (05/22/06)
     
  1066. DDW: Noninvasive Biomarker Test for Fatty Liver - (05/22/06)
     
  1067. DDW: Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients - (05/22/06)
     
  1068. DDW: The prevalence of metabolic syndrome (53%) in veterans with chronic hepatitis C virus - (05/22/06)
     
  1069. Study details hepatitis C ability to block immune system response - (05/19/06)
     
  1070. Elevated ALT Associated with Heart Disease - (05/19/06)
     
  1071. CPG 10101, new tollreceptor antagonist HCV drug, receives Fast Track Deisngation for Treatment-Refractory Patients - (05/17/06)
     
  1072. Hepatitis C: A Bitter Harvest EDITORIAL - (05/16/06)
     
  1073. The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 - (05/16/06)
     
  1074. EASL: Phase II Multi-Center, Dose-Escalating study of LB80380 (ANA380) in hepatitis B Patients with Lamivudine-Resistant YMDD Mutant HBV - (05/16/06)
     
  1075. AVI BioPharma Presents Initial Results on Hepatitis C Virus Clinical Trial at the International Conference on Antiviral Research Annual Meeting - (05/15/06)
     
  1076. EASL: NM283 HCV Polymerase Inhibitor in Previous Nonresponders to PegIFN/RBV - (05/15/06)
     
  1077. EASL: 5 Year Followup of SVRs with PegIntron/RBV-98% Continued SVR5 - (05/15/06)
     
  1078. EASL: Early Viral Response to New HCV Drug CPG 10101 Toll-Receptor Antagonist, in Combination with Pegylated Interferon and/or Ribavirin, in Chronic HCV Genotype 1 Infected Patients with Prior Relapse Response - (05/09/06)
     
  1079. EASL: Randomized, Placebo-Controlled, Dose-Escalation Trial of New HCV Drug CPG 10101 Toll-Receptor Antagonist in Patients with Chronic Hepatitis C Virus - (05/09/06)
     
  1080. EASL: Psych Disorders Caused 4 Times Higher HCV Therapy Withdrawal Rates; Quality of Life Before Therapy Lower in HCV+ with Psych Disorders - (05/08/06)
     
  1081. EASL: Viramidine Phase III Study-did not meet efficacy endpoint Valeant looking at weight-based dosing of Viramidine based on post-hoc analysis - (05/05/06)
     
  1082. EASL: Pegasys/RBV In Post Liver Transplant for Recurrent HCV - (05/05/06)
     
  1083. EASL: The HCV Protease Inhibitor SCH 503034 in Combination with PEG-IFN a-2b in the treatment of HCV-1 PEG-IFN +/- Ribavirin Non-Responders: Antiviral Activity & HCV Variant Analysis - (05/03/06)
     
  1084. EASL: PHARMACOKINETIC BOOSTING OF VX-950 AND SCH 503034, INHIBITORS OF HCV PROTEASE, BY CO-DOSING WITH RITONAVIR - (05/02/06)
     
  1085. EASL: Initial Results of a 14-Day Study of the Hepatitis C Virus Protease Inhibitor VX-950, In Combination with Peginterferon-alfa-2a - (05/02/06)
     
  1086. EASL: Interim results of a multiple ascending dose study of R1626, a novel nucleoside analogue targeting HCV polymerase, in chronic HCV patients - (05/02/06)
     
  1087. EASL: Further reduction of ribavirin dose in HCV genotype 2/3 patients receiving peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) - (05/02/06)
     
  1088. EASL: VX-950 HCV Protease Inhibitor Resistance Profile - (05/02/06)
     
  1089. EASL: Researchers Report Initial Results for 14-day Phase Ib Study of VX-950, and Pegylated Interferon, Showing Anti-HCV Activity in Combination in Hepatitis C Patients - (05/02/06)
     
  1090. EASL: New Drug for HCV Thrombocytopenia Appears Effective In Interim Study Results - (05/02/06)
     
  1091. EASL: New HCV Drugs- Protease Inhibitors & Polymerase inhibitors and Drug Resistance - (05/02/06)
     
  1092. EASL: HCV Polymerase Inhibitor Drug NM-283 Dose Reduced - (05/02/06)
     
  1093. EASL: Peginterferon alfa-2a (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 or 3 - (05/01/06)
     
  1094. EASL: 24-week treatment regimen with peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in HCV genotype 1 or 4 'super-responders' -Week 4 Rapid Viral Response (RVR) - (05/01/06)
     
  1095. EASL: NM283, HCV Polymerase Inhibitor Study in Naives: dose change for development - (05/01/06)
     
  1096. Vertex Adds 24-Week Arm to 12-Week VX-950 study - (04/26/06)
     
  1097. EASL: Ritonavir Increases levels of Schering HCV Protease Inhibitor SCH503034 - (04/27/06)
     
  1098. Higher Dose COPEGUS(R) 400mg Tablets Approved in the Netherlands as First Step to European Availability - (04/26/06)
     
  1099. Novelos Therapeutics IND for Novel Hepatitis C Drug is Accepted by FDA; Company Is on Track to Begin Patient Enrollment by July 2006 - (04/24/06)
     
  1100. AVI-4065, an Antisense Approach to HCV Therapy - (04/24/06)
     
  1101. Phase II Study Enrolled: SCHERING-PLOUGH PROVIDES UPDATE ON ORAL HCV PROTEASE INHIBITOR SCH 503034 CLINICAL DEVELOPMENT PROGRAM FOR HEPATITIS C - (04/24/06)
     
  1102. EASL Preview of Selected Abstracts (studies reported) - (04/24/06)
     
  1103. Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Dual Infection - (04/21/06)
     
  1104. Interferon 'Enhancing' Therapy-phase I/II Study - (04/21/06)
     
  1105. 24 weeks Pegasys/RBV: Rapid Viral Response & HCV RNA Predict SVR in Genotype - (04/21/06)
     
  1106. Tailoring antiviral therapy in hepatitis C - (04/21/06)
     
  1107. Extrahepatic manifestations of hepatitis C virus infection, 2 - (04/21/06)
     
  1108. Extrahepatic Manifestations of Hepatitis C Virus - (04/19/06)
     
  1109. Hepatitis C Virus Infection in African Americans - (04/19/06)
     
  1110. HCV/HIV Coinfection Higher Death Rates Higher in VA Study - (04/19/06)
     
  1111. Genetic Host Factor May Be Associated with HCV Viral Clearance & Disease, Study Finds - (04/13/06)
     
  1112. Liver Biopsy Remains Gold Standard - (04/13/06)
     
  1113. Hepatitis C Treatment Eligibility and Outcomes Among Patients With Psychiatric Illness: successful therapy can be accomplished - (04/10/06)
     
  1114. Stanford Scientist to Discuss New Approach to Treating Hepatitis C Virus - (04/06/06)
     
  1115. HCV Therapy Successful for With Mental illness/substance abuse - (04/05/06)
     
  1116. HCV Drug Development Slowed for Two Drugs - (04/04/06)
     
  1117. SVR rates and health-related quality of life after interferon+ribavirin therapy in patients with chronic HCV and persistently normal ALT levels - (04/04/06)
     
  1118. Review article: predicting response in hepatitis C virus therapy - (04/04/06)
     
  1119. Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection - (04/04/06)
     
  1120. Researchers show laboratory hepatitis C strain is also infectious in animal models - (03/30/06)
     
  1121. Only 4% of IDUs Eligible for HCV Therapy, in this study - (03/30/06)
     
  1122. HCV Toll-Receptor Drug Actilon 12 Week Data Looks Promising - (03/23/06)
     
  1123. Depression, anemia and health-related quality of life in chronic hepatitis C: history of depression is most important predictor of quality of life & outcome for both on HCV treatment & before treatment in HCV+ individuals, study finds - (03/21/06)
     
  1124. Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin - (03/21/06)
     
  1125. SCHERING-PLOUGH AND PTC THERAPEUTICS ANNOUNCE COLLABORATION FOR DEVELOPMENT OF PTC'S PRECLINICAL HEPATITIS C COMPOUNDS - (03/21/06)
     
  1126. Valeant Releases Viramidine Data - Falls Short of Efficacy Goal - (03/21/06)
     
  1127. SCH 503034 Protease Inhibitor Monotherapy in Hepatitis C Virus Genotype-1 IFN-a Non-Responders - (03/16/06)
     
  1128. SCH 503034 HCV Protease Inhibitor Plus PEG-IFN a-2b in HCV-1 PEG-IFN a-2b Non-responders: Phase 1b Results - (03/16/06)
     
  1129. Management of Recurrent Viral Hepatitis B and C After Liver Transplantation - (03/15/06)
     
  1130. Albuferon vs Pegasys Phase 2B Study Results - (03/15/06)
     
  1131. HCV Mother-to-child transmission: HAART May Reduce HCV MTC; C-Section Did Not Reduce MTC - (03/15/06)
     
  1132. "Non-invasive evaluation of hepatic fibrosis: don't count your chickens before they're hatched" - (03/09/06)
     
  1133. HCV+ with Schizophrenia Get HCV Therapy - (03/08/06)
     
  1134. Sleep disorders and brain MRI as early indicators of subclinical hepatic encephalopathy - (03/08/06)
     
  1135. Schering-Plough Statement on Status of SCH 503034 Clinical Development Plans - (03/08/06)
     
  1136. Vertex's Hepatitis C Drug Has 'Gold Standard' Potential - (03/03/06)
     
  1137. CROI: Starting HAART Earlier Results in Highest CD4 Count (03/02/06)
     
  1138. CROI: Heart Disease in HIV: Carotid IMT, measuring plaque in arteries (03/02/06)
     
  1139. Hepatitis C Treatment for People With Severe Mental Illness & Depression - (03/01/06)
     
  1140. Coley Pharmaceutical Group Initiates Phase II Clinical Study of Actilon Toll-receptor Agonist for Hepatitis C - (02/28/06)
     
  1141. New HCV Drug Tarvacin, an 'anti-phosphotidylserine mmunotherapeutic' - (02/28/06)
     
  1142. AASLD: Safety & Efficacy of Schering HCV Protease Inhibitor + Peg-Intron for Genotype 1 Non-responders to Peginterferon/ribavirin, with & without Ribavirin Phase II Study (02/24/06)
     
  1143. Hep C Protease Inhibitor: Waging War on Hepatitis C - (02/24/06)
     
  1144. New HCV Drug Tarvacin, monoclonal antibody - (02/24/06)
     
  1145. Liver Fibrosis Found in HIV/HCV-Coinfected Patients With Normal ALT - (02/24/06)
     
  1146. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors - (02/24/06)
     
  1147. CROI: Pegasys Rapid Response at Week 4 in APRICOT Yields 75-82% SVR in Genotype 1 Patients (02/21/06)
     
  1148. Peregrine advances hepatitis C drug - (02/17/06)
     
  1149. New Compound May Protect Against Liver Cancer - (02/15/06)
     
  1150. Scientists Call For Hepatitis Treatment Of Young Injection Drug Users, Public Health Intervention - (02/08/06)
     
  1151. Vertex stock price shoots up on hepatitis C results - (02/08/06)
     
  1152. Arrow Therapeutics selects Hepatitis C clinical candidate - (02/08/06)
     
  1153. Noninvasive measures of liver fibrosis- a Review - (02/08/06)
     
  1154. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study - (02/08/06)
     
  1155. Acute hepatitis C: In search of the optimal approach to cure - (02/08/06)
     
  1156. Thalidomide in the Treatment of Chronic Hepatitis C Unresponsive to Alfa-Interferon and Ribavirin - (02/08/06)
     
  1157. 96% of IDUs Not eligible for HCV Therapy, in this study - (02/01/06)
     
  1158. Reversal of hepatic fibrosis - Fact or fantasy? - (02/01/06)
     
  1159. AASLD: Study Finds EPO Improved SVR Only in High Dose RBV Group (02/01/06)
     
  1160. HCV coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort - (02/01/06)
     
  1161. Hepatitis C's effect on HIV disease remains elusive despite three new studies; Coinfection Death Rate - (02/01/06)
     
  1162. AASLD: Study Finds EPO Improved SVR Only in High Dose RBV Group (01/31/06)
     
  1163. AASLD: WIN-R Study: final results of Weight-Based dosing study of ribavirin in treatment-naive patients (01/31/06)
     
  1164. Intl Coinfection Wrkshp: Fibrosis Progression in HIV/HCV Coinfected Patients with Paired Liver Biopsies: evaluation of risk factors (01/30/06)
     
  1165. Acute hepatitis C: In search of the optimal approach to cure Editorial - (01/30/06)
     
  1166. Schering-Plough HCV Protease Inhibitor: FDA Grants Fast Track - (01/30/06)
     
  1167. Fatty Liver (Steatosis) May Cause Fibrosis & Liver Cancer - (01/30/06)
     
  1168. Acetaminophen (Tylenol, Paracetamol) Overdose IS Easier Than Many Realize - (01/30/06)
     
  1169. HBV+HCV+HDV-dynamic diseases when in combination - (01/30/06)
     
  1170. Hope of liver cancer blood test - (01/30/06)
     
  1171. New Antisense HCV Drug AVI-4065 in Study - (01/30/06)
     
  1172. STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER? - (01/27/06)
     
  1173. HIV Sexual Transmission Risks: during acute & chronic with <400 c/ml - (01/27/06)
     
  1174. Significance of liver negative-strand HCV RNA quantitation in chronic hepatitis C - (01/25/06)
     
  1175. Intl Coinfection Wrkshp: Fatigue may be misdiagnosed as depression during anti-HCV therapy in HIV coinfected (01/25/06)
     
  1176. Intl Coinfection Wrkshp: Accelerated HCV Progression in HIV: paired liver biopsies (01/25/06)
     
  1177. Alcohol & Depression, Anemia: barriers to HCV treatment - (01/24/06)
     
  1178. Migenix to start HCV drug trial in Q2 - (01/24/06)
     
  1179. Liver Disease in HIV: predictors of severity - (01/24/06)
     
  1180. Hepatitis/HIV in Europe: 10% of HCV+ initiated therapy - (01/23/06)
     
  1181. Epidemiology of viral hepatitis and HIV co-infection - (01/23/06)
     
  1182. Management of hepatocellular carcinoma in HIV- infected patients - (01/23/06)
     
  1183. New HCV drug study: cancer drug Tarvacin - (01/23/06)
     
  1184. Consensus Interferon in IFN/RBV Non-responders - (01/23/06)
     
  1185. New HCV Drugs Discovery - (01/23/06)
     
  1186. HCV Genotype 3 Associated with ART Hepatoxicity, Perhaps Due to Fatty Liver - (01/20/06)
     
  1187. Diagnosis of Hepatic Fibrosis and Cirrhosis by FibroScan, Transient Elastography, in HIV/Hepatitis C Virus-Coinfected Patients - (01/20/06)
     
  1188. Maintenance PegIntron Study in HCV/HIV Coinfected Patients - (01/18/06)
     
  1189. HCV Impaired CD4 Response to ART, in this study - (01/18/06)
     
  1190. Intl Coinfection Wrkshp: HIV May Cause Steatosis- 50% rates of steatosis in HIV & HCV (01/18/06)
     
  1191. Intl Coinfection Wrkshp: New Drugs for HCV & HBV (01/17/06)
     
  1192. Intl Coinfection Wrkshp: Liver Transplantation in HIV Infected Patients (01/17/06)
     
  1193. Intl Coinfection Wrkshp: Optiming Response Rates to Peg/RBV in Coinfected Patients: increased Ribavirin dosing; extending therapy duration (01/13/06)
     
  1194. New Peg-Intron Maintenance Study - (01/13/06)
     
  1195. Intl Coinfection Wrkshp: TDM for ART Hepatoxicity (01/12/06)
     
  1196. Coinfection Should Be Addressed Immediately - (01/12/06)
     
  1197. Review article: drug therapy for non-alcoholic fatty liver disease - (01/12/06)
     
  1198. Viral Eradication of HCV - (01/12/06)
     
  1199. CHILDHOOD HEPATITIS C VIRUS INFECTION - (01/12/06)
     
  1200. Lipids are Lower in Chronic HCV - (01/11/06)
     
  1201. The challenge of progressive hepatitis C following liver transplantation - (01/11/06)
     
  1202. Romark to Develop Alinia(R) (nitazoxanide) as New Treatment for Chronic Hepatitis C - (01/10/06)
     
  1203. Plan to Advance Albuferon to Phase 3 in Chronic Hepatitis C - (01/10/06)
     
  1204. ICAAC: Pegasys/RBV in APRICOT Study- Adherence Improves SVR 300% in genotype 1 (01/09/06)
     
  1205. ICAAC: Coinfection Report from ICAAC 2005: 33% of coinfected with normal ALT had advanced liver disease in Spanish study (01/09/06)
     
  1206. Pioglitazone May Reduce Signs of Metabolic Syndrome & Cardiovascular Risk in Nondiabetics as well as in Diabetics - (01/09/06)
     
  1207. Bristol-Myers Squibb and Gilead Announce Data Supporting Bioequivalence for Single-Pill Fixed-Dose Regimen of Sustiva (efavirenz) and Truvada (FTC and tenofovir) - (01/09/06)
     
  1208. Gilead Announces the Advancement of HIV Integrase Inhibitor GS 9137 to a Phase II Clinical Trial - (01/09/06)
     
  1209. Ophthalmologic side effects during alpha-interferon therapy for viral hepatitis - (01/09/06)
     
  1210. NM283+Pegasys Reduced HCV RNA by 4 log After 4 weeks - (01/09/06)
     
  1211. VX-950 + PegIFN Achieves 5.5 Log Drop in HCV RNA After 14 Days - (01/09/06)
     
  1212. Milk Thistle Interactions - (01/05/06)
     
  1213. MedMira Granted Hepatitis C Patent in Europe - (01/05/06)
     
  1214. InterMune Completes Divestiture of Infergen for up to $135.5 Million in Cash - (01/05/06)
     
  1215. Transplant/BODY PARTS SCANDAL - (01/05/06)
     
  1216. Liver Disease, Fatty Liver in HIV - (01/05/06)
     
  1217. HCC Mismanaged in Medicare Population - (01/05/06)
     
  1218. Tibotec Identifies HCV Drug Candidate - (01/05/06)
     
  1219. AASLD: Double-Dose Peginterferon Alfa-2b with weight-Based Ribavirin Improves Response for Interferon/Ribavirin Non-Responders with Hepatitis C: Final Results of RENEW Study (12/29/05)
     
  1220. EACS: HAART & SVR in APRICOT Study (12/29/05)
     
  1221. XTL-6865 To prevent Hepatitis C Reinfection Following Liver Transplant - (12/28/05)
     
  1222. Saliva-based hepatitis C test developed - (12/28/05)
     
  1223. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo - (12/28/05)
     
  1224. Editorial: 24 weeks PegIFN 2b for genotype 1/Low HCV-RNA - (12/28/05)
     
  1225. How Should TMA Be Used-- Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse - (12/28/05)
     
  1226. HCV Care & Treatment in Mass & S Dakota Prisons - (12/28/05)
     
  1227. Milk Thistle for Alcoholic and/or Hepatitis B or C Liver Diseases: study showed no benefit-A - (12/21/05)
     
  1228. Liver Fibrosis in HIV+ Patients With Hepatitis C Virus: Role of Persistently Normal Alanine Aminotransferase Levels - (12/21/05)
     
  1229. Roche New Anemia Drug Dosed 2-4 Weeks Apart - (12/21/05)
     
  1230. Antifibrotic therapy in chronic liver disease - (12/21/05)
     
  1231. ViRexx to Present Hepatitis C Vaccine Data at HepDART 2005 - (12/14/05)
     
  1232. AASLD: Double-Dose Peginterferon Alfa-2b with weight-Based Ribavirin Improves Response for Interferon/Ribavirin Non-Responders with Hepatitis C: Final Results of RENEW Study (12/14/05)
     
  1233. AASLD: Safety of Double Dose Pegasys (REPEAT Study) (12/12/05)
     
  1234. HBV, HCV, & HIV Prevalence High in Psych Hospitals - (12/12/05)
     
  1235. HCV & Coinfection-Expected Increased Hospitalizations Rates: complications expected to quadruple - (12/08/05)
     
  1236. Hospitalizations increased for liver-related complications from 8% to 13% and for chronic HCV from 1% to 5% in this period: 1996-2000; 4-fold increase - (12/08/05)
     
  1237. FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 - (12/08/05)
     
  1238. HCV RNA level is a predictor of ESLD death among persons with chronic HCV infection, study finds - (12/07/05)
     
  1239. AASLD: 24 Week Pegasys+RBV Treatment SVR in Genotype 1 Predicted by Wk 4 Response (12/07/05)
     
  1240. AASLD: 24 Week Pegasys + RBV for Genotype 1: SVR predicted by week 4 response (12/07/05)
     
  1241. HCV Protease VX950 Study Starts - (12/06/05)
     
  1242. Presco Study, Interim Results: Pegasys + Weight-Based Ribavirin Suggest Similar SVR Rates as n HCV-Monoinfected Patients - (12/06/05)
     
  1243. AASLD: Pharmacokinetics, Safety, and Tolerability of the Isatoribine Oral Prodrug ANA975 in a Phase I Heakthy Volunteer Study (12/14/05)
     
  1244. VALEANT PHARMACEUTICALS AGREES TO ACQUIRE RIGHTS TO HEP-C DRUG INFERGEN FROM INTERMUNE - (12/02/05)
     
  1245. AASLD: Five Million Americans Infected with the Hepatitis C Virus: A Corrected Estimate (12/02/05)
     
  1246. AASLD: A Phase 2 Study of Albuferon in Combination with Ribavirin in non-responders to proir interferon therapy for chronic Hepatitis C (11/28/05)
     
  1247. AASLD: NM283 +Pegasys for Nonresponders: phase II 12 weeks (11/28/05)
     
  1248. AASLD: Consensus IFN+ IFN Gamma-1b in African-American Peg Nonresponders (11/28/05)
     
  1249. AASLD: Consensus Interferon: study results at AASLD (11/17/05)
     
  1250. AASLD: Albuferon-Alpha (Albumin-Interferon Alpha) (11/17/05)
     
  1251. AASLD: REPEAT Study: Non-responders to ≥12 weeks' treatment with standard-dose pegylated interferon alfa-2b (PegIntron) plus ribavirin received standard dose of Pegasys + ribavrin or double dose Pegasys + ribavirin (11/15/05)
     
  1252. AASLD: Albuferon + Ribavirin in PegIFN Nonresponders: phase 2 study (11/15/05)
     
  1253. AASLD: SCH 503034 HCV Protease Inhibitor Monotherapy in HCV Genotype 1 IFN Nonresponders (11/15/05)
     
  1254. AASLD: VX-950 Hep C Protease Inhibitor (11/15/05)
     
  1255. AASLD: Combination therapy with SCH-503034 HCV Protease Inhibitor & PegIntron in Non-Responders: phase !b study results (11/15/05)
     
  1256. AASLD: Combination therapy with SCH-503034 HCV Protease Inhibitor & PegIntron in Non-Responders: phase !b study results (11/15/05)
     
  1257. AASLD: THE PERFORMANCE OF APRI FOR THE DIAGNOSIS OF SIGNIFICANT HEPATIC FIBROSIS IS IMPROVED BY A SIMPLE MODIFICATION (11/14/05)
     
  1258. AASLD: LONG TERM RESULTS AFTER THERAPY WITH PEGYLATED INTERFERON ALPHA 2A (PEGASYS) IN HCV POSITIVE LIVER TRANSPLANT RECIPIENTS (11/14/05)
     
  1259. AASLD: PREDICTING OUTCOME IN PATIENTS WITH HCV AFTER OLT: A 15-YEARS FOLLOW-UP (11/14/05)
     
  1260. AASLD: RECURRENT HEPATITIS C IS A RISK FACTOR FOR POOR OUTCOME AFTER LIVER RETRANSPLANTATION (11/14/05)
     
  1261. AASLD: MULTICENTER RANDOMIZED TRIAL OF HCV TREATMENT WITH PEGINTERFERON-ALFA 2A (Pegasys) AND RIBAVIRIN AFTER LIVER TRANSPLANTATION:ONE-YEAR REPORT (11/14/05)
     
  1262. AASLD: ON TREATMENT VIROLOGICAL RESPONSE OF 70% IN 100 PATIENTS TREATED WITH COMBINATION ANTIVIRAL THERAPY FOR RECURRENT HCV FOLLOWING LIVER TRANSPLANTATION (11/14/05)
     
  1263. AASLD: IS LIVER BIOPSY JUSTIFIED IN HEPATITIS C GENOTYPE 2 AND 3? (11/14/05)
     
  1264. AASLD: FIBROSCAN, MONITORING LIVER STIFFNESS: A NEW TOOL TO MEASURE LIVER FIBROSIS DURING THERAPY (11/14/05)
     
  1265. AASLD: Telbivudine (LdT) Phase 3 One Year Study Results (11/14/05)
     
  1266. AASLD: 2.2% Liver Cancer developed Among SVRs; Sexual Dysfunction among HCV+ (11/14/05)
     
  1267. AASLD: FIVE MILLION AMERICANS INFECTED WITH THE HEPATITIS C VIRUS: A CORRECTED ESTIMATE (11/14/05)
     
  1268. AASLD: VIROLOGICAL AND HISTOLOGICAL FEATURES OF HCV IN PATIENTS WITH NORMAL ALT: RESULTS OF A TEN YEAR PROPSECTIVE FOLLOW-UP STUDY (11/14/05)
     
  1269. AASLD: African-American patients had fewer office visits and were less likely to return for a second office visit (11/14/05)
     
  1270. AASLD: COFFEE DRINKING DECREASES THE RISK OF CHRONIC LIVER DISEASE IN THE UNITED STATES POPULATION (11/14/05)
     
  1271. AASLD: Troglitazone significantly reduced tumor growth in vivo, and caused tumor regression in liver cells (11/14/05)
     
  1272. AASLD: Liver Transplant Articles AASLD (11/14/05)
     
  1273. AASLD: Study Evaluations of Non-Invasive Fibrosis Tests AASLD (11/14/05)
     
  1274. AASLD: LIVER HISTOLOGY IN HEPATITIS C PATIENTS WITH NORMAL ALT LEVELS (11/14/05)
     
  1275. AASLD: Hispanics Developed Cirrhosis More Quickly Due to the presence of Fatty Liver & Diabetes (11/14/05)
     
  1276. AASLD: IMPACT OF CAFFEINE CONSUMPTION ON ALT AND HISTOLOGICAL ACTIVITY IN PATIENTS WITH CHRONIC ACTIVE HCV (11/14/05)
     
  1277. AASLD: CANNABINOIDS BLOCK INTERFERON-MEDIATED SUPPRESSION OF HEPATITIS C VIRUS (HCV) REPLICATION (11/14/05)
     
  1278. AASLD: CRYOGLOBULINEMIA IS ASSOCIATED WITH STEATOSIS AND FIBROSIS IN CHRONIC HCV (11/14/05)
     
  1279. AASLD: INDEPENDENT VALIDATION AND COMPARISON WITH FIBROSCAN, FIBROTEST AND LIVER BIOPSY OF CLINICAL GLYCOMICS FOR THE NON INVASIVE ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HCV (11/14/05)
     
  1280. New Hep C Polymerase Inhibitor HCV-796 Study in Patients - (11/11/05)
     
  1281. HCV Transmission Risks from Mother-To-Child up to 6.2% - (11/09/05)
     
  1282. Liver Steatosis Common in HIV+ - (11/09/05)
     
  1283. Hep C Hospital Charges Up 8-Fold Hepatitis C: The Uncounted Disease - (11/09/05)
     
  1284. Transplant barriers fall for HIV-positive - (11/07/05)
     
  1285. New Liver Cancer Therapy Approach Improves Survival - (11/07/05)
     
  1286. Effects of chronic liver disease on bone mineral density and bone metabolism markers in postmenopausal women - (11/07/05)
     
  1287. HCC (Liver Cancer) Deaths Doubled & Hospital Services Costs Increase Significantly - (11/05/05)
     
  1288. Roche Announces Expansion of First Major Study to Examine Efficacy of Pegasys(R) in Hepatitis C Treatment in Latinos - (11/04/05)
     
  1289. Metabolic syndrome cardiovascular disease risk and more - (11/04/05)
     
  1290. Concluding remarks: metabolic syndrome, liver and HCV - (11/04/05)
     
  1291. Interferon Controlled Release Delivery System Starts Trial - (11/03/05)
     
  1292. Interferon Decreased mtDNA Mutation Rate & Improved Liver - (11/03/05)
     
  1293. Antisense Drug ISIS 14803 Did Not Reduce HCV RNA - (11/03/05)
     
  1294. Lipids/Diabetes & HCV Liver disease - (11/03/05)
     
  1295. Hepatitis C complicated by morphine withdrawal - (11/01/05)
     
  1296. HIV/hepatitis C virus co-infection: its human face - (11/01/05)
     
  1297. Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1 - (11/01/05)
     
  1298. HCV Fatigue Reduces Quality of Life: 61% report fatigue - (11/01/05)
     
  1299. Perspectives on HIV/HCV co-infection, illicit drug use and mental illness: barriers to care - (11/01/05)
     
  1300. The neuropsychological and neurological impact of HCV infection in HIV+ - (11/01/05)
     
  1301. 17-40% of HCV-Infected Report Impaired Psych Function in HIV+ - (11/01/05)
     
  1302. New HCV Drug BLX-883, a form of alfa-interferon: Biolex Therapeutics Successfully Completes Phase 1 Study for First LEX System (TM) Produced Therapeutic Protein - (10/27/05)
     
  1303. HCV Natural History: recent study in women... - (10/25/05)
     
  1304. Merck Hep C Vaccine Research Deal - (10/25/05)
     
  1305. HCV Drug Albuferon Phase 2B Enrollment Completed - (10/25/05)
     
  1306. Recurrence of hepatitis C infection Post transplantation: Where are we now? - (10/24/05)
     
  1307. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease - (10/24/05)
     
  1308. HIV+ Liver Transplant Candidates Need Accelerated Attention, Early Referral: Require Priority - (10/24/05)
     
  1309. High HCV+ Rates in China: Past Illegal Blood Donation in China Linked to Hepatitis C Virus Infection - (10/21/05)
     
  1310. Chronic Hepatitis C in Childhood: An 18-Year Experience - (10/21/05)
     
  1311. Lack of Evidence of Sexual Transmission of Hepatitis C Virus in a Prospective Cohort Study of Men Who Have Sex With Men - (10/20/05)
     
  1312. Coffee and Tea Consumption are Associated with a Lower Incidence of Chronic Liver Disease in the United States - (10/19/05)
     
  1313. Hepatitis C virus in the semen of men coinfected with HIV- 1: prevalence and origin - (10/19/05)
     
  1314. PK of Ribavirin & NRTIs in APRICOT Study - (10/18/05)
     
  1315. New HCV Drug Candidate for Treatment - (10/18/05)
     
  1316. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source - (10/18/05)
     
  1317. PK of Ribavirin & NRTIs in APRICOT Study - (10/18/05)
     
  1318. New HCV Drug Candidate for Treatment - (10/18/05)
     
  1319. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source - (10/18/05)
     
  1320. ARTISTS/POETS with HCV - (10/14/05)
     
  1321. AASLD: FIVE MILLION AMERICANS INFECTED WITH THE HEPATITIS C VIRUS: A CORRECTED ESTIMATE - (10/13/05)
     
  1322. Herbal hepatotoxicity - (10/11/05)
     
  1323. Increased Rates of Liver Cell Death in HCV/HIV Coinfection - (10/07/05)
     
  1324. Didanosine plus ribavirin can be toxic in HIV patients treated for hepatitis C - (10/07/05)
     
  1325. Toll-Like Receptors: new therapy to stimulate immune system - (10/06/05)
     
  1326. Increased Rates of Liver Cell Death in HCV/HIV Coinfection - (10/05/05)
     
  1327. Biomarkers used to predict recurrent disease in hepatitis C transplant patients - (10/05/05)
     
  1328. 24 Week PegIntron/RBV Therapy Approved in Europe for HCV Genotype 1 & Low Viral Load - (10/05/05)
     
  1329. Presence of Hepatitis C Virus (HCV) RNA in the Genital Tracts of HCV/HIV-1-Coinfected Women - (10/05/05)
     
  1330. Undetectable HIV May Slow Fibrosis in HCV/HIV Coinfected Patients - (10/04/05)
     
  1331. New HCV Antisense Drug - (10/04/05)
     
  1332. Hepatitis C Vaccine Candidate - (10/04/05)
     
  1333. Two New HCV Polymerase Inhibitors: early study data show potency & perhaps once daily dosing - (10/04/05)
     
  1334. New HCV Drug NM283 HBV Drug LdT at AASLD - (10/03/05)
     
  1335. New HCV Protease Inhibitor VX-950 - (10/03/05)
     
  1336. Hepatitis C and liver transplantation - (10/03/05)
     
  1337. Breakthrough for HCV research: in vitro HCV replication - (10/03/05)
     
  1338. Asians 'risk fatal liver disease' - (10/03/05)
     
  1339. New HCV & HBV Drugs: XTL-6865, XTL2125 - (09/30/05)
     
  1340. Britain 'failing' on hepatitis C - (09/30/05)
     
  1341. Hepatitis C: Current approaches in pediatrics - (09/30/05)
     
  1342. Noninvasive Fibrosis Test Performs Well - (09/30/05)
     
  1343. New Toll-like Receptor Drug Actilon for HCV Therapy - (09/29/05)
     
  1344. Psych Impairment in Coinfected Women - (09/29/05)
     
  1345. Flamel Technologies Announces Positive Preliminary Results of a Phase I/II Trial of IFN-alpha-XL in Patients with Chronic Hepatitis C Virus Infection - (09/29/05)
     
  1346. Chronic Hepatitis C in Latinos: Natural History, Treatment Eligibility, Acceptance, and Outcomes - (09/29/05)
     
  1347. MIGENIX Completes First Clinical Study of Celgosivir in Chronic Hepatitis C Patients - (09/29/05)
     
  1348. Bioenvision's Phase II Trial of Virostat Very Active in Hepatitis C - (09/29/05)
     
  1349. New Hep C Protease Inhibitor - (09/21/05)
     
  1350. Liver Injury and Changes in Hepatitis C Virus (HCV) RNA Load Associated with Protease Inhibitor-Based Antiretroviral Therapy for Treatment-Naive HCV-HIV-Coinfected Patients: Lopinavir-Ritonavir versus Nelfinavir - (09/21/05)
     
  1351. PEGINTERFERON a-2b THERAPY IN ACUTE HEPATITIS C: IMPACT OF ONSET AND DURATION OF THERAPY ON SUSTAINED VIROLOGIC RESPONSE - (09/20/05)
     
  1352. Fatigue & Hypermetabolism in HCV: high HCV RNA may cause fatigue & interferon appears to reduce fatigue - (09/19/05)
     
  1353. HCV natural history in the west & developing world: The retrospective and prospective in perspective - (09/19/05)
     
  1354. (Marijuana/Hash) Endocannabinoids and liver disease - review - (09/19/05)
     
  1355. Impact of Hepatitis C Virus on Immune Restoration in HIV-Infected Patients Who Start Highly Active Antiretroviral Therapy: A Meta-analysis - (09/14/05)
     
  1356. Hepatitis C Virus Infection in HIV Type 1-Infected Individuals Does Not Accelerate a Decrease in the CD4+ Cell Count but Does Increase the Likelihood of AIDS-Defining Events - (09/14/05)
     
  1357. VA Study: HCV Increases Risk of Death Among HAART-Treated HIV+ Patients by 30-80% - (09/14/05)
     
  1358. Influence of Hepatitis C Virus Infection on HIV-1 Disease Progression and Response to Highly Active Antiretroviral Therapy - (09/14/05)
     
  1359. Hepatic steatosis with stavudine in HIV/hepatitis C virus co-infection - (09/14/05)
     
  1360. Promising Therapy for Human Hepatoma (liver cancer, HCC): Telomerase Inhibition by GRN163 - (09/13/05)
     
  1361. Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain - (09/13/05)
     
  1362. Is Cirrhosis Inevitable in HCV? - (09/13/05)
     
  1363. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C - (09/13/05)
     
  1364. Hepatocellular carcinoma in 40 HIV/HCV-coinfected versus 50 HCV-monoinfected patients. North American HCC in HIV Study Gro (09/09/05)
     
  1365. Caucasians Had Better HCV Viral Load Reductions Than African-Americans During First 3 Days & During Weeks 1-4 After Starting Peg/RBV (09/09/05)
     
  1366. Hepatitis C infection is not associated with systemic HIV-associated non-Hodgkin's lymphoma: a cohort study (09/09/05)
     
  1367. PI & NNRTI Drug Levels in Coinfected Patients (09/09/05)
     
  1368. Pegasys/RBV Improves Histology in Non-Responders & Cirrhotics (09/09/05)
     
  1369. PegIFN/RBV May Be Less Effective in Acute HCV for HIV+ (09/09/05)
     
  1370. PK of Once Daily Regimen: Fosamprenavir/r, Tenofovir and FTC in Naives (09/09/05)
     
  1371. Occult HCV- HCV RNA Found in Liver of Patients Negative for Antibody-HCV & Serum HCV RNA - (09/05/05)
     
  1372. EDITORIAL COMMENTARY Hepatitis C Virus (HCV) Occult Infection or Occult HCV RNA Detection? - (09/05/05)
     
  1373. HCV Did Not Persist in Patients with SVR - (09/05/05)
     
  1374. Divining the role of liver biopsy in hepatitis C - (09/05/05)
     
  1375. Chronic hepatitis C and 'normal' ALT levels: Treat the disease not the test - (09/05/05)
     
  1376. Gilead, Achillion initiate phase I trial evaluating GS 9132 for treatment of hep C - (09/05/05)
     
  1377. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection - (09/05/05)
     
  1378. Predicting SVR/Nonresponse at Weeks 1, 4, 12 with Pegasys/RBV - (09/05/05)
     
  1379. Reemergence of Hepatitis C Virus after 8.5 Years in a Patient with Hypogammaglobulinemia: Evidence for an Occult Viral Reservoir - (09/05/05)
     
  1380. Hepatitis A Virus Testing and Vaccination Rates are Low in HCV+ Patients - (09/05/05)
     
  1381. Noninvasive Markers of Fibrosis for Longitudinal Assessment of Fibrosis in Chronic Liver Disease: Are They Ready for Prime Time? EDITORIAL - (09/05/05)
     
  1382. Amantadine in treatment of chronic hepatitis C virus infection? - (09/05/05)
     
  1383. Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA - (09/05/05)
     
  1384. Interferon-gamma May Reverse Cirrhosis - (09/05/05)
     
  1385. CCR5-delta32 Mutation Had Higher HCV Clearance & Not Associated with Disease Outcome or Severity - (09/05/05)
     
  1386. Ondansetron Reduced IFN-Fatigue/depression - (09/05/05)
     
  1387. Genotype 4 Response to Peg/RBV; Nonresponders Improve Histologically - (09/05/05)
     
  1388. LOCTERON: New Interferon: Once Every Two weeks - (09/05/05)
     
  1389. Study finds ddI but not d4T associated with risk for symptomatic mitochondrial toxicity in RIBAVIC during IFN/RBV therapy - (09/02/05)
     
  1390. New HCV Protease Inhibitor - (08/17/05)
     
  1391. Technical considerations in liver transplantation: What a hepatologist needs to know (and every surgeon should practice) - (08/15/05)
     
  1392. Phase I Study New Hep C Drug for Peg/RBV Nonresponders - (08/11/05)
     
  1393. IAS: 24 vs 48 weeks Pegasys/RBV in HCV Genotype 2/3 Coinfection: does this study answer the question (08/01/05)
     
  1394. Liver Biopsy vs Alternative Testing in HCV/HBV - (08/09/05)
     
  1395. Peginterferon-A-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C - (08/05/05)
     
  1396. IAS: Cirrhotic Non-Responders Improve Liver Condition with Pegasys/RBV in APRICOT Study (08/05/05)
     
  1397. European Union's CHMP Adopts Positive Opinion for Shorter Course of PEGINTRON(R) and REBETOL(R) Combination Therapy for Certain Hepatitis C Patients with Genotype 1 and Low Viral Load - (08/04/05)
     
  1398. IAS: 24 vs 48 weeks Pegasys/RBV in HCV Genotype 2/3 Coinfection: does this study answer the question (08/01/05)
     
  1399. Roche Launches New Campaign to Educate Consumers About Hepatitis C - (07/29/05)
     
  1400. Epoetin Alfa Once Weekly Improves Anemia in HIV/Hepatitis C Virus-Coinfected Patients Treated With Interferon/Ribavirin: A Randomized Controlled Trial - (07/22/05)
     
  1401. Phase III Study of Consensus IFN Fully Enrolled - (07/21/05)
     
  1402. MIGENIX and Schering-Plough Sign Agreement for MX-3253 Hepatitis C Drug Development and License Option - (07/21/05)
     
  1403. Interferon Can Resolve HCV-related Arthritis: case study - (07/21/05)
     
  1404. Stealth and Cunning: Hepatitis B and Hepatitis C Viruses - (07/21/05)
     
  1405. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: Results of the HALT-C cohort - (07/21/05)
     
  1406. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy - (07/21/05)
     
  1407. New Hep C Drug for Post Transplantation: XTLbio Receives Fast Track Designation for Hepatitis C Therapy from US Food and Drug Administration - (07/21/05)
     
  1408. Complete Replication of Hepatitis C Virus in Cell Culture - (07/21/05)
     
  1409. AZT Increased Ribavirin Levels & Risk for Anemia; RBV Levels at Wks 4 & 12 Increased Viral Response - (07/21/05)
     
  1410. Unsafe Sex and Increased Incidence of Hepatitis C Virus Infection among HIV-Infected Men Who Have Sex with Men: The Swiss HIV Cohort Study - (07/21/05)
     
  1411. Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase? - (07/21/05)
     
  1412. Metabolics, Fatty Liver, Heart Disease Circulatory dysfunction in NAFLD - Which is first, which is last, and what do we do in between? EDITORIAL - (07/21/05)
     
  1413. Fatty Liver Predicted Heart Disease - (07/20/05)
     
  1414. Diagnosis of Small Hepatocellular Carcinoma - (07/11/05)
     
  1415. Neuropsychological Aspects of Coinfection with HIV and Hepatitis C Virus - (07/11/05)
     
  1416. Insulin Resistance Plays a Significant Role in Liver Fibrosis in Chronic Hepatitis C and in the Response to Antiviral Therapy - (07/07/05)
     
  1417. Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study - (07/07/05)
     
  1418. Smoking and HCV infection increase the risk of non-Hodgkin lymphoma - (07/05/05)
     
  1419. Fatty Liver Accelerates Liver Disease: Steatosis, Co-factor in other liver diseases - (07/01/05)
     
  1420. Daily Cannabis Smoking as a Risk Factor for Fibrosis Progression in Chronic Hepatitis C - (06/27/05)
     
  1421. Noninvasive markers of hepatic fibrosis: Are they ready for prime time in the management of HIV/HCV co-infected patients? - (06/23/05)
     
  1422. Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3 - (06/23/05)
     
  1423. Researchers create infectious hepatitis C virus in a test tube - (06/22/05)
     
  1424. New Research Exploring How HCV Evades the Immune System: can a vaccine be found? - (06/22/05)
     
  1425. HCV Infection among Prisoners in the California State Correctional System: sexual transmission, women at risk - (06/21/05)
     
  1426. Sexual dysfunction in males with chronic hepatitis C and antiviral therapy: interferon-induced functional androgen deficiency or depression? - (06/20/05)
     
  1427. COALITION PRINCIPLES ON HIV/HCV COINFECTION POLICY - (06/20/05)
     
  1428. Progression of liver fibrosis in patients coinfected with HCV and HIV undergoing antiretroviral therapy - (06/16/05)
     
  1429. Coinfection with HIV and HCV in Injection Drug Users and Minority Populations - (06/07/05)
     
  1430. Outcomes among Patients with End-Stage Liver Disease Who Are Coinfected with HIV and HCV - (06/07/05)
     
  1431. Vertically Acquired HCV: natural history - (06/07/05)
     
  1432. New Drug Targets for HIV and Hepatitis C Virus Coinfection - (06/06/05)
     
  1433. Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial - (06/06/05)
     
  1434. Predicting SVR: 12 Better than 4 Week Early Viral Response - (06/06/05)
     
  1435. Liver Transplantation for Hepatocellular Carcinoma - (06/02/05)
     
  1436. HCV Drug NM283 Trial Fully Enrolled - (06/02/05)
     
  1437. New HCV Drug Albuferon Starts Study in Genotype 1 Naives - (06/02/05)
     
  1438. Innogenetics says hepatitis C vaccine trials 'inconclusive', extends study - (06/01/05)
     
  1439. New HCV & HBV Drugs: toll-like receptors - (06/01/05)
     
  1440. Long-Dormant Threat Surfaces: Deaths From Hepatitis C Are Expected to Triple - (05/31/05)
     
  1441. Pioglitazone: heart disease, lipids, diabetes - (05/31/05)
     
  1442. DDW: "Triple Anti-HCV Drug Therapy for Nonresponders to Peginterferon/Ribavirin: Interferon Gamma (Actimmune) + Ribavirin + Pegasys or Infergen: A Pilot Study" (05/31/05)
     
  1443. DDW: Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in south London: 25% of coinfected unaware they have HCV (05/31/05)
     
  1444. DDW: Psychiatric/Substance Use Barriers to HCV Treatment (05/31/05)
     
  1445. Fatty Liver Is Worse in HIV "IMPACT of HIV COINFECTION on the DEVELOPMENT of STEATOSIS (FATTY LIVER) in PATIENTS with Chronic HCV Infection" - (05/31/05)
     
  1446. Hepatitis virus-positive livers OK for transplants - (05/27/05)
     
  1447. Cognitive Impairment, HCV, HIV & Meth "Risk of Cognitive Impairment High in HCV-HIV Coinfection and Methamphetamine Addiction" - (05/26/05)
     
  1448. A cluster of acute hepatitis C virus infection among men who have sex with men - results from contact tracing and public health implications - (05/23/05)
     
  1449. DDW: Consensus Interferon + IFN Gamma in PegIFN/RBV Non-Responders (05/23/05)
     
  1450. DDW: Pegasys in IFN/RBV Relapsers & Nonresponders Canadian EAP (05/23/05)
     
  1451. DDW: SAFETY, PHARMACODYNAMIC (PD) & PHARMACOKINETIC (PK) PROFILES OF CPG 10101 (ACTILON), A NOVEL TLR9 AGONIST: comparison in normal volunteers & HCV infected individuals (05/23/05)
     
  1452. Deal to Develop Chiron's HCV Protease Inhibitors - (05/23/05)
     
  1453. DDW: VX-950: HCV PROTEASE INHIBITOR INITIAL RESULTS OF A PHASE 1b, MULTIPLE DOSE STUDY OF VX-950, A HEPATITIS C VIRUS PROTEASE INIHIBITOR (05/20/05)
     
  1454. DDW: "VALOPICITABINE (NM283) ALONE & IN COMBINATION WITH PEG-INTERFERON IN PATIENTS WITH GENOTYPE-1 CHRONIC HEPATITIS C: Preliminary results from an ongoing phase II, multicenter study" (05/20/05)
     
  1455. DDW: Double-Dose Peginteferon Alfa-2b (pegIntron) Plus Weight-Based Ribavirin for Re-Treatment of African-american Non-Responders with Hepatitis C (05/19/05)
     
  1456. DDW: InterMune presents encouraging HCV drug data on HCV protease Inhibitor (05/17/05)
     
  1457. DDW: Consensus Interferon for Peg-IFN Non Responders (05/17/05)
     
  1458. DDW: Consensus Interferon in Peg/RBV Nonresponders (05/17/05)
     
  1459. DDW: HEPATITIS B: SCIENCE & TREATMENT 2005 (05/16/05)
     
  1460. DDW: Pioglitazone Improves Fatty Liver (05/16/05)
     
  1461. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C - (05/13/05)
     
  1462. Interferon--induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression - (05/13/05)
     
  1463. Chronic hepatitis C, depression and interferon - (05/13/05)
     
  1464. VX-950-New HCV Protease Inhibitor-Shows Potency in 14-Day Study - (05/12/05)
     
  1465. NEW HEPATITIS C STUDY FOR CHILDREN (PEDS-C) - (05/09/05)
     
  1466. Fatty Diets May Lead to Cirrhosis - (05/09/05)
     
  1467. Antiviral therapy in advanced chronic liver disease due to hepatitis C virus infection: Pilot study - (05/09/05)
     
  1468. Feds Tested AIDS Drugs on Foster Kids Without Protection from Independent Advocate - (05/05/05)
     
  1469. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C in Spain - (05/05/05)
     
  1470. EASL: HIV & High HCV Viral load Increased HCV Perinatal Transmission (05/05/05)
     
  1471. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study - (05/03/05)
     
  1472. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C - (05/03/05)
     
  1473. EASL: HOMOSEXUALLY TRANSMITTED HCV-ACUTE INFECTION RELATED TO A CLUSTERED GENOTYPE 4 HCV IN HIV-1 INFECTED MEN AND INEFFICACY OF EARLY ANTIVIRAL THERAPY (05/02/05)
     
  1474. Clinical Developments in Hepatocellular Carcinoma - (05/02/05)
     
  1475. EASL: Diabetes & Lipids Associated with Liver Disease (05/27/05)
     
  1476. EASL: Ribavirin Levels & Viral Response to PegIFN/RBV HCV Therapy (05/25/05)
     
  1477. EASL: SUSTAINED RESPONSE TO PEGASYS IN HBeAg-NEGATIVE CHRONIC HEPATITIS B. (05/25/05)
     
  1478. EASL: PegIFN/Ribavirin Therapy for Cirrhotics (05/25/05)
     
  1479. EASL: PegInterferon Maintenance Therapy: EASL Report (05/25/05)
     
  1480. HCV & HBV HIV Coinfection Treatment: Consensus Statement - (05/25/05)
     
  1481. EASL: PegInterferon Maintenance Therapy: EASL Report (05/25/05)
     
  1482. EASL: PegInterferon Maintenance Therapy: EASL Report (05/22/05)
     
  1483. EASL: Viramidine- New HCV Drug: new 24/48 week Phase II study results (05/19/05)
     
  1484. EASL: NM-283 New HCV Drug, new 24 week data; New Developments in HCV at EASL (05/18/05)
     
  1485. EASL: Age & Ribavirin Dose Reductions Reduce SVR to Peginterferon+Ribavirin (05/15/05)
     
  1486. EASL: Cost Effectiveness of Peginterferon in HCV/HIV Coinfection (05/15/05)
     
  1487. EASL: Albuferon: new HCV drug (05/14/05)
     
  1488. EASL: New Hep C Drug NM283: 24 week data at EASL (05/14/05)
     
  1489. EASL: New Hepatitis C Drugs in Development: EASL Report (05/14/05)
     
  1490. Interplay between hepatitis C, liver steatosis and antiretroviral therapy in HIV-infected patients - (05/14/05)
     
  1491. Clinical Course of Chronic Hepatitis C in Patients with Very High Serum alpha-Fetoprotein Levels and Normal Hepatic Imaging - (05/14/05)
     
  1492. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus - (05/09/05)
     
  1493. What Defines Cure for HCV Infection? - (05/09/05)
     
  1494. Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapy - (05/09/05)
     
  1495. HCV/HIV Coinfection: challenges & strategies for care & treatment - (05/09/05)
     
  1496. Dual hepatitis B virus and hepatitis C virus infection: To treat or not to treat, and how? EDITORIAL - (05/09/05)
     
  1497. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis - (05/09/05)
     
  1498. Interplay between hepatitis C, liver steatosis and antiretroviral therapy in HIV-infected patients - (05/09/05)
     
  1499. Nonresponders to Previous Chronic Hepatitis C Treatment - (05/09/05)
     
  1500. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy - (05/09/05)
     
  1501. Management of cirrhosis due to chronic hepatitis C - (05/06/05)
     
  1502. Clinical Course of Chronic Hepatitis C in Patients with Very High Serum alpha-Fetoprotein Levels and Normal Hepatic Imaging - (05/06/05)
     
  1503. Hepatitis B or hepatitis C and HIV (05/05/05)
     
  1504. Sensitive HCV RNA Test: use at week 24 - (03/31/05)
     
  1505. Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment - (03/31/05)
     
  1506. Statins and hepatotoxicity: Focus on patients with fatty liver - (03/31/05)
     
  1507. Mitochondrial DNA depletion in liver tissue of patients infected with hepatitis C virus: contributing effect of HIV infection? - (03/31/05)
     
  1508. Sex and Hepatitis C Transmission - (03/31/05)
     
  1509. Insulin Resistance Impairs Response to IFN/RBV - (03/31/05)
     
  1510. Roche Announces New Study to Evaluate Pegasys and Copegus to Treat Hepatitis C in Liver Transplant Patients - (03/22/05)
     
  1511. Pegasys + Methadone PK - (03/21/05)
     
  1512. Second Forum on Liver Transplantation: Liver transplantation for hepatitis C: how to control the virus? - (03/18/05)
     
  1513. Should we treat patients with chronic hepatitis C on the waiting list? - (03/18/05)
     
  1514. Diabetes Increases Risk of Liver Cancer - (03/15/05)
     
  1515. CROI: 12th CROI HCV Report - (03/08/05)
     
  1516. First European recommendations for the treatment of patients co-infected with HIV and Hepatitis B and C viruses - (03/07/05)
     
  1517. CROI: Accelerated Liver Disease Progression in HCV/HIV Coinfection - (03/07/05)
     
  1518. FDA Approves Pegasys and Copegus as Only Hepatitis C Treatment for HIV Patients - (03/02/05)
     
  1519. HCV, HIV & Non-Hodgins Lymphoma - (03/02/05)
     
  1520. CROI: Sexual HCV Transmission Reported Among MSM - (03/02/05)
     
  1521. CROI: AZT Causes Anemia During Ribavirin/Interferon Therapy; EPO Improves Anemia - (03/01/05)
     
  1522. How Hepatitis C Short-Circuits the Immune System - (02/22/05)
     
  1523. Coinfected Patients Can Respond Better Than previously Observed - (02/22/05)
     
  1524. Medicaid Utilization of IFN/RBV for HCV Therapy - (02/22/05)
     
  1525. CD8/CTLs Predict Response to IFN/RBV Therapy - (02/22/05)
     
  1526. Infection with concurrent multiple hepatitis C virus genotypes is associated with faster HIV disease progression - (02/18/05)
     
  1527. The Spectrum of Chronic Hepatitis C Virus Infection in the Virginia Correctional System: Development of a Strategy for the Evaluation and Treatment of Inmates with HCV - (02/18/05)
     
  1528. ViroPharma Announces Start of HCV-796 Phase 1 Program - (02/15/05)
     
  1529. Hepatitis B or Hepatitis C and HIV-infection Diagnosis/Care/Treatent - (02/11/05)
     
  1530. Study Finds Interferon Reduces Cancer Risk in HCV+ Cirrhotics - (02/10/05)
     
  1531. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma (liver cancer) - (02/09/05)
     
  1532. Early discontinuation of 'ineffective' anti-viral therapy may prove less popular with patients than with health care providers - (02/08/05)
     
  1533. Inapprorpriate Rejection for HCV Therapy for Psychiatric Disorder - (02/08/05)
     
  1534. Vitamin E Did Not Reduce Risk for Ribavirin-associated Anemia - (02/07/05)
     
  1535. Why HCV Therapy Is Not Utilized in Coinfection - (02/07/05)
     
  1536. Iron and Hepatitis C - (02/07/05)
     
  1537. Pegasys Approved for Coinfection in Europe - (02/03/05)
     
  1538. Small Molecule, Toll-Like Receptor 7 Agonist, a Potential Frontline Oral Treatment for HCV - (02/02/05)
     
  1539. Study Finds that Severity of Liver Damage May Predict Risk for Hepatotoxicity on HAART - (02/02/05)
     
  1540. HIV and Hepatitis C Virus Coinfection Update - (02/01/05)
     
  1541. Hepatitis C Treatment - (02/01/05)
     
  1542. Antiviral Therapy for Hepatitis C - (02/01/05)
     
  1543. HCV/HIV COINFECTION TREATMENT & COGNITIVE IMPAIRMENT - (02/01/05)
     
  1544. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression - (02/01/05)
     
  1545. Hepatitis New Drug Research - (01/26/05)
     
  1546. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C - (01/25/05)
     
  1547. CD4 Deficiency May Explain HIV Affect on HCV - (01/20/05)
     
  1548. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels - (01/19/05)
     
  1549. Assessing fibrosis without a liver biopsy: Are we there yet? - (01/19/05)
     
  1550. The potential of RNA interference as a tool in the management of viral hepatitis - (01/13/05)
     
  1551. Liver transplantation in HIV-infected recipients - (01/13/05)
     
  1552. Liver Disease in Pregnancy- (01/12/05)
     
  1553. Hepatitis C Virus Among African-American Persons - (01/12/05)
     
  1554. New HCV Drug NM283 + PegIFN- 12 weeks data - (01/10/05)
     
  1555. New HCV Drug Reduces HCV RNA - (01/10/05)
     
  1556. Researcher cites "bias" toward Peg-Intron in trial - (01/10/05)
     
  1557. New HCV Drug- Polymerase Inhibitor - (01/06/05)
     
  1558. Studies Showing that HCV is Not Persistent & SVR is Durable - (01/05/05)
     
  1559. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection - (01/03/05)
     
  1560. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C- 2 Editorials - (01/03/05)
     
  1561. Toxicities Associated with Oxymatrine - (01/03/05)
     
  1562. Oxymatrine: medicinal herb for treating hepatitis C & B - (01/03/05)
     
  1563. Medicinal Herbs for HCV (oxymatrin) - (12/30/04)
     
  1564. Complementary and alternative therapies in the treatment of chronic hepatitis C: a systematic review - (12/30/04)
     
  1565. Hep C Maintenance Therapy Study in Coinfection: ACTG Study - (12/23/04)
     
  1566. PegIntron + Ribavirin in Coinfected Patiernts, RIBAVIC Study Results - (12/16/04)
     
  1567. Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV-Infected Patients - (12/16/04)
     
  1568. Hepatocellular Carcinoma - (12/15/04)
     
  1569. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination - (12/13/04)
     
  1570. Prevalence of hepatic steatosis (fatty liver) in an urban population in the United States: Impact of ethnicity - (12/13/04)
     
  1571. NIH Action plan for liver disease research - (12/13/04)
     
  1572. The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy - (12/08/04)
     
  1573. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome - (12/08/04)
     
  1574. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir - (12/08/04)
     
  1575. AASLD: Pegasys/RBV Improves Fibrosis in Responders, relapsers & Nonresponders with Advanced Fibrosis - (12/06/04)
     
  1576. ICAAC: Predictability of SVR at Week 4 in Coinfection in APRICOT Study - (12/06/04)
     
  1577. Controlling pain in liver biopsy, or "we will probably need to repeat the biopsy in a year or two to assess the response" - (12/03/04)
     
  1578. Early Prediction of Hepatitis C Virus (HCV) Infection Relapse in Nonresponders to Primary Interferon Therapy by means of HCV RNA Whole-Blood Analysis - (12/03/04)
     
  1579. The management of side-effects during therapy for hepatitis C - (12/03/04)
     
  1580. Hepatitis C: It's a long way to new therapy, it's a long way to go... - (12/01/04)
     
  1581. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: A population-based study - (12/01/04)
     
  1582. BILN 2061 HCV Protease Inhibitor Development Held Due to Toxicity - (11/30/04)
     
  1583. Roche Announces First Major Study to Examine Efficacy of Hepatitis C Treatment in Latinos - (11/29/04)
     
  1584. Infrequent Reinfection after Successful Treatment for Hepatitis C Virus Infection in Injection Drug Users - (11/29/04)
     
  1585. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients - (11/29/04)
     
  1586. HCV coinfection increases mortality in HIV patients - (11/22/04)
     
  1587. Response to Hepatitis C Therapy Can Last for Years - (11/22/04)
     
  1588. Celebrities with hepatitis C - (11/18/04)
     
  1589. ICAAC: Predicting outcomes in people with HIV and HCV by Mark Mascolini - (11/16/04)
     
  1590. HIV and HCV infection rates higher than expected in London drug users - (11/15/04)
     
  1591. AASLD: Pegasys/RBV 16 vs 24 Weeks for Genotype 2 & 3 - (11/15/04)
     
  1592. AASLD: Peg-IFN Maintenance Therapy Study: interim analysis at 2 yrs shows positive results - (11/15/04)
     
  1593. Vitamin E warning sounded - (11/12/04)
     
  1594. AASLD: Prolonged Pegasys+RBV Therapy to 72 Weeks May Improve SVR in Patients Who were HCV RNA+ after 4 weeks & slow responders - (11/10/04)
     
  1595. AASLD: HCV & HIV Prevalence in NYC Drug Rehab Facility - (11/09/04)
     
  1596. AASLD: Pilot Study, Hi-Dose Pegasys Induction- 37% SVR for IFN/RBV Nonresponders - (11/09/04)
     
  1597. AASLD: Durability of SVR, 5 Year follow-up Pegasys plus Copegus - (11/09/04)
     
  1598. AASLD: Nonresponders in Apricot Achieve Histologic Response, Improve Liver - (11/05/04)
     
  1599. ICAAC: Failure of PegIFN/RBV in People With HCV/HIV Predicted at 12 Weeks by Mark Mascolini - (11/02/04)
     
  1600. AASLD: NEW HCV PROTEASE INHIBITOR STARTS FIRST 14-DAY HUMAN STUDY IN NOVEMBER - (11/04/04)
     
  1601. AASLD: Consensus Interferon for Peg/RBV Nonresponders - (11/02/04)
     
  1602. AASLD: New HCV Drug NM283 + Peginterferon Study - (11/02/04)
     
  1603. AASLD: Viramidine, substitute for ribavirin: end-of-treatment response in therapy-naïve patients - (11/01/04)
     
  1604. Co-occurring Hepatitis C, Substance Use, and Psychiatric Illness: Treatment Issues and Developing Integrated Models of Care - (10/29/04)
     
  1605. New HCV Polymerase Drug: Roche partners with Pharmasset - (10/28/04)
     
  1606. Prevalence of HCV/HIV Coinfection in Children with Perinatal HIV - (10/27/04)
     
  1607. Occult hepatitis B in HCV+ - (10/25/04)
     
  1608. Twice Weekly PegIntron Controversy - (10/14/04)
     
  1609. Occult HBV Seen in 26% of HCV+ - (10/14/04)
     
  1610. Potential future therapeutic options for Hepatitis C - (10/14/04)
     
  1611. Thymosin-a + Interferon for HCV Not effective in Study - (10/14/04)
     
  1612. New HCV Drug Starts 12-week Study in Patients - (10/14/04)
     
  1613. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death - (10/12/04)
     
  1614. FDA Grants Priority Review to Pegasys with Copegus for HCV in HIV Patients - (10/07/04)
     
  1615. How effective is HAART in HCV and HIV coinfection? - (10/07/04)
     
  1616. Valeant Pharmaceuticals to Present Viramidine End-of-Treatment Data From Phase 2 Clinical Trial - (10/07/04)
     
  1617. Liver Biopsy: how it is performed - (10/07/04)
     
  1618. Interferon Alpha-2b and Ribavirin for Patients with Chronic Hepatitis C and Normal ALT - (10/07/04)
     
  1619. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study - (10/07/04)
     
  1620. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study - (10/05/04)
     
  1621. Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Chronic Hepatitis C Genotype 4 - (10/05/04)
     
  1622. Clearance of Hepatitis C Virus after Newly Acquired Infection in IDUs - (10/04/04)
     
  1623. Genelabs, Gilead Team Up In Potential $46M HCV Bid - (10/04/04)
     
  1624. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study; 33% showed progression of at least 1 fibrosis point - (10/04/04)
     
  1625. Michigan prisons get $1.2M to test for hepatitis C - (10/01/04)
     
  1626. Fatty Liver Accelerates Fibrosis: diabetes, mitochondrial dyfunction, obesity associated - (09/30/04)
     
  1627. Long-Term Outcomes in HCV with SVR: cure, regression of fibrosis - (09/29/04)
     
  1628. Acute hepatitis C in HIV-infected men who have sex with men - (09/28/04)
     
  1629. NIH Action plan for Liver Disease Research: Call for public comment - (09/28/04)
     
  1630. EPO for Anemia During IFN/RBV Therapy for HCV - (09/28/04)
     
  1631. Frequent Hepatitis C Virus Superinfection in Injection Drug Users - (09/22/04)
     
  1632. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections - (09/22/04)
     
  1633. RBV Kinetics--Improves Early Response - (09/22/04)
     
  1634. Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients - (09/22/04)
     
  1635. Hepatitis C Virus Infection in United States Correctional Institutions - (09/20/04)
     
  1636. Alcohol and Hepatitis C: Implications for Disease Progression and Treatment - (09/20/04)
     
  1637. Cost-effectiveness of Combination Peginterferon Alfa-2a (Pegasys) and Ribavirin Compared with Interferon Alfa-2b (Intron A) and Ribavirin in HCV Patients - (09/20/04)
     
  1638. HIV/HCV Coinfection Update: special issues, natural history/medical management - (09/20/04)
     
  1639. Medical Clinic Notifies Patients of Possible Hepatitis Exposure During Exams - (09/14/04)
     
  1640. Consensus Interferon Study for Peginterferon Nonresponders: 41 study sites - (09/13/04)
     
  1641. Chiron Grants Nonexclusive HCV License to InterMune & Limits HCV Research - (09/13/04)
     
  1642. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation - (09/13/04)
     
  1643. Long-Term Outcomes for Liver Transplantation Due to HCV: NIDDK study - (09/08/04)
     
  1644. Vertex Pharma Reports Completion of Dosing in the Phase Ia Clinical Study of VX-950, an Oral HCV Protease Inhibitor for the Treatment of Hepatitis C - (09/08/04)
     
  1645. Strong Association of Hepatitis C Virus (HCV) Infection and Thrombocytopenia: - (09/07/04)
     
  1646. Hepatitis C infection and injection drug use: The role of hepatologists in evolving treatment efforts - (09/07/04)
     
  1647. The Risk For Sexual Transmission of the Hepatitis C Virus: MSM; Heterosexual - (09/07/04)
     
  1648. Reported Hepatitis C Cases Up in Wisconsin - (09/03/04)
     
  1649. Hepatitis C infection and injection drug use: The role of hepatologists in evolving treatment efforts - (09/03/04)
     
  1650. Pegasys + Copegus Coinfection Request for FDA Approval Filed by Roche - (09/02/04)
     
  1651. Can You Have Multiple Genotypes? - (09/02/04)
     
  1652. Intrahepatic CD4+ Cell Depletion in Hepatitis C Virus/HIV-Coinfected Patients - (09/01/04)
     
  1653. How Durable is the HCV Sustained Viral Response? - (08/30/04)
     
  1654. Solid-Organ Transplantation in HIV-Infected Patients in the Potent Antiretroviral Therapy Era - (08/30/04)
     
  1655. Simvastatin has long-term survival benefit: heart disease & cancer examined - (08/30/04)
     
  1656. Treatment of Chronic Hepatitis C in Blacks and Non-Hispanic Whites - (08/25/04)
     
  1657. Risk of HIV & Hepatitis Infections From Blood & Tissue Donors - (08/25/04)
     
  1658. Neuropsychiatric impact of hepatitis C on advanced HIV - (08/20/04)
     
  1659. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients - (08/19/04)
     
  1660. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy - (08/19/04)
     
  1661. HCV Worsens HIV's Neuropsychiatric Impact - (08/19/04)
     
  1662. Treatment of HCV infection in patients with advanced cirrhosis - (08/17/04)
     
  1663. Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase? - (08/09/04)
     
  1664. Hepatitis C testing in HIV infected patients - (08/09/04)
     
  1665. Sexual Transmission of HCV - (08/09/04)
     
  1666. HCV Prevents Hypertriglyceridemia - (08/09/04)
     
  1667. HCV Protease Inhibitors-BILN 2061: a major step toward new therapeutic strategies in hepatitis C - (08/09/04)
     
  1668. HAART and the HCV-infected liver: friend or foe? - (08/09/04)
     
  1669. Hepatitis Viruses & HIV Co-infection: pathogenesis & treatment - (08/06/04)
     
  1670. Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection - (08/05/04)
     
  1671. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance - (08/04/04)
     
  1672. Long-term follow-up after successful interferon therapy of acute hepatitis C - (08/04/04)
     
  1673. Mt Sinai School of Medicine Press Release on APRICOT COINFECTION STUDY RESULTS - (08/04/04)
     
  1674. Hepatitis C Virus Infection in Cocaine Users: A Silent Epidemic; study suggests snorting cocaine is transmission risk - (08/03/04)
     
  1675. ACTG 5071-Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons - (07/29/04)
     
  1676. APRICOT- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients - (07/29/04)
     
  1677. Treating Hepatitis C in "Difficult-to-Treat" Patients - (07/29/04)
     
  1678. Role of Vitamin K2 in the Development of Hepatocellular Carcinoma in Women With Viral Cirrhosis of the Liver - (07/26/04)
     
  1679. XV International AIDS Conference in Bangkok: Early 12-Week Viral Response in HCV/HIV Coinfection Predicts Sustained Viral Response (SVR) in APRICOT Study - (07/26/04)
     
  1680. XV International AIDS Conference in Bangkok: Factors That Predict Response to Pegasys + Ribavirin (Copegus) in HCV/HIV Co-infection in the APRICOT Study - (07/26/04)
     
  1681. XV International AIDS Conference in Bangkok: IMPACT OF HCV VIREMIA ON HIV DISEASE PROGRESSION IN WOMEN: HCV INCREASES RISK FOR AIDS (WIHS) - (07/22/04)
     
  1682. XV International AIDS Conference in Bangkok: Mitochondrial DNA depletion in HIV-infected patients is enhanced with chronic hepatitis C and treatment with pegylated interferon plus ribavirin - (07/22/04)
     
  1683. XV International AIDS Conference in Bangkok: Safety of Pegasys Plus Ribavirin in HIV/HCV Co-infection (APRICOT STUDY) - (07/20/04)
     
  1684. Hepatitis C Outbreak Adds a New Woe to Drug Rehab Centers - (07/20/04)
     
  1685. New Illinois Law Permits Organ Donors With H.I.V. - (07/19/04)
     
  1686. XV International AIDS Conference in Bangkok: New Pegasys Study data: 43% of non-responders have histological improvement - (07/12/04)
     
  1687. Thyroid disorders common in patients with chronic hepatitis C - (07/09/04)
     
  1688. HCV Acute Infection: immune and clinical responses - (07/06/04)
     
  1689. Perinatal Transmission and Viral Evolution of Hepatitis C Virus Quasispecies in Infants Coinfected With HIV - (06/30/04)
     
  1690. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients - (06/30/04)
     
  1691. Hepatitis C, interferon, and risk of rejection after liver transplantation - (06/30/04)
     
  1692. Feds review complaints that Chiron hinders HCV research - (06/28/04)
     
  1693. Weight Loss Improves Fatty Liver - (06/23/04)
     
  1694. Harm Reduction for Substance Abuse in the Psychiatric Setting - (06/23/04)
     
  1695. Treating Co-Occurring Substance Use Disorders and Hepatitis C: role of alcohol, IVDU & psychiatry in HCV - (06/23/04)
     
  1696. The effect of a herbal medicine (Mao-to) for the prevention of interferon-induced psychiatric complications in chronic hepatitis C: a pilot study - (06/23/04)
     
  1697. VA Hepatitis C Prevalence Study Results Summary and VA Hepatitis C Program Actions - (06/11/04)
     
  1698. New HCV Protease Inhibitor Study Planned for 2004 4th Quarter - (06/08/04)
     
  1699. New Pegasys Study for HCV+ Untreated Patients with Genotype 1, High Weight & High Viral Load - (06/07/04)
     
  1700. The Future Face of Coinfection: Prevalence and Incidence of HIV and Hepatitis C Virus Coinfection Among Young Injection Drug Users (30% coinfection rate) in Vancouver - (06/07/04)
     
  1701. DDW: Doctors Conclude Majority of Both HCV & Coinfected Not Elgible for IFN/RBV - (06/07/04)
     
  1702. PegIntron (Peginterferon Alfa-2b) and Ribavirin for the Treatment of Chronic Hepatitis C in Blacks and Non-Hispanic Whites - (06/01/04)
     
  1703. PegIntron plus Ribavirin study in African-Americans - (06/01/04)
     
  1704. Pegasys plus Ribavirin for African-Americans with Genotype 1 - (06/01/04)
     
  1705. DDW: MMPD (new HCV Drug), Pegasys, & Ribavirin Study - (05/28/04)
     
  1706. DDW: NM283: new oral HCV drug, polymerase inhibitor - (05/26/04)
     
  1707. Newly Published Study Investigates Pegasys and Copegus (ribavirin) for the Treatment of Chronic Hepatitis C In Black Americans - (05/26/04)
     
  1708. Decline in lung function, impaired response to salbutamol in HCV+ asthmatics - (05/25/04)
     
  1709. DDW: Study Examines HCV & Mistletoe & Herbal Concoction, When Interferon Fails - (05/20/04)
     
  1710. DDW: Consensus Interferon for Nonresponders- revisited - (05/19/04)
     
  1711. DDW: Consensus Interferon in Peg/RBV Nonresponders - (05/18/04)
     
  1712. DDW: Twice Weekly Higher Dosing of PegIntron Had Better Viral Response Rates in Genotype 1 Patients - (05/17/04)
     
  1713. DDW: Viramidine May Not Lead to Ribavirin Associated Anemia: "Clinical Study of Viramidine in Treatment of Hepatitis C Supports RBC-Sparing Mechanisms of Action" - (05/17/04)
     
  1714. Long-term outcome of hepatitis C in children - (05/13/04)
     
  1715. Hepatitis C Virus (HCV) Diversity in HIV-HCV Coinfected Subjects Initiating Highly Active Antiretroviral Therapy - (05/10/04)
     
  1716. HCV/HIV Coinfection & Lipid Abnormalities - (05/04/04)
     
  1717. Veteran Denied Liver Transplant: files law suit - (05/03/04)
     
  1718. EASL: ALBUFERON: New HCV Drug Dosed Every Every 2-4 Weeks by subcutaneous injection - (04/28/04)
     
  1719. EASL: Model to Predict Outcome of Pegasys plus Ribavirin Therapy - (04/27/04)
     
  1720. EASL: Small, Unrandomized Study Compares Pegasys to PegIntron - (04/26/04)
     
  1721. EASL: Daily Cannabis Smoking as a Risk Factor for Fibrosis Progression in Chronic Hepatitis C - (04/23/04)
     
  1722. Hepatitis C Virus (HCV) Diversity in HIV-HCV Coinfected Subjects Initiating Highly Active Antiretroviral Therapy - (04/22/04)
     
  1723. EASL: First Major Study Showing 12 Week Viral Response to Pegasys/ribavirin in Coinfected Patients Predicts Outcome - (04/22/04)
     
  1724. EASL: 18 Months Therapy (Pegasys+Ribavirin): study found relapse rate reduced by 70%; viral response rate in genotype 1 increased by 50% - (04/21/04)
     
  1725. EASL: Study Finds Undetectable HIV Viral Load Slows Liver Disease Progression in HCV/HIV Coinfection - (04/19/04)
     
  1726. EASL: New Drugs for HCV; Viramidine: 24 week study results - (04/19/04)
     
  1727. EASL: New HCV Drug, NM283, polymerase inhibitor: first data in patient: 1 log viral load decline in highest dose - (04/19/04)
     
  1728. Drinking Alcohol and Risk for Progression of Liver Disease - (04/13/04)
     
  1729. Treating Non-Responders with Pegasys plusRibavirin: HALT-C Study - (04/13/04)
     
  1730. Superinfection with HCV in HBV+ Patients Worsens Hepatitis - (04/13/04)
     
  1731. Schering-Plough launches generic hepatitis C drug By Bill Berkrot and Ransdell Pierson - (04/12/04)
     
  1732. Prices Much Higher Than Expected for New Generic Ribavirin from Three Rivers - (04/12/04)
     
  1733. Study Finds Quality of Life for Pegasys-Ribavirin Better Than for Interferon-Ribavirin and It Improves For Sustained Viral Responders - (04/12/04)
     
  1734. Psychological Stress May Accelerate HCV Progression - (04/12/04)
     
  1735. Three Rivers Pharmaceuticals announces FDA Approval of Ribasphere™ (Ribavirin capsules) 200mg for the Treatment of Chronic Hepatitis C - (04/08/04)
     
  1736. 75% HCV/HIV Coinfection Rates in SF Homeless- few treated - (04/07/04)
     
  1737. AASLD response to recommendations on screening HCV by US Preventive Services Task force - (04/05/04)
     
  1738. Hepatitis A - (04/05/04)
     
  1739. Prevention and treatment of hepatocellular carcinoma - (04/02/04)
     
  1740. Obesity and diabetes as a risk factor for hepatocellular carcinoma - (04/02/04)
     
  1741. Drinking Alcohol and Risk for Progression of Liver Disease - (04/01/04)
     
  1742. Intra-hepatic messenger RNA levels for interferons and related genes in hepatitis C virus/HIV co-infected patients - (03/30/04)
     
  1743. The patient's perspective in hepatitis C: coping with HCV, doctors, adherence, depression - (03/30/04)
     
  1744. Hepatitis C virus-infected patients (41%) report communication problems with physicians - (03/29/04)
     
  1745. CROI: EPO Once Weekly Improves Anemia & Quality of Life in Coinfected Patients Treated with Interferon/Ribavirin - (03/29/04)
     
  1746. Innogenetics reports significantly improved liver fibrosis in hepatitis C patients after 3 years of therapeutic vaccination - (03/26/04)
     
  1747. Ribavirin's antiviral effect aids interferon in hepatitis C therapy - (03/24/04)
     
  1748. Diagnosis, Management and Treatment of Hepatitis C: AASLD PRACTICE GUIDELINES - (03/22/04)
     
  1749. Stigma of Hepatitis C and Lack of Awareness Stops Americans From Getting Tested and Treated - (03/18/04)
     
  1750. Hepatitis C Leads to Insulin Resistance in Mice & Perhaps Diabetes in HCV+ - (03/12/04)
     
  1751. NIH budget approved at $28 billion: Concerns over FY 2005 funding - (03/12/04)
     
  1752. Drug-Induced Liver Injury Associated with Antiretroviral Therapy that Includes HIV-1 Protease Inhibitors - (03/08/04)
     
  1753. CROI: Evaluation of HCV RNA and Liver Injury in HCV/HIV Coinfected Patients Initiating Lopinavir/r or Nelfinavir-based Therapy - (03/08/04)
     
  1754. CROI: CROI Report- HIV/HCV Co-Infection: Organ Transplantation and Liver Cancer - (03/08/04)
     
  1755. Peginterferon-alpha2a (Pegasys) and Ribavirin Combination Therapy in Chronic Hepatitis C A Randomized Study of Treatment Duration and Ribavirin Dose - (03/04/04)
     
  1756. PDF FORMAT - National HIV/Hepatitis C Co-Infection Coalition letter to Congress and to the Administration - (03/04/04)
     
  1757. Hepatitis C. Development of new drugs and clinical trials: Promises and pitfalls - (03/04/04)
     
  1758. SCHERING-PLOUGH ANNOUNCES AVAILABILITY OF PEG-INTRON REDIPEN - (03/01/04)
     
  1759. CROI: Hepatitis C and HIV: incremental advances; plenary talk on HCV protease, new drug research & basic science; final results of 3 important co-infection studies - Reported for NATAP by David Margolis, MD, University of Texas, Southwestern Medical Center (02/26/04)
     
  1760. CROI: Peg/RBV treatment, liver transplants, RBV/nuke interaction study, HCV & HAART response - Reported by Nancy Shulman, MD, Stanford University (02/26/04)
     
  1761. CROI: HCV/HIV Coinfection May Cause Depression & Cognitive Dysfunction Compared to HIV Monoinfection - (02/26/04)
     
  1762. CROI: PegIntron Plus Ribaivin in HCV/HIV Coinfection: French RIBAVIC Study - (02/19/04)
     
  1763. CROI: ACTG 5071: Pegasys plus Ribavirin vs IFN/RBV in HCV/HIV Coinfection - (02/19/04)
     
  1764. CROI: HIV Vaccine $$, ADAP & Hepatitis - (02/13/04)
     
  1765. CROI: Ribavirin-NRTIs Interaction Study - (02/12/04)
     
  1766. CROI: Pegylated Interferon plus Ribavirin: Pegasys/RBV in Co-infection (APRICOT Study, 72-week results) - (02/11/04)
     
  1767. CROI: Hepatitis C and Neuropsychological Function In Treatment Naive HIV-1-infected Subjects - A5097s Baseline Analysis - (02/09/04)
     
  1768. Health-Related Quality of Life of Patients with HIV Disease: Impact of Hepatitis C Coinfection - (02/09/04)
     
  1769. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of individual patient data - (02/03/04)
     
  1770. Liver disease research funding - (02/03/04)
     
  1771. Hepatitis Vaccination Promoted for Gay Men - (02/02/04)
     
  1772. Methamphetamine: medical implications, HIV & Hepatitis - (02/02/04)
     
  1773. Scope of Worldwide Hepatitis C Problem - (01/30/04)
     
  1774. Pilot Study of the Relationship Between Histologic Progression and Hepatic Iron Concentration in Chronic Hepatitis C - (01/30/04)
     
  1775. Infection with Hepatitis C Virus Genotype 4 in the United States - (01/30/04)
     
  1776. Outcome of Liver Transplantation for Patients Infected by Hepatitis C, Including Those Infected by Genotype 4 - (01/28/04)
     
  1777. Hepatitis C Lawsuit for Exposure to Reused Syringes in Clinic - (01/28/04)
     
  1778. Low Dose PegIntron and Ribavirin in Small Study: efficacy and safety - (01/28/04)
     
  1779. Schering-Plough Announces Availability of REBETOL(R) Oral Solution For Use in Treating Pediatric Hepatitis C - (01/27/04)
     
  1780. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy - (01/27/04)
     
  1781. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches - (01/27/04)
     
  1782. HEP DART: NM 283 new HCV Inhibitor - (01/26/04)
     
  1783. HEP DART: Combination Interferon Therapy: Infergen plus Actimmune - (01/26/04)
     
  1784. HEP DART: Merimepodib (VX-497), New HCV Drug - (01/27/04)
     
  1785. Care of patients with hepatitis C and HIV co-infection: Consensus Panel Recommendations - (01/26/04)
     
  1786. Steatosis in Hepatitis C: What Does It Mean? - (01/22/04)
     
  1787. Hepatotoxicity Safety Change to Label of Viramune (nevirapine) - (01/20/04)
     
  1788. GB Virus Type C Coinfection in HIV-Infected African Mothers and Their Infants, KwaZulu Natal, South Africa - (01/20/04)
     
  1789. GB Virus Type C: A Virus in Search of a Disease or a Role in HIV Therapy? - (01/20/04)
     
  1790. Coley Pharmaceutical Group Initiates Phase I Clinical Trials of Actilon(TM) for Chronic Hepatitis C Infection - (01/16/04)
     
  1791. Global Burden of Disease (GBD) for Hepatitis C - (01/15/04)
     
  1792. Treatment considerations in patients with hepatitis C and cirrhosis - (01/15/04)
     
  1793. Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection - (01/14/04)
     
  1794. PDF FORMAT - Structural Biology of Hepatitis C Virus - (01/14/04)
     
  1795. Pioglitazone Improves Liver, Body Fat, Glucose - (01/08/04)
     
  1796. Study highlights possible root of HCV persistence - (01/07/04)
     
  1797. Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression - (01/06/04)